EurekaMag Full Text Articles Chapter 51,208

Lilly, M. 2008: A personal reflection: critical care family communication. Dimensions of Critical Care Nursing: Dccn 27(5): 213-217

Goforth, C. 2009: A personal reflection: dedication. Dimensions of Critical Care Nursing: Dccn 28(3): 112-113

Lilly, M. 2008: A personal reflection: family survival in the pediatric intensive care unit. Dimensions of Critical Care Nursing: Dccn 27(4): 157-159

Kramer, L.Weston. 2007: A personal reflection: graduate study challenges and strategies for success. Dimensions of Critical Care Nursing: Dccn 26(4): 158-159

Miracle, V.A. 2007: A personal reflection: humor--I'd rather laugh than cry. Dimensions of Critical Care Nursing: Dccn 26(6): 241-243

Brus, M.A. 2010: A personal reflection: nursing art of withdrawing life support. Dimensions of Critical Care Nursing: Dccn 29(6): 293-296

Mather, M.E. 2010: A personal reflection: nursing in times of disaster. Dimensions of Critical Care Nursing: Dccn 29(6): 284-287

Riley-Giomariso, O. 2013: A personal reflection: pedagogy of the wounded healer. Dimensions of Critical Care Nursing: Dccn 32(3): 128

Baldonado, A.V. 2010: A personal reflection: personal struggles in graduate study. Dimensions of Critical Care Nursing: Dccn 29(3): 136-137

Ghetti, C. 2007: A personal reflection: tactile music therapy at night for patients on ECMO in the pediatric intensive care setting. Dimensions of Critical Care Nursing: Dccn 26(4): 173

Aldridge, M.D. 2012: A personal reflection: the difficult decision to leave critical care nursing. Dimensions of Critical Care Nursing: Dccn 31(6): 330-335

Stambovsky, M. 2011: A personal reflection: the slippery slope of hope. Dimensions of Critical Care Nursing: Dccn 30(4): 196-197

Federle, D. 2012: A personal reflection: views of a family member. Dimensions of Critical Care Nursing: Dccn 31(2): 86-88

Lau, J.C. 2009: A personal reflection: what does the general public know about certification of critical care nurses?. Dimensions of Critical Care Nursing: Dccn 28(3): 114-115

Miracle, V.A. 2012: A personal reflection: what you need to know before getting involved in a clinical trial. Dimensions of Critical Care Nursing: Dccn 31(3): 167-169

Jay, A. 2000: A personal response to: The Woman Who Walked Into Doors by Roddy Doyle. Medical Humanities 26(1): 58-59

Willis, J. 2000: A personal response to: Zen and the Art of Motorcycle Maintenance by Robert Pirsig. Medical Humanities 26(2): 110-112

Nicholas Leibovic, K. 2013: A personal retrospective on the second half of the 20th century. Bio Systems 112(3): 183-188

Stanley, J.A. 2009: A personal retrospective: in the eye of the accreditation storm (Part I of II). Journal of Correctional Health Care: the Official Journal of the National Commission on Correctional Health Care 15(2): 150-156

Stanley, J.A. 2009: A personal retrospective: in the eye of the accreditation storm (Part II of II). Journal of Correctional Health Care: the Official Journal of the National Commission on Correctional Health Care 15(3): 222-226

Simpson, L.; Simpson, L. 2011: A personal scientific odyssey. Protist 162(1): 188-206

Bogg, D. 2010: A personal service. Mental Health Today 2010: 13-15

Harrison, D.J. 2013: A personal stroll through the historical development of Canadian microfluidics. Lab on a Chip 13(13): 2500-2503

Warrington, D. 2013: A personal taste of organizational reform. Nephrology Nursing Journal: Journal of the American Nephrology Nurses' Association 40(6): 555-556

Clipp, S.L.; Comstock, G.W. 2008: A personal tribute to Dr. George W. Comstock. American Journal of Epidemiology 168(7): 671-672

Lee, V.H.L.; Robinson, J. 2008: A personal tribute to Joseph R. Robinson: an inspiration for all generations. Pharmaceutical Research 25(1): 1-2

Khumalo, N.P.; Kirsch, R. 2010: A personal tribute to Ralph Kirsch. South African Medical Journal 100(5): 262

Stuzin, J.M.; Kawamoto, H.; Stuzin, J.M. 2012: A personal tribute to a great educator: how Henry Kawamoto influenced my interest in facial soft tissue anatomy and changed my plastic surgery career. Journal of Craniofacial Surgery 23(7 Suppl. 1): 1944-1945

Bhattacharjee, Y. 2009: A personal tutor for algebra. Science 323(5910): 64-65

Higashida, H.; Nirenberg, M. 2012: A personal view from a long-lasting collaborator on the research strategies of Marshall Nirenberg. Neurochemistry International 61(6): 821-827

Brown, J.U. 1991: A personal view of biomedical engineering. IEEE Engineering in Medicine and Biology Magazine: the Quarterly Magazine of the Engineering in Medicine and Biology Society 10(3): 34-37

Forbes, J.M. 2007: A personal view of how ruminant animals control their intake and choice of food: minimal total discomfort. Nutrition Research Reviews 20(2): 132-146

Zamora, S. 2014: A personal view of nutrition in Spain. Nutricion Hospitalaria 29(4): 699-703

Scheuplein, R.J. 2013: A personal view of skin permeation (1960-2013). Skin pharmacology and physiology 26(4-6): 199-212

Moore, J.W. 2010: A personal view of the early development of computational neuroscience in the USA. Frontiers in Computational Neuroscience 4

Hicks, J.E. 2009: A personal view of the personal health record. HIM professional sees the personal and professional benefits of PHRs. Journal of Ahima 80(6): 80

Hood, L.; Flores, M. 2012: A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. New Biotechnology 29(6): 613-624

Cooper, D.J. 2010: A personal view--6 months in a FOB. Journal of the Royal Army Medical Corps 156(1): 57-59

Rose, G.E. 2007: A personal view: probability in medicine, levels of (Un)certainty, and the diagnosis of orbital disease (with particular reference to orbital "pseudotumor"). Archives of Ophthalmology 125(12): 1711-1712

Lindahl, U. 2014: A personal voyage through the proteoglycan field. Matrix Biology: Journal of the International Society for Matrix Biology 35: 3-7

Cheskin, L.J. 2008: A personal-contact weight-loss maintenance intervention reduced weight regain in overweight and obese adults. Acp Journal Club 149(1): 4

Vonk Noordegraaf, A.; Anema, J.R.; van Mechelen, W.; Knol, D.L.; van Baal, W.M.; van Kesteren, P.J.M.; Brölmann, H.A.M.; Huirne, J.A.F. 2014: A personalised eHealth programme reduces the duration until return to work after gynaecological surgery: results of a multicentre randomised trial. Bjog: An International Journal of Obstetrics and Gynaecology 121(9): 1127-35; Discussion 1136

Marín, G.; Silberman, M.; Etchegoyen, G. 2008: A personalised health care programme (PANDELAS) operating in Buenos Aires , Argentina , during 2006. Revista de Salud Publica 10(2): 203-214

Cheskin, L.J. 2008: A personalised intervention reduced weight regain in overweight and obese adults who had recently lost weight. Evidence-Based Medicine 13(4): 109

Vanlaere, L.; Gastmans, C. 2011: A personalist approach to care ethics. Nursing Ethics 18(2): 161-173

Axelsson, M.; Brink, E.; Lötvall, J. 2014: A personality and gender perspective on adherence and health-related quality of life in people with asthma and/or allergic rhinitis. Journal of the American Association of Nurse Practitioners 26(1): 32-39

Thompson, K.; Mather, R.D. 2013: A personality for modern living: a review of Kevin Dutton, the Wisdom of Psychpaths: what Saints, Spies, and Serial Killers can Teach Us about Success. Evolutionary Psychology: An International Journal of Evolutionary Approaches to Psychology and Behavior 11(1): 120-125

Klein, H.R. 1948: A personality study of 100 unselected patients attending a gastro-intestinal clinic. American Journal of Psychiatry 104(7): 433-439

Landisberg, S. 1947: A personality study of institutionalized epileptics. American Journal of Mental Deficiency 52(1): 16-22

Krueger, R.F.; Eaton, N.R. 2010: A personality trait model for the Diagnostic and Statistical Manual of Mental Disorders (DSM): the challenges ahead. Personality Disorders 1(2): 135-137

Littlefield, A.K.; Sher, K.J.; Wood, P.K. 2010: A personality-based description of maturing out of alcohol problems: extension with a five-factor model and robustness to modeling challenges. Addictive Behaviors 35(11): 948-954

Martens, M.P. 2011: A personality-based intervention moderately reduces risk of drinking in at-risk 13-14-year-old British school children. Evidence-Based Mental Health 14(1): 23

Kao, D.P.; Wagner, B.D.; Robertson, A.D.; Bristow, M.R.; Lowes, B.D. 2012: A personalized BEST: characterization of latent clinical classes of nonischemic heart failure that predict outcomes and response to bucindolol. Plos one 7(11): E48184

Mynbaev, O.A.; Eliseeva, M.Yu.; Tinelli, A.; Malvasi, A.; Kosmas, I.P.; Medvediev, M.V.; Babenko, T.I.; Mazitova, M.I.; Kalzhanov, Z.R.; Stark, M. 2014: A personalized adhesion prevention strategy: E. Arslan, T. Talih, B. Oz, B. Halaclar, K. Caglayan, M. Sipahi, Comparison of lovastatin and hyaluronic acid/carboxymethyl cellulose on experimental created peritoneal adhesion model in rats, Int. J. Surg. 12 (2) (2014) 120-124. International Journal of Surgery 12(9): 901-905

Pina, A.A.; Holly, L.E.; Zerr, A.A.; Rivera, D.E. 2014: A personalized and control systems engineering conceptual approach to target childhood anxiety in the contexts of cultural diversity. Journal of Clinical Child and Adolescent Psychology: the Official Journal for the Society of Clinical Child and Adolescent Psychology American Psychological Association Division 53 43(3): 442-453

Kalafut, J.F.; Kemper, C.A.; Suryani, P.; Schoepf, U. 2009: A personalized and optimal approach for dosing contrast material at coronary computed tomography angiography. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference 2009: 3521-3524

Honka, A.M.; van Gils, M.J.; Pärkkä, J. 2011: A personalized approach for predicting the effect of aerobic exercise on blood pressure using a Fuzzy Inference System. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference 2011: 8299-8302

Hui, D.; Bruera, E. 2014: A personalized approach to assessing and managing pain in patients with cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 32(16): 1640-1646

Duffy, M.J.; Crown, J. 2008: A personalized approach to cancer treatment: how biomarkers can help. Clinical Chemistry 54(11): 1770-1779

Faulkner, M.S.; Michaliszyn, S.F.; Hepworth, J.T. 2010: A personalized approach to exercise promotion in adolescents with type 1 diabetes. Pediatric Diabetes 11(3): 166-174

Amerini, A.; Hatam, N.; Malasa, M.; Pott, D.; Tewarie, L.; Isfort, P.; Goetzenich, A.; Hildinger, M.; Autschbach, R.üd.; Spillner, J. 2014: A personalized approach to interventional treatment of tricuspid regurgitation: experiences from an acute animal study. Interactive Cardiovascular and Thoracic Surgery 19(3): 414-418

Brietzke, S.A. 2010: A personalized approach to metabolic aspects of obesity. Mount Sinai Journal of Medicine new York 77(5): 499-510

Marcellin, P.; Liang, J. 2010: A personalized approach to optimize hepatitis B treatment in treatment-naive patients. Antiviral Therapy 15(Suppl 3): 53-59

Hirsh, V.; Melosky, B.; Goss, G.; Morris, D.; Morzycki, W. 2012: A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada. Current Oncology 19(2): 78-90

Yuan, M.J.; Hébert, E.T.; Johnson, R.K.; Long, J.; Vandewater, E.A.; Vickers, A.J. 2012: A personalized automated messaging system to improve adherence to prostate cancer screening: research protocol. Jmir Research Protocols 1(2): E20

Fuerst, B.; Mansi, T.; Zhang, J.; Khurd, P.; Declerck, J.; Boettger, T.; Navab, N.; Bayouth, J.; Comaniciu, D.; Kamen, A. 2012: A personalized biomechanical model for respiratory motion prediction. Medical Image Computing and Computer-Assisted Intervention: Miccai . International Conference on Medical Image Computing and Computer-Assisted Intervention 15(Part 3): 566-573

Kiranyaz, S.; Ince, T.; Pulkkinen, J.; Gabbouj, M. 2009: A personalized classification system for Holter registers. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference 2009: 1883-1888

Jahid, M.Jamiul.; Huang, T.H.; Ruan, J. 2014: A personalized committee classification approach to improving prediction of breast cancer metastasis. Bioinformatics 30(13): 1858-1866

Coskun, A.F.; Wong, J.; Khodadadi, D.; Nagi, R.; Tey, A.; Ozcan, A. 2013: A personalized food allergen testing platform on a cellphone. Lab on a Chip 13(4): 636-640

Koutkias, V.G.; Chouvarda, I.; Triantafyllidis, A.; Malousi, A.; Giaglis, G.D.; Maglaveras, N. 2010: A personalized framework for medication treatment management in chronic care. IEEE Transactions on Information Technology in Biomedicine: a Publication of the IEEE Engineering in Medicine and Biology Society 14(2): 464-472

Laufs, H. 2012: A personalized history of EEG-fMRi integration. Neuroimage 62(2): 1056-1067

Jungnickel, H.; Luch, A. 2012: A personalized life: biomarker monitoring from cradle to grave. Experientia Supplementum 101: 471-498

Fletcher, R.H. 2008: A personalized mailed brochure was cost-effective for promoting colonoscopy in asymptomatic patients referred for screening. Acp Journal Club 148(2): 52

Gross, E.R.; Zambelli, V.O.; Small, B.A.; Ferreira, J.C.B.; Chen, C-Hong.; Mochly-Rosen, D. 2015: A personalized medicine approach for Asian Americans with the aldehyde dehydrogenase 2*2 variant. Annual Review of Pharmacology and Toxicology 55: 107-127

Tak, P.P. 2012: A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatology 51(4): 600-609

Ginghină, C.; Botezatu, C.D.; Șerban, M.; Jurcuţ, R. 2011: A personalized medicine target: heart failure in women. Journal of Medicine and Life 4(3): 280-286

Wang, B.; Wang, X.-F.; Howell, P.; Qian, X.; Huang, K.; Riker, A.I.; Ju, J.; Xi, Y. 2010: A personalized microRNA microarray normalization method using a logistic regression model. Bioinformatics 26(2): 228-234

Burlina, P.; Mukherjee, R.; Sprouse, C. 2012: A personalized mitral valve closure simulator. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference 2012: 6636-6640

Okkels, N.; Andersson, N.A.W. 2013: A personalized patient page. Psychiatric Services 64(10): 1067-1068

Puig, I.; Chicote, I.; Tenbaum, S.P.; Arqués, O.; Herance, J.é R.úl.; Gispert, J.D.; Jimenez, J.é; Landolfi, S.; Caci, K.; Allende, H.; Mendizabal, L.; Moreno, D.; Charco, R.ón.; Espín, E.; Prat, A.; Elez, M.E.; Argilés, G.; Vivancos, A.; Tabernero, J.; Rojas, S.; Palmer, H.éc.G. 2013: A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 19(24): 6787-6801

Merrill, D.R.; Davis, R.; Turk, R.; Burridge, J.H. 2011: A personalized sensor-controlled microstimulator system for arm rehabilitation poststroke. Part 1: System architecture. Neuromodulation: Journal of the International Neuromodulation Society 14(1): 72-79; Discussion 79

Burridge, J.H.; Turk, R.; Merrill, D.; Dibb, B.; Hughes, A.-M.; Sparrow, O.; Roberts, H.; Davis, R. 2011: A personalized sensor-controlled microstimulator system for arm rehabilitation poststroke. Part 2: Objective outcomes and patients' perspectives. Neuromodulation: Journal of the International Neuromodulation Society 14(1): 80-88; Discussion 88

Balanescu, B.; Franklin, R.; Ciurea, J.; Mindruta, I.; Rasina, A.; Bobulescu, R.C.; Donos, C.; Barborica, A. 2014: A personalized stereotactic fixture for implantation of depth electrodes in stereoelectroencephalography. Stereotactic and Functional Neurosurgery 92(2): 117-125

Kanodia, A.K.; Kim, I.; Sturmberg, J.P. 2011: A personalized systems medicine approach to refractory rumination. Journal of Evaluation in Clinical Practice 17(3): 515-519

Hensing, T.; Chawla, A.; Batra, R.; Salgia, R. 2014: A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Advances in Experimental Medicine and Biology 799: 85-117

Wayteck, L.; Breckpot, K.; Demeester, J.; De Smedt, S.C.; Raemdonck, K. 2014: A personalized view on cancer immunotherapy. Cancer Letters 352(1): 113-125

Pearce, C.; Bainbridge, M. 2014: A personally controlled electronic health record for Australia. Journal of the American Medical Informatics Association: Jamia 21(4): 707-713

Manners, J.M. 2006: A perspective. Annals of Cardiac Anaesthesia 9(1): 15-16

Yun, Y-Huan.; Liang, Y-Zeng.; Xie, G-Xiang.; Li, H-Dong.; Cao, D-Sheng.; Xu, Q-Song. 2013: A perspective demonstration on the importance of variable selection in inverse calibration for complex analytical systems. Analyst 138(21): 6412-6421

Roberts, J.D. 2009: A perspective distilled from seventy years of research. Journal of organic chemistry 74(14): 4897-4917

Sakuma, S.; Tachiki, H.; Uchiyama, H.; Fukui, Y.; Takeuchi, N.; Kumamoto, K.; Satoh, T.; Yamamoto, Y.; Ishii, E.; Sakai, Y.; Takeuchi, S.; Sugita, M.; Yamashita, S. 2011: A perspective for biowaivers of human bioequivalence studies on the basis of the combination of the ratio of AUC to the dose and the biopharmaceutics classification system. Molecular Pharmaceutics 8(4): 1113-1119

Khan, T.; Anwar, M.; Mueen Ahmed, K. 2011: A perspective for clinical pharmacy curriculum development and validation in asian developing nations. Journal of Young Pharmacists: Jyp 3(2): 151-154

Murthy, K.H. 1984: A perspective for susruta samhita. Ancient Science of Life 3(3): 151-156

Traversa, G.; Sagliocca, L.; Magrini, N.; Venegoni, M. 2013: A perspective for the role of drug registries in the post-marketing surveillance. Recenti Progressi in Medicina 104(6): 280-287

Buell, S. 2013: A perspective from Bolivia on the implications of the World Report on Disability for people with communication disabilities. International Journal of Speech-Language Pathology 15(1): 32-36

MacGinty, R.P.; Lesosky, M.; Barnett, W.; Stein, D.J.; Zar, H.J. 2018: Associations between maternal mental health and early child wheezing in a South African birth cohort. Pediatric Pulmonology 53(6): 741-754

Murphy, S. 2011: A perspective from Indian Health Service--supporting breastfeeding. Breastfeeding Medicine: the Official Journal of the Academy of Breastfeeding Medicine 6: 261-263

López, M.H.R.íg.- 2008: A perspective from Mexico. Journal of Public Health Policy 29(1): 26-31

Ross, K.M.; Reiff, M. 2013: A perspective from clinical providers and patients: researchers' duty to actively look for genetic incidental findings. American Journal of Bioethics: Ajob 13(2): 56-58

Corbacho, A.; Rivera, M.; Trujillo, F.; Martí, M.; Carbonell, Jé.; Fernández, F.; Rosselló, A.; Perramon, J.; Salse, J.; Ramos, I. 2014: A perspective from drug user organisations on 'ECDC and EMCDDA guidance: prevention and control of infectious diseases among people who inject drugs'. Bmc Infectious Diseases 14 Suppl. 6: S10

Rosen, I.C. 2009: A perspective from more than a half century with Menninger: remarks for clinic graduation ceremonies August 22, 2008. Bulletin of the Menninger Clinic 73(1): 1-6

Waguespack, S.G. 2009: A perspective from pediatric endocrinology on the hereditary medullary thyroid carcinoma syndromes. Thyroid: Official Journal of the American Thyroid Association 19(6): 543-546

Liang, Y.; Ren, H-Yan.; Zuo, P-Xiang. 2018: Associations Between Maternal Nutrition Knowledge, Attitude, and Practice and 25-Hydroxyvitamin D Levels and Rickets in Children in Xinjiang Province, People's Republic of China. Asia-Pacific Journal of Public Health 30(4): 378-386

Haynes, S. 2013: A perspective from the dental industry on minimum intervention dentistry. Australian Dental Journal 58(Suppl 1): 66-69

Yilmaz, A.; Unsal, N.; Celik, N.; Karabel, M.; Keskin, E.; Tan, S.; Aldemir, S. 2012: A perspective from the practice of swaddling by Turkish mothers. Hippokratia 16(2): 130-136

Li, C.; Yu, S. 2014: A perspective from transport protein particle: vesicle tether and human diseases. Sheng Li Xue Bao: 66(1): 1-6

Qi, L.; Zhang, H. 2011: A perspective of YY0709-2009 testing of alarm system for medical use. Zhongguo Yi Liao Qi Xie Za Zhi 35(4): 291-293

Mezghani, E.; Da Silveira, M.; Pruski, C.éd.; Exposito, E.; Drira, K. 2014: A perspective of adaptation in healthcare. Studies in Health Technology and Informatics 205: 206-210

Morgulis, S.; Jacobi, H.P. 1946: A perspective of biochemical defects in muscle in vitamin e deficiency. Quarterly Bulletin. Northwestern University . Medical School 20: 92-98

Wang, T.-f.; Du, C.-f.; Wang, Q.-g.; Wu, X.-y.; Wang, Z.-y.; Zhao, Y.; Xue, X.-l.; Deng, H.-l.; Yue, H.; Yu, L.-l.; Qu, K.; Yu, C.-g.; Xu, W.-j. 2009: A perspective of developing syndrome diagnostic criteria based on syndrome factors and combination of disease in modern medicine system and syndrome in traditional Chinese medicine system. Zhong Xi Yi Jie he Xue Bao 7(10): 901-906

Mutto, E.Mario.; Cantoni, Mónica.Nélida.; Rabhansl, Mía.Margarita.; Villar, M.J. 2012: A perspective of end-of-life care education in undergraduate medical and nursing students in Buenos Aires, Argentina. Journal of Palliative Medicine 15(1): 93-98

Leon, M.A.; Paz, E. 2014: A perspective of food safety laws in Mexico. Journal of the Science of Food and Agriculture 94(10): 1954-1957

Cicatiello, J.S. 2000: A perspective of health care in the past--insights and challenges for a health care system in the new millennium. Nursing Administration Quarterly 25(1): 18-29

Montañez, M.Isabel.; Ruiz-Sanchez, A.J.; Perez-Inestrosa, E. 2010: A perspective of nanotechnology in hypersensitivity reactions including drug allergy. Current Opinion in Allergy and Clinical Immunology 10(4): 297-302

Kitajima, Y.; Aoyama, Y. 2007: A perspective of pemphigus from bedside and laboratory-bench. Clinical Reviews in Allergy and Immunology 33(1-2): 57-66

Chepurnov, S.A.; Aristov, A.V.; Berdiev, R.K.; Abbasova, K.R.; Chepurnova, N.E. 2010: A perspective of present approaches to EEG analyses performed with intention to find seizure predictors. Uspekhi Fiziologicheskikh Nauk 41(4): 27-44

Dolfini, D.; Zambelli, F.; Pavesi, G.; Mantovani, R. 2009: A perspective of promoter architecture from the CCAAT box. Cell Cycle 8(24): 4127-4137

Williams, A.J. 2008: A perspective of publicly accessible/open-access chemistry databases. Drug Discovery Today 13(11-12): 495-501

Rayfield, E.J. 2015: A perspective of sensor-augmented insulin pump therapy in the treatment of type 1 diabetes. Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 21(1): 91-92

Sun, R. 2011: A perspective of the development of medical metrology. Zhongguo Yi Liao Qi Xie Za Zhi 35(6): 459-461

Dange, T.; Joseph, A.; Grünwald, D. 2011: A perspective of the dynamic structure of the nucleus explored at the single-molecule level. Chromosome Research: An International Journal on the Molecular Supramolecular and Evolutionary Aspects of Chromosome Biology 19(1): 117-129

Adam, I.; Elhassan, E.M.; Haggaz, A.E.D.; Ali, A.A.A.; Adam, G.K. 2011: A perspective of the epidemiology of malaria and anaemia and their impact on maternal and perinatal outcomes in Sudan. Journal of Infection in Developing Countries 5(2): 83-87

Albers, R.W. 1986: A perspective of the sodium pump. Neurochemistry International 8(4): 477-479

Lackovic, K.; Lessene, G.; Falk, H.; Leuchowius, K-Johan.; Baell, J.; Street, I. 2014: A perspective on 10-years HTS experience at the Walter and Eliza Hall Institute of Medical Research - eighteen million assays and counting. Combinatorial Chemistry and High Throughput Screening 17(3): 241-252

Goldstein, R.; Zuckerman, B. 2010: A perspective on 360-degree evaluations. Journal of Pediatrics 156(1): 1-2.E1-2

Rapp, R.P. 2007: A perspective on 45 years in clinical pharmacy education. Annals of PharmacoTherapy 41(6): 1047-1049

Looney, R.J.; Anolik, J.; Sanz, I. 2010: A perspective on B-cell-targeting therapy for SLE. Modern Rheumatology 20(1): 1-10

Brown-Bryant, R.; Brumbaugh, K. 2010: A perspective on CDC's efforts in safe motherhood: 2001 to the present. Journal of Women's Health 19(5): 833-836

Sahadevan, J.; Waldo, A.L. 2010: A perspective on DIONYSOS. Journal of Cardiovascular Electrophysiology 21(6): 606-607

Xinghan, K.F.; Harkensee, C. 2015: A perspective on IL-7Rα deficient T-B+NK+ severe combined immunodeficiency. Pediatric Infectious Disease Journal 34(3): 301-303

Trimpin, S. 2010: A perspective on MALdi alternatives-total solvent-free analysis and electron transfer dissociation of highly charged ions by laserspray ionization. Journal of Mass Spectrometry: Jms 45(5): 471-485

Bartley, J.M.; Olmsted, R.N. 2009: A perspective on OR laminar air flow. Or Manager 25(2): 16; 18

Rich, P.R.; Mitchell, P. 2008: A perspective on Peter Mitchell and the chemiosmotic theory. Journal of Bioenergetics and Biomembranes 40(5): 407-410

Kumar, S.; Kumar, R.; Sugimoto, C. 2009: A perspective on Theileria equi infections in donkeys. Japanese Journal of Veterinary Research 56(4): 171-180

Mori, H. 2014: A perspective on acetylcholine. Brain and Nerve 66(5): 501-505

Falke, L.L.; Goldschmeding, R.; Nguyen, T.Q. 2014: A perspective on anti-CCN2 therapy for chronic kidney disease. Nephrology Dialysis Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 29(Suppl 1): I30-I37

Griffiths, P.D. 2009: A perspective on antiviral resistance. Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology 46(1): 3-8

Buchanan, D.; Young, J. 2009: A perspective on bi-allelic MUTYH mutations in patients with hyperplastic polyposis syndrome. Gastroenterology 136(7): 2407-2408

Acarregui, A.; Murua, A.; Pedraz, J.é L.; Orive, G.; Hernández, R.M. 2012: A perspective on bioactive cell microencapsulation. Biodrugs: Clinical Immunotherapeutics Biopharmaceuticals and Gene Therapy 26(5): 283-301

Huo, Q. 2007: A perspective on bioconjugated nanoparticles and quantum dots. Colloids and Surfaces. B Biointerfaces 59(1): 1-10

Cocker, J. 2014: A perspective on biological monitoring guidance values. Toxicology Letters 231(2): 122-125

Traverso, S. 2008: A perspective on biological signaling: ionic conduction and percolation. Rivista di Biologia 101(3): 331-340

Apedaile, E. 2001: A perspective on biosolids management. Canadian Journal of Infectious Diseases 12(4): 202-204

Chaffer, C.L.; Weinberg, R.A. 2011: A perspective on cancer cell metastasis. Science 331(6024): 1559-1564

Taube, S.E.; Clark, G.M.; Dancey, J.E.; McShane, L.M.; Sigman, C.C.; Gutman, S.I. 2009: A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. Journal of the National Cancer Institute 101(21): 1453-1463

Bauman, A.; O'Hara, L.; Signal, L.; Smith, B.; Ritchie, J.; Parker, E.; Rissel, C. 2007: A perspective on changes in values in the profession of health promotion. Health Promotion Journal of Australia: Official Journal of Australian Association of Health Promotion Professionals 18(1): 3-6

Anderson, B. 2010: A perspective on changing dynamics in nursing over the past 20 years. British Journal of Nursing 19(18): 1190-1191

Zaleski, D.P.; Stephens, S.L.; Walker, N.R. 2014: A perspective on chemistry in transient plasma from broadband rotational spectroscopy. Physical Chemistry Chemical Physics: Pccp 16(46): 25221-25228

Pierson, C.A.; Schumann, L.; Berner, B. 2008: A perspective on chronic illness. Journal of the American Academy of Nurse Practitioners 20(3): 107-108

Bryson, R.A. 1974: A perspective on climatic change. Science 184(4138): 753-760

Jampol, L.M.; Packer, S.; Mills, R.P.; Day, S.H.; Lichter, P.R. 2009: A perspective on commercial relationships between ophthalmology and industry. Archives of Ophthalmology 127(9): 1194-1202

Baum, N.; Petrou, S.; Argenio, S. 2011: A perspective on communicating with the female patient. Journal of Medical Practice Management: Mpm 26(5): 274-276

Fudge, S. 1992: A perspective on consulting in guatemala. Occupational Therapy in Health Care 8(1): 15-37

Rabitz, H. 2011: A perspective on controlling quantum phenomena. Faraday Discussions 153: 415-418

Mitchell, M.E. 1992: A perspective on convenience euthanasia. Canadian Veterinary Journal 33(4): 218

Riche, D.M.; Dale, K.M. 2007: A perspective on coronary revascularization in the PROactive 05 study. Journal of the American College of Cardiology 50(17): 1705-6; author reply 1706

Lober, R.M.; Harsh, G.R. 2013: A perspective on craniopharyngioma. World Neurosurgery 79(5-6): 645-646

Davis, M.A. 2009: A perspective on cultivating clinical empathy. Complementary Therapies in Clinical Practice 15(2): 76-79

Curry, C. 2008: A perspective on developing emergency medicine as a specialty. International Journal of Emergency Medicine 1(3): 163-167

Su, Z-Yuan.; Shu, L.; Khor, T.Oo.; Lee, J.Hun.; Fuentes, F.; Kong, A-Ng.Tony. 2013: A perspective on dietary phytochemicals and cancer chemoprevention: oxidative stress, nrf2, and epigenomics. Topics in Current Chemistry 329: 133-162

Parker, M.Alec. 2007: A perspective on doctor-patient communication in the dental office. North Carolina Medical Journal 68(5): 365-367

Guinto, J.B.; Szabatura, A.H. 2013: A perspective on dose banding. Journal of the National Comprehensive Cancer Network: Jnccn 11(3): 357-359

Munkwitz, M.; Hopkins, R.O.; Miller Iii, R.R.; Luckett, P.M.; Hirshberg, E.L. 2010: A perspective on early mobilization for adult patients with respiratory failure: Lessons for the pediatric population. Journal of Pediatric Rehabilitation Medicine 3(3): 215-227

Peters, E. 2009: A perspective on eating behaviors from the field of judgment and decision making. Annals of Behavioral Medicine: a Publication of the Society of Behavioral Medicine 38(Suppl 1): S81-S87

Roberts, M.T. 2011: A perspective on emerging law, consumer trust and social responsibility in China's food sector: the "bleaching" case study. Food and Drug Law Journal 66(3): 405

Hendrickx, G.; Lancelot, R. 2010: A perspective on emerging mosquito and phlebotomine-borne diseases in Europe. Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles 15(10): 19503

Budowle, B.; Bottrell, M.C.; Bunch, S.G.; Fram, R.; Harrison, D.; Meagher, S.; Oien, C.T.; Peterson, P.E.; Seiger, D.P.; Smith, M.B.; Smrz, M.A.; Soltis, G.L.; Stacey, R.B. 2009: A perspective on errors, bias, and interpretation in the forensic sciences and direction for continuing advancement. Journal of Forensic Sciences 54(4): 798-809

Pollard, T.C.B. 2011: A perspective on femoroacetabular impingement. Skeletal Radiology 40(7): 815-818

Lewis, N.S. 2009: A perspective on forward research and development paths for cost-effective solar energy utilization. Chemsuschem 2(5): 383-386

Porter, N.A. 2013: A perspective on free radical autoxidation: the physical organic chemistry of polyunsaturated fatty acid and sterol peroxidation. Journal of Organic Chemistry 78(8): 3511-3524

Symmans, W.F. 2012: A perspective on genomic tests for breast cancer: the need for progress. Oncology 26(4): 364-365; 369

Post, D.C. 2010: A perspective on health care development in Micronesia. Pacific Health Dialog 16(1): 181-184

Skolnik, C. 2009: A perspective on health inequities and the need for universal healthcare. Mcgill Journal of Medicine: Mjm: An International Forum for the Advancement of Medical Sciences by Students 12(2): 126

Haramati, A. 2013: A perspective on health professions education. Explore 9(5): 272-273

Tripathi, R.C.; Singh, N. 2009: A perspective on healthcare related web interfaces. Bioinformation 4(2): 87-89

Zhang, K.; Wong, J.W.; Wang, P.G. 2011: A perspective on high throughput analysis of pesticide residues in foods. Se Pu 29(7): 587-593

Kavanagh, K.T.; Saman, D.M.; Yu, Y. 2013: A perspective on how the United States fell behind Northern Europe in the battle against methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and ChemoTherapy 57(12): 5789-5791

Nuval, A.; Nguyen, T.D.; Watts, R.; Wang, Y. 2003: An improved real-time navigator gating algorithm for reducing motion effects in coronary magnetic resonance angiography. Journal of X-Ray Science and Technology 11(3): 115-123

Mokarram, N.; Bellamkonda, R.V. 2014: A perspective on immunomodulation and tissue repair. Annals of Biomedical Engineering 42(2): 338-351

Cooper, R.A.; Dicianno, B.E.; Brewer, B.; LoPresti, E.; Ding, D.; Simpson, R.; Grindle, G.; Wang, H. 2008: A perspective on intelligent devices and environments in medical rehabilitation. Medical Engineering and Physics 30(10): 1387-1398

Naugler, C. 2014: A perspective on laboratory utilization management from Canada. Clinica Chimica Acta; International Journal of Clinical Chemistry 427: 142-144

Richardson, M.; de Pauw, B. 2008: A perspective on liposomal amphotericin B (AmBisome). Clinical Microbiology and Infection: the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 14(Suppl 4): 1-4

Rupprecht, C.E.; Turmelle, A.; Kuzmin, I.V. 2011: A perspective on lyssavirus emergence and perpetuation. Current Opinion in Virology 1(6): 662-670

Binkley, N. 2009: A perspective on male osteoporosis. Best Practice and Research. Clinical Rheumatology 23(6): 755-768

Wang, T.-M.; Zhang, D.-P.; Liu, D. 2008: A perspective on medical robotics. Zhongguo Yi Liao Qi Xie Za Zhi 32(4): 235-238

Kreiter, C.D.; Axelson, R.D. 2013: A perspective on medical school admission research and practice over the last 25 years. Teaching and Learning in Medicine 25 Suppl. 1: S50-S56

Kusadasi, N.; Groeneveld, A.B.J. 2013: A perspective on mesenchymal stromal cell transplantation in the treatment of sepsis. Shock 40(5): 352-357

Nunes, M.D.S.; Arif, S.; Schlötterer, C.; McGregor, A.P. 2013: A perspective on micro-evo-devo: progress and potential. Genetics 195(3): 625-634

Lee, J.W.; Kjeang, E. 2010: A perspective on microfluidic biofuel cells. Biomicrofluidics 4(4): 41301

Guedj, J.; Rong, L.; Dahari, H.; Perelson, A.S. 2010: A perspective on modelling hepatitis C virus infection. Journal of Viral Hepatitis 17(12): 825-833

Andersen, J.B.; Thorgeirsson, S.S. 2014: A perspective on molecular therapy in cholangiocarcinoma: present status and future directions. Hepatic Oncology 1(1): 143-157

Gilchrist, A. 2008: A perspective on more effective GPCR-targeted drug discovery efforts. Expert Opinion on Drug Discovery 3(4): 375-389

Stemp, L.I. 2008: A perspective on morphine "anesthesia". Journal of Cardiothoracic and Vascular Anesthesia 22(3): 510-511

Mummert, A.; Weiss, H.; Long, L.-P.; Amigó, J.é M.; Wan, X.-F. 2013: A perspective on multiple waves of influenza pandemics. Plos one 8(4): E60343

Cluff, T.; Crevecoeur, F.éd.ér.; Scott, S.H. 2015: A perspective on multisensory integration and rapid perturbation responses. Vision Research 110(Part B): 215-222

Witzany, Günther. 2009: A perspective on natural genetic engineering and natural genome editing. Introduction. Annals of the New York Academy of Sciences 1178: 1-5

Heinrich, M.; Frei Haller, B.; Leonti, M. 2014: A perspective on natural products research and ethnopharmacology in Mexico: the eagle and the serpent on the prickly pear cactus. Journal of Natural Products 77(3): 678-689

Brady, S.; Morfini, G. 2010: A perspective on neuronal cell death signaling and neurodegeneration. Molecular Neurobiology 42(1): 25-31

Prendergast, G.C.; Metz, R. 2012: A perspective on new immune adjuvant principles: Reprogramming inflammatory states to permit clearance of cancer cells and other age-associated cellular pathologies. Oncoimmunology 1(6): 924-929

Norman, P. 2011: A perspective on nonresonant and resonant electronic response theory for time-dependent molecular properties. Physical Chemistry Chemical Physics: Pccp 13(46): 20519-20535

Aubry, G.; Lu, H. 2014: A perspective on optical developments in microfluidic platforms for Caenorhabditis elegans research. Biomicrofluidics 8(1): 011301

Fox, M.A. 2009: A perspective on organic chemistry: physical organic chemistry. Journal of Organic Chemistry 74(22): 8497-8509

Wolf, J.A.; Hanson, H.; Moir, M.J. 2011: A perspective on organizational well-being. Advances in Health Care Management 10: Xxi-Xxvi

Li, X.; Ballerini, D.R.; Shen, W. 2012: A perspective on paper-based microfluidics: Current status and future trends. Biomicrofluidics 6(1): 11301-1130113

Hannapel, D.J. 2013: A perspective on photoperiodic phloem-mobile signals that control development. Frontiers in Plant Science 4: 295

Platz, M.S. 2014: A perspective on physical organic chemistry. Journal of Organic Chemistry 79(6): 2341-2353

Nair, P.; Zhang, Q.; Brennan, J.D. 2015: A perspective on point-of-care tests to detect eosinophilic bronchitis. Journal of Asthma: Official Journal of the Association for the Care of Asthma 52(3): 254-261

Utter, F.; Seeb, J. 2010: A perspective on positive relationships between genetic diversity and abundance in fishes. Molecular Ecology 19(22): 4831-4833

Butson, F.J.; Sangster, J.F. 1972: A perspective on preceptor training. Canadian Family Physician Medecin de Famille Canadien 18(6): 73-76

Kiser, P.F.; Mesquita, P.M.M.; Herold, B.C. 2012: A perspective on progress and gaps in HIV prevention science. Aids Research and Human Retroviruses 28(11): 1373-1378

Ahmad, Y.; Lamond, A.I. 2014: A perspective on proteomics in cell biology. Trends in Cell Biology 24(4): 257-264

La Salvia, E.; Chemali, Z. 2011: A perspective on psychosis in late life and deficits in social cognition. Harvard Review of Psychiatry 19(4): 190-197

Bowen, J.P.; Güner, O.F. 2013: A perspective on quantum mechanics calculations in ADMET predictions. Current Topics in Medicinal Chemistry 13(11): 1257-1272

Sheehan, J.; Steiner, L. 2013: A perspective on radiosurgery: creativity, elegance, simplicity, and flexibility to change. World Neurosurgery 80(1-2): 83-86

Jarvis, R.A. 1983: A perspective on range finding techniques for computer vision. IEEE Transactions on Pattern Analysis and Machine Intelligence 5(2): 122-139

Conti, M. 2007: A perspective on rational drug design with cyclopentenone: targeting the proteome with the cyclopentenone chemical moiety. Expert Opinion on Drug Discovery 2(9): 1153-1159

Adams, K.F.; Ghali, J.K.; Herbert Patterson, J.; Stough, W.G.; Butler, J.; Bauman, J.L.; Ventura, H.O.; Sabbah, H.; Mackowiak, J.I.; van Veldhuisen, D.J. 2014: A perspective on re-evaluating digoxin's role in the current management of patients with chronic systolic heart failure: targeting serum concentration to reduce hospitalization and improve safety profile. European Journal of Heart Failure 16(5): 483-493

Gacek, R.R. 2013: A perspective on recurrent vertigo. Orl; Journal for Oto-Rhino-Laryngology and its Related Specialties 75(2): 91-107

Mohs, R.C. 2008: A perspective on risks that impede development of drugs to modify the course of Alzheimer's disease: can they be reduced?. Alzheimer's and Dementia: the Journal of the Alzheimer's Association 4(1 Suppl 1: S85-S87

Netravali, N.A.; Shen, F.; Park, Y.; Bargar, W.L. 2013: A perspective on robotic assistance for knee arthroplasty. Advances in Orthopedics 2013: 970703

Etchegoin, P.G.; Le Ru, E.C. 2008: A perspective on single molecule SERS: current status and future challenges. Physical Chemistry Chemical Physics: Pccp 10(40): 6079-6089

Sansone, R.A.; Sansone, L.A. 2009: Tramadol: seizures, serotonin syndrome, and coadministered antidepressants. Psychiatry 6(4): 17-21

Chang, C.-C.; Yang, R.-J. 2009: A perspective on streaming current in silica nanofluidic channels: Poisson-Boltzmann model versus Poisson-Nernst-Planck model. Journal of Colloid and Interface Science 339(2): 517-520

Dunstone, N.J. 2014: A perspective on sustained marine observations for climate modelling and prediction. Philosophical Transactions. Series A Mathematical Physical and Engineering Sciences 372(2025)

Selby, M.D.; de Koning, P.D.; Roberts, D.F. 2011: A perspective on synthetic and solid-form enablement of inhalation candidates. Future Medicinal Chemistry 3(13): 1679-1701

Bhakat, S.; Karubiu, W.; Jayaprakash, V.; Soliman, M.E.S. 2014: A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, West Nile and Chikungunya viruses. European Journal of Medicinal Chemistry 87: 677-702

Giles, T.D. 2007: A perspective on telmisartan and cardiovascular risk. Reviews in Cardiovascular Medicine 8(3): 154-159

Alkemade, A.; Keuken, M.C.; Forstmann, B.U. 2013: A perspective on terra incognita: uncovering the neuroanatomy of the human subcortex. Frontiers in Neuroanatomy 7: 40

Brusick, D.J. 2009: A perspective on testing of existing pharmaceutical excipients for genotoxic impurities. Regulatory Toxicology and Pharmacology: Rtp 55(2): 200-204

Acuña-Soto, R.; Castañeda-Davila, L.; Chowell, G. 2011: A perspective on the 2009 A/H1N1 influenza pandemic in Mexico. Mathematical Biosciences and Engineering: Mbe 8(1): 223-238

Kubo, A.; Deardorff, J.; Laurent, C.A.; Ferrara, A.; Greenspan, L.C.; Quesenberry, C.P.; Kushi, L.H. 2018: Associations Between Maternal Obesity and Pregnancy Hyperglycemia and Timing of Puberty Onset in Adolescent Girls: A Population-Based Study. American Journal of Epidemiology 187(7): 1362-1369

Aker, A.M.; Johns, L.; McElrath, T.F.; Cantonwine, D.E.; Mukherjee, B.; Meeker, J.D. 2018: Associations between maternal phenol and paraben urinary biomarkers and maternal hormones during pregnancy: A repeated measures study. Environment International 113: 341-349

Wilson, J.A. 2010: A perspective on the Fe-based superconductors. Journal of Physics. Condensed Matter: An Institute of Physics Journal 22(20): 203201

Zhang, Q.; Ames, J.M.; Smith, R.D.; Baynes, J.W.; Metz, T.O. 2009: A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic disease. Journal of Proteome Research 8(2): 754-769

Kullo, I.J.; Trejo-Gutierrez, J.F.; Lopez-Jimenez, F.; Thomas, R.J.; Allison, T.G.; Mulvagh, S.L.; Arruda-Olson, A.M.; Hayes, S.N.; Pollak, A.W.; Kopecky, S.L.; Hurst, R.Todd. 2014: A perspective on the New American College of Cardiology/American Heart Association guidelines for cardiovascular risk assessment. Mayo Clinic proceedings 89(9): 1244-1256

Patnaik, A.Murali.Mohan.; Kejriwal, G.Shankar. 2012: A perspective on the PCPNDT Act. Indian Journal of Radiology and Imaging 22(2): 137-140

McDonald, S.M.; Yeo, S.; Liu, J.; Wilcox, S.; Sui, X.; Pate, R.R. 2018: Associations between maternal physical activity and fitness during pregnancy and infant birthweight. Preventive Medicine Reports 11: 1-6

Webber, M.J.; Khan, O.F.; Sydlik, S.A.; Tang, B.C.; Langer, R. 2015: A perspective on the clinical translation of scaffolds for tissue engineering. Annals of Biomedical Engineering 43(3): 641-656

Hamaker, B.R.; Tuncil, Y.E. 2014: A perspective on the complexity of dietary fiber structures and their potential effect on the gut microbiota. Journal of Molecular Biology 426(23): 3838-3850

Yu, H.; Tweedie, D. 2013: A perspective on the contribution of metabolites to drug-drug interaction potential: the need to consider both circulating levels and inhibition potency. Drug Metabolism and Disposition: the Biological Fate of Chemicals 41(3): 536-540

Guelfi, J.D. 2013: A perspective on the current issues in the DSM-5 classification of personality disorders. Dialogues in Clinical Neuroscience 15(2): 131-132

Worth, P.F. 2007: A perspective on the current issues in the diagnosis of Parkinson's disease. British Journal of Hospital Medicine 68(5): S6 S8

Casagrande, M.; Cremolini, C.; Loupakis, F.; Aprile, G. 2013: A perspective on the current management of advanced colorectal cancer. Future Oncology 9(11): 1687-1691

Sobel, B.E. 2010: A perspective on the development of coronary revascularization. Coronary Artery Disease 21(3): 199-203

Martinez-Arias, A. 2009: A perspective on the development of genetics in Spain during the XX century. International Journal of Developmental Biology 53(8-10): 1179-1191

Rush, B. 2012: A perspective on the effectiveness of interventions for alcohol and other substance use disorders. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 57(6): 339-341

Wiviott, S.D.; Braunwald, E.; Murphy, S.A.; Antman, E.M. 2008: A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. American Journal of Cardiology 101(9): 1367-1370

Ghoshal, A.; Mandal, C. 2011: A perspective on the emergence of sialic acids as potent determinants affecting leishmania biology. Molecular Biology International 2011: 532106

Kavanagh, K.; Abusalem, S.; Saman, D.M. 2012: A perspective on the evidence regarding methicillin-resistant Staphylococcus aureus surveillance. Journal of Patient Safety 8(3): 140-143

Diao, E. 2014: A perspective on the evolution of distal radius fracture treatment. American Journal of Orthopedics 43(8): 349-350

Rodgers, G.M. 2012: A perspective on the evolution of management of cancer- and chemotherapy-induced anemia. Journal of the National Comprehensive Cancer Network: Jnccn 10(4): 434-437

Hu, C.-P.; Li, M. 2009: A perspective on the evolving pattern of lung adenocarcinoma form pathogenesis of bronchioloalveolar carcinoma. Zhonghua Jie he He Hu Xi Za Zhi 32(11): 804

Wiedemann, H.P. 2008: A perspective on the fluids and catheters treatment trial (FACTT). Fluid restriction is superior in acute lung injury and ARDS. Cleveland Clinic Journal of Medicine 75(1): 42-48

Tarantola, D. 2008: A perspective on the history of health and human rights: from the Cold War to the Gold War. Journal of Public Health Policy 29(1): 42-53

Van Marle-Köster, E.é; Webb, E.C. 2014: A perspective on the impact of reproductive technologies on food production in Africa. Advances in Experimental Medicine and Biology 752: 199-211

Malijevský, A.; Jackson, G. 2012: A perspective on the interfacial properties of nanoscopic liquid drops. Journal of Physics. Condensed Matter: An Institute of Physics Journal 24(46): 464121

Constable, P.A. 2014: A perspective on the mechanism of the light-rise of the electrooculogram. Investigative Ophthalmology and Visual Science 55(4): 2669-2673

Trevors, J.T. 2012: A perspective on the mobilization, localization and delivery of molecules in the crowded bacterial cytoplasm. Current Issues in Molecular Biology 14(2): 39-46

Walker, A.M. 2009: A perspective on the nursing shortage. Surgical Neurology 71(1): 81-82

Sepucha, K.; Mulley, A.G. 2009: A perspective on the patient's role in treatment decisions. Medical Care Research and Review: Mcrr 66(1 Suppl): 53s-74s

Austin, S. 2009: A perspective on the patterns of loss, lack, disappointment and shame encountered in the treatment of six women with severe and chronic anorexia nervosa. Journal of analytical psychology 54(1): 61-80

Di, L.; Feng, B.; Goosen, T.C.; Lai, Y.; Steyn, S.J.; Varma, M.V.; Obach, R.S. 2013: A perspective on the prediction of drug pharmacokinetics and disposition in drug research and development. Drug Metabolism and Disposition: the Biological Fate of Chemicals 41(12): 1975-1993

Wong, K.; Xagoraraki, I. 2012: A perspective on the prevalence of DNA enteric virus genomes in anaerobic-digested biological wastes. Environmental Monitoring and Assessment 184(8): 5009-5016

Widmalm, G.ör. 2013: A perspective on the primary and three-dimensional structures of carbohydrates. Carbohydrate Research 378: 123-132

Goodkin, K.; Fernandez, F.; Forstein, M.; Miller, E.N.; Becker, J.T.; Douaihy, A.; Cubano, L.; Santos, F.H.; Filho, N.S.; Zirulnik, J.; Singh, D. 2011: A perspective on the proposal for neurocognitive disorder criteria in DSM-5 as applied to HIV-associated neurocognitive disorders. Neuropsychiatry 1(5): 431-440

Mecollari, V.; Nieuwenhuis, B.; Verhaagen, J. 2014: A perspective on the role of class IIi semaphorin signaling in central nervous system trauma. Frontiers in Cellular Neuroscience 8: 328

Lee, S.K.; Ding, J.L. 2013: A perspective on the role of extracellular hemoglobin on the innate immune system. Dna and Cell Biology 32(2): 36-40

Clark, R.D. 2012: A perspective on the role of quantitative structure-activity and structure-property relationships in herbicide discovery. Pest Management Science 68(4): 513-518

Al-Ubaidi, M.R.; Naash, M.I.; Conley, S.M. 2013: A perspective on the role of the extracellular matrix in progressive retinal degenerative disorders. Investigative Ophthalmology and Visual Science 54(13): 8119-8124

Hoffmann, G.R. 2009: A perspective on the scientific, philosophical, and policy dimensions of hormesis. Dose-Response: a Publication of International Hormesis Society 7(1): 1-51

Lemieux, M.J. 2008: A perspective on the structural studies of inner membrane electrochemical potential-driven transporters. Biochimica et Biophysica Acta 1778(9): 1805-1813

Somberg, J.C. 2013: A perspective on the support of scientific research. American Journal of Therapeutics 20(3): 231

Massad, M.G.; Prasad, S.M.; Chedrawy, E.G.; Lele, H. 2008: A perspective on the surgical management of congestive heart failure. World Journal of Surgery 32(3): 375-380

Botana, L.M. 2012: A perspective on the toxicology of marine toxins. Chemical Research in Toxicology 25(9): 1800-1804

Cooper, S.M. 1999: A perspective on the use of minocycline for rheumatoid arthritis. Journal of Clinical Rheumatology: Practical Reports on Rheumatic and Musculoskeletal Diseases 5(4): 233-237; Discussion: 237-238

Colmer, T.D.; Winkel, A.; Pedersen, O. 2011: A perspective on underwater photosynthesis in submerged terrestrial wetland plants. Aob Plants 2011: Plr030

Scheifele, D.W.; Tingle, A.J. 1993: A perspective on vaccine evaluation research in Canada: past and future. Canadian Journal of Infectious Diseases 4(2): 79-83

Mason, R.P.; Zhao, D.; Liu, L.; Trawick, M.L.; Pinney, K.G. 2011: A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment. Integrative Biology: Quantitative Biosciences from Nano to Macro 3(4): 375-387

Burlá, C.; Camarano, A.A.él.; Kanso, S.; Fernandes, D.; Nunes, R. 2013: A perspective overview of dementia in Brazil: a demographic approach. Ciencia and Saude Coletiva 18(10): 2949-2956

Wan Ab Naim, W.Naimah.; Ganesan, P.Balan.; Sun, Z.; Chee, K.Han.; Hashim, S.Amry.; Lim, E. 2014: A perspective review on numerical simulations of hemodynamics in aortic dissection. Thescientificworldjournal 2014: 652520

Rolla, M.; Berretta, R.; Patrelli, T.S.; Merisio, C.; Gramellini, D.; Fadda, G.M.; Bacchi Modena, A.; Nardelli, G.B. 2009: A perspective study on correlation between HPV DNA and lymph nodes in surgically treated cervical carcinoma patients. Preliminary data. European Journal of Gynaecological Oncology 30(5): 557-561

Ural, D. 2012: A perspective to lipid lowering therapy after ESC/EAS guidelines for the management of dyslipidaemias and the European guidelines on cardiovascular disease prevention in clinical practice. Turk Kardiyoloji Dernegi arsivi: Turk Kardiyoloji Derneginin yayin organidir 40(4): 293-297

Laughlin, R.B. 2014: A perspective: Robert B Laughlin. Physical Biology 11(5): 053003

Zhang, X.; Awad, H.A.; O'Keefe, R.J.; Guldberg, R.E.; Schwarz, E.M. 2008: A perspective: engineering periosteum for structural bone graft healing. Clinical Orthopaedics and Related Research 466(8): 1777-1787

Chaudhary, J. 2013: A perspective: from the policy world to the clinical world. Academic Psychiatry: the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry 37(5): 365-367

Warnecke, F.; Hess, M. 2009: A perspective: metatranscriptomics as a tool for the discovery of novel biocatalysts. Journal of Biotechnology 142(1): 91-95

Lu, X. 2010: A perspective: photosynthetic production of fatty acid-based biofuels in genetically engineered cyanobacteria. Biotechnology Advances 28(6): 742-746

Chung, H.H.; Jang, B.I. 2013: A perspective: role of targeted therapy in colon cancer. Korean Journal of Gastroenterology 61(3): 128-135

Nowrangi, M.A.; Kortte, K.B.; Rao, V.A. 2014: A perspectives approach to suicide after traumatic brain injury: case and review. Psychosomatics 55(5): 430-437

Wolf, R.K. 2005: A perspicacious view. Innovations 1(1): 1-2

Walji, M.F.; Coker, O.; Valenza, J.A.; Henson, H.; Warren-Morris, D.; Zhong, L. 2008: A persuasive toothbrush to enhance oral hygiene adherence. AMIA . Annual Symposium Proceedings. AMIA Symposium 2008: 1167

Artaud, I.; Galardon, E. 2014: A persulfide analogue of the nitrosothiol SNAP: formation, characterization and reactivity. Chembiochem: a European Journal of Chemical Biology 15(16): 2361-2364

Shi, P.-Z.; Qian, H. 2011: A perturbation analysis of rate theory of self-regulating genes and signaling networks. Journal of Chemical Physics 134(6): 065104

Marshall, B.D.; García-Cuéllar, A.J.; Chapman, W.G. 2012: A perturbation density functional theory for the competition between inter and intramolecular association. Journal of Chemical Physics 136(15): 154103

Au, K.K.C.; Pérez-Gómez, J.é; Neto, H.él.; Müller, C.; Meyer, A.J.; Fricker, M.D.; Moore, I. 2012: A perturbation in glutathione biosynthesis disrupts endoplasmic reticulum morphology and secretory membrane traffic in Arabidopsis thaliana. Plant Journal: for Cell and Molecular Biology 71(6): 881-894

Yong, Y.K.; Zhang, Z. 1993: A perturbation method for finite element modeling of piezoelectric vibrations in quartz plate resonators. IEEE Transactions on Ultrasonics Ferroelectrics and Frequency Control 40(5): 551-562

Gavignet, E.; Ballandras, S.; Bigler, E. 1997: A perturbation method for modeling the thermal sensitivity of surface transverse waves. IEEE Transactions on Ultrasonics Ferroelectrics and Frequency Control 44(1): 201-207

Eu, B.C.; Qin, Y. 2007: A perturbation method for the Ornstein-Zernike equation and the generic van der Waals equation of state for a square well potential model. Journal of Physical Chemistry. B 111(14): 3716-3726

Su, Y.-H.; Li, E.; Geiss, G.K.; Longabaugh, W.J.R.; Krämer, A.; Davidson, E.H. 2009: A perturbation model of the gene regulatory network for oral and aboral ectoderm specification in the sea urchin embryo. Developmental Biology 329(2): 410-421

Punal, V.M.; Roth, B.J. 2012: A perturbation solution of the mechanical bidomain model. Biomechanics and Modeling in Mechanobiology 11(7): 995-1000

Xie, L.; Wang, P.; Pan, X.Q. 2014: A perturbation theory study of electron vortices in electromagnetic fields: the case of infinitely long line charge and magnetic dipole. Micron 63: 9-14

Mansfield, A.; Peters, A.L.; Liu, B.A.; Maki, B.E. 2007: A perturbation-based balance training program for older adults: study protocol for a randomised controlled trial. BMC geriatrics 7: 12

Shiang, K.-D. 2009: A perturbation-based estimate algorithm for parameters of coupled ordinary differential equations, applications from chemical reactions to metabolic dynamics. Computer Methods and Programs in Biomedicine 94(2): 118-142

Massimini, M.; Boly, M.; Casali, A.; Rosanova, M.; Tononi, G. 2009: A perturbational approach for evaluating the brain's capacity for consciousness. Progress in Brain Research 177: 201-214

Jin, Z.; Tang, Y.; Wu, J. 2011: A perturbative density functional theory for square-well fluids. Journal of Chemical Physics 134(17): 174702

Endicott, J.S.; Joubert-Doriol, Lïc.; Izmaylov, A.F. 2014: A perturbative formalism for electronic transitions through conical intersections in a fully quadratic vibronic model. Journal of Chemical Physics 141(3): 034104

De Sarkar, S.; Sensarma, R.; Sengupta, K. 2014: A perturbative renormalization group approach to driven quantum systems. Journal of Physics. Condensed Matter: An Institute of Physics Journal 26(32): 325602

Echave, J.án.; Fernández, F.M. 2010: A perturbative view of protein structural variation. Proteins 78(1): 173-180

Ziv, I.; Matiuhin, Y.; Kirkpatrick, D.S.; Erpapazoglou, Z.; Leon, S.; Pantazopoulou, M.; Kim, W.; Gygi, S.P.; Haguenauer-Tsapis, R.; Reis, N.; Glickman, M.H.; Kleifeld, O. 2011: A perturbed ubiquitin landscape distinguishes between ubiquitin in trafficking and in proteolysis. Molecular and Cellular Proteomics: Mcp 10(5): M111.009753

Hochwald, O.; Bamberger, E.S.; Rubin, L.; Gershtein, R.; Srugo, I. 2010: A pertussis outbreak among daycare children in Northern Israel: who gets sick?. Israel Medical Association Journal: Imaj 12(5): 283-286

Lee, H.Y.; Kim, S.D.; Shim, J.W.; Kim, H.J.; Yun, J.; Baek, S.-H.; Kim, K.; Bae, Y.-S. 2010: A pertussis toxin sensitive G-protein-independent pathway is involved in serum amyloid A-induced formyl peptide receptor 2-mediated CCL2 production. Experimental and Molecular Medicine 42(4): 302-309

Conrad, G.W. 1978: A peruvian burial. Science 200(4342): 663-664

Yang, X.; Fraser, T.; Myat, D.; Smart, S.; Zhang, J.; Diniz da Costa, J.ão.C.; Liubinas, A.; Duke, M. 2014: A pervaporation study of ammonia solutions using molecular sieve silica membranes. Membranes 4(1): 40-54

Lee, S.I.; Ghasemzadeh, H.; Mortazavi, B.J.; Sarrafzadeh, M. 2013: A pervasive assessment of motor function: a lightweight grip strength tracking system. IEEE Journal of Biomedical and Health Informatics 17(6): 1023-1030

Aziz, O.; Atallah, L.; Lo, B.; Elhelw, M.; Wang, L.; Yang, G.Z.; Darzi, A. 2007: A pervasive body sensor network for measuring postoperative recovery at home. Surgical Innovation 14(2): 83-90

Triantafyllidis, A.K.; Koutkias, V.G.; Chouvarda, I.; Maglaveras, N. 2013: A pervasive health system integrating patient monitoring, status logging and social sharing. IEEE Journal of Biomedical and Health Informatics 17(1): 30-37

Abate, A.F.; Acampora, G.; Loia, V.; Ricciardi, S.; Vasilakos, A.V. 2010: A pervasive visual-haptic framework for virtual delivery training. IEEE Transactions on Information Technology in Biomedicine: a Publication of the IEEE Engineering in Medicine and Biology Society 14(2): 326-334

Yilma, Z.; van Kempen, L.; de Hoop, T. 2012: A perverse 'net' effect? Health insurance and ex-ante moral hazard in Ghana. Social Science and Medicine 75(1): 138-147

Kirschner, M. 2013: A perverted view of "impact". Science 340(6138): 1265

Chen, H.; Guan, Y.; Yuan, G.; Zhang, Q.; Jing, N. 2014: A perylene derivative regulates HIF-1α and Stat3 signaling pathways. Bioorganic and Medicinal Chemistry 22(4): 1496-1505

Slater, B.J.; Davies, E.S.; Argent, S.P.; Nowell, H.; Lewis, W.; Blake, A.J.; Champness, N.R. 2011: A perylene diimide rotaxane: synthesis, structure and electrochemically driven de-threading. Chemistry 17(52): 14746-14751

Novotny, P.; Colligan, R.C.; Szydlo, D.W.; Clark, M.M.; Rausch, S.; Wampfler, J.; Sloan, J.A.; Yang, P. 2010: A pessimistic explanatory style is prognostic for poor lung cancer survival. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 5(3): 326-332

Moore, J.A. 1979: A pesticide. Science 203(4382): 741-742

El-Attar, L.M.R.; Scott, S.; Goh, S.; Good, L. 2012: A pestivirus DNA vaccine based on a non-antibiotic resistance Escherichia coli essential gene marker. Vaccine 30(9): 1702-1709

Flanagan, R.J.; Watson, K.D. 2009: A petition to Mr Peel: Gideon Mantell and the trial of Hannah Russell. Medicine Science and the Law 49(3): 153-169

Rinner, B.; Kretschmer, N.; Knausz, H.; Mayer, A.; Boechzelt, H.; Hao, X-Jiang.; Heubl, G.; Efferth, T.; Schaider, H.; Bauer, R. 2010: A petrol ether extract of the roots of Onosma paniculatum induces cell death in a caspase dependent manner. Journal of Ethnopharmacology 129(2): 182-188

Van Aalst, P.M. 2007: A phaeochromocytoma in a Lhasa Apso dog. Tijdschrift Voor Diergeneeskunde 132(10): 393-395

Collier, A.; Ghosh, S.; Breckenridge, A.; Perry, C.G.; Freel, E.M.; Davidson, D.F. 2012: A phaeochromocytoma occurring in a patient with Parkinson's disease on L-dopa therapy: a diagnostic challenge. Clinical Endocrinology 76(5): 763-764

Xie, M.-H.; Wu, Q.-J.; Jiang, Y.-F.; Bao, P.; Zhang, Y. 2009: A phage RNA-binding protein binds to a non-cognate structured RNA and stabilizes its core structure. Biochemical and Biophysical Research Communications 378(2): 168-173

Skottrup, P.D.; Sørensen, G.; Ksiazek, M.; Potempa, J.; Riise, E. 2012: A phage display selected 7-mer peptide inhibitor of the Tannerella forsythia metalloprotease-like enzyme Karilysin can be truncated to Ser-Trp-Phe-Pro. Plos one 7(10): E48537

Solforosi, L.; Mancini, N.; Canducci, F.; Clementi, N.; Sautto, G.A.; Diotti, R.A.; Clementi, M.; Burioni, R. 2012: A phage display vector optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody fragments. New Microbiologica 35(3): 289-294

Staniszewska, M.; Gu, X.; Romano, C.; Kazlauskas, A. 2012: A phage display-based approach to investigate abnormal neovessels of the retina. Investigative Ophthalmology and Visual Science 53(8): 4371-4379

Chung, I.-Y.; Jang, H.-J.; Bae, H.-W.; Cho, Y.-H. 2014: A phage protein that inhibits the bacterial ATPase required for type IV pilus assembly. Proceedings of the National Academy of Sciences of the United States of America 111(31): 11503-11508

Sarris, P.F.; Ladoukakis, E.D.; Panopoulos, N.J.; Scoulica, E.V. 2014: A phage tail-derived element with wide distribution among both prokaryotic domains: a comparative genomic and phylogenetic study. Genome Biology and Evolution 6(7): 1739-1747

Kraemer, J.A.; Erb, M.L.; Waddling, C.A.; Montabana, E.A.; Zehr, E.A.; Wang, H.; Nguyen, K.; Pham, D.S.L.; Agard, D.A.; Pogliano, J. 2012: A phage tubulin assembles dynamic filaments by an atypical mechanism to center viral DNA within the host cell. Cell 149(7): 1488-1499

Hu, Z.-Q.; Li, H.-P.; Zhang, J.-B.; Huang, T.; Liu, J.-L.; Xue, S.; Wu, A.-B.; Liao, Y.-C. 2013: A phage-displayed chicken single-chain antibody fused to alkaline phosphatase detects Fusarium pathogens and their presence in cereal grains. Analytica Chimica Acta 764: 84-92

Meng, F.; Suo, S.; Zarlenga, D.S.; Cong, Y.; Ma, X.; Zhao, Q.; Ren, X. 2014: A phage-displayed peptide recognizing porcine aminopeptidase N is a potent small molecule inhibitor of PEDV entry. Virology 456-457: 20-27

Yano, S.T.; Rothman-Denes, L.B. 2011: A phage-encoded inhibitor of Escherichia coli DNA replication targets the DNA polymerase clamp loader. Molecular Microbiology 79(5): 1325-1338

Sawada, R.; Peterson, C.Y.; Gonzalez, A.M.; Potenza, B.M.; Mueller, B.; Coimbra, R.; Eliceiri, B.P.; Baird, A. 2011: A phage-targeting strategy for the design of spatiotemporal drug delivery from grafted matrices. Fibrogenesis and Tissue Repair 4: 7

Rocha, J.ão.J.E.; Korolchuk, V.I.; Robinson, I.M.; O'Kane, C.J. 2011: A phagocytic route for uptake of double-stranded RNA in RNAi. Plos one 6(4): E19087

Kato, S.; Koizumi, K.; Yamada, M.; Inujima, A.; Takeno, N.; Nakanishi, T.; Sakurai, H.; Nakagawa, S.; Saiki, I. 2010: A phagocytotic inducer from herbal constituent, pentagalloylglucose enhances lipoplex-mediated gene transfection in dendritic cells. Biological and Pharmaceutical Bulletin 33(11): 1878-1885

Ciumas, C.; Schaefers, G.; Bouvard, S.; Tailhades, E.; Perrin, E.; Comte, J.-C.; Canet-Soulas, E.; Bonnet, C.; Ibarrola, D.; Polo, G.; Moya, J.; Beuf, O.; Ryvlin, P. 2014: A phantom and animal study of temperature changes during fMRi with intracerebral depth electrodes. Epilepsy Research 108(1): 57-65

Lee, K.-C.; Lee, Y.-S.; Huang, G.-J.; Chan, H.-L.; Yu, J.-F. 2013: A phantom and in vivo study of mice following an ischemic stroke using sodium MRi. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference 2013: 1065-1068

Mathys, C.; Rybacki, K.; Wittsack, H.-J.ör.; Lanzman, R.S.; Miese, F.R.; Macht, S.; Eicker, S.; Meyer zu Hörste, G.; Antoch, G.; Turowski, B. 2012: A phantom approach to interscanner comparability of computed tomographic brain perfusion parameters. Journal of Computer Assisted Tomography 36(6): 732-738

Verburg, F.A.; Romijn, R.L.; Nekolla, S.; Verzijlbergen, J.F. 2009: A phantom assessment of cold stomach-related artifacts in myocardial perfusion imaging. Nuclear Medicine Communications 30(7): 569-573

Krohn, T.; Verburg, F.A.; Brockmann, H.; Winz, O.H.; Mottaghy, F.M.; Behrendt, F.F. 2012: A phantom assessment of portable imaging and radio-guided surgery systems with technetium-99m and fluorine-18. Nuclear Medicine Communications 33(5): 452-458

Bertram, R.; Rhoads, J.; Cimbora, W.P. 2008: A phantom bursting mechanism for episodic bursting. Bulletin of Mathematical Biology 70(7): 1979-1993

Johnson, E.A.; Ferguson, M.R.; Johnston, T.A.; Jones, T.K.; Law, Y.M. 2012: A phantom case of coarctation of the aorta. Circulation 126(25): E351-E353

Pallotta, S.; Marrazzo, L.; Ceroti, M.; Silli, P.; Bucciolini, M. 2012: A phantom evaluation of Sentinel(™), a commercial laser/camera surface imaging system for patient setup verification in radiotherapy. Medical Physics 39(2): 706-712

Tsukamoto, T.; Tanaka, H.; Yoshinaga, H.; Mitsumoto, T.; Maruhashi, A.; Ono, K.; Sakurai, Y. 2011: A phantom experiment for the evaluation of whole body exposure during BNCT using cyclotron-based epithermal neutron source (C-BENS). Applied Radiation and Isotopes: Including Data Instrumentation and Methods for use in Agriculture Industry and Medicine 69(12): 1830-1833

Stonehill, A.A. 1948: A phantom for animal eye surgery. American Journal of Ophthalmology 31(10): 1312

Furstoss, C.; Ménard, S.; Clairand, I.; Chau, Q. 2007: A phantom for effective dose measurement: organ dose distribution assessment based on a numerical approach. Radiation Protection Dosimetry 125(1-4): 180-184

Skretting, A.; Glomset, O.; Bogsrud, T.V. 2010: A phantom for investigation of tumour signal and noise in PET reconstruction with various smoothing filters: experiments and comparisons with simulated intensity diffusion. Radiation Protection Dosimetry 139(1-3): 191-194

Dunn, L.; Kron, T.; Taylor, M.L.; Callahan, J.; Franich, R.D. 2012: A phantom for testing of 4D-CT for radiotherapy of small lesions. Medical Physics 39(9): 5372-5383

Madebo, M.; Pillainayagam, J.; Kron, T.; Franich, R. 2012: A phantom for verification of dwell position and time of a high dose rate brachytherapy source. Australasian Physical and Engineering Sciences in Medicine 35(3): 335-339

Lai, C.-Y.; Kruse, D.; Seo, J.W.; Kheirolomoom, A.; Ferrara, K.W. 2013: A phantom for visualization of three-dimensional drug release by ultrasound-induced mild hyperthermia. Medical Physics 40(8): 083301

Xing, J.; Rochester, J.; Messer, C.K.; Reiter, B.P.; Korsten, M.A. 2007: A phantom gallbladder on endoscopic retrograde cholangiopancreatography. World Journal of Gastroenterology 13(46): 6274-6276

Misra, S.; Unnikrishnan, K.P.; Koshy, T.; Dash, P.K.; Panda, S. 2011: A phantom in the aortic valve: tumor, thrombus, or artifact?. Journal of Cardiothoracic and Vascular Anesthesia 25(2): 380-381

Fernandez, A.; Chen, E.; Moore, J.; Cheung, C.; Erdeljan, P.; Fuller, A.; McDougall, E.M.; Peters, T.M.; Pautler, S.E. 2012: A phantom model as a teaching modality for laparoscopic partial nephrectomy. Journal of Endourology 26(1): 1-5

Kissick, M.W.; Mo, X.; McCall, K.C.; Schubert, L.K.; Westerly, D.C.; Mackie, T.R. 2010: A phantom model demonstration of tomotherapy dose painting delivery, including managed respiratory motion without motion management. Physics in Medicine and Biology 55(10): 2983-2995

Ristolainen, A.; Colucci, G.; Kruusmaa, M. 2013: A phantom pig abdomen as an alternative for testing robotic surgical systems: our experience. Alternatives to Laboratory Animals: Atla 41(5): 359-367

Therriault-Proulx, F.; Briere, T.M.; Mourtada, F.; Aubin, S.; Beddar, S.; Beaulieu, L. 2011: A phantom study of an in vivo dosimetry system using plastic scintillation detectors for real-time verification of 192Ir HDR brachytherapy. Medical Physics 38(5): 2542-2551

Nielsen, M.S.; Carl, J.; Nielsen, J. 2008: A phantom study of dose compensation behind hip prosthesis using portal dosimetry and dynamic MLC. RadioTherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology 88(2): 277-284

Johnsson, A.A.; Svalkvist, A.; Vikgren, J.; Boijsen, M.; Flinck, A.; Kheddache, S.; Båth, M. 2010: A phantom study of nodule size evaluation with chest tomosynthesis and computed tomography. Radiation Protection Dosimetry 139(1-3): 140-143

Isambert, A.; Bonniaud, G.; Lavielle, F.; Malandain, G.; Lefkopoulos, D. 2008: A phantom study of the accuracy of CT, MR and PET image registrations with a block matching-based algorithm. Cancer Radiotherapie: Journal de la Societe Francaise de Radiotherapie Oncologique 12(8): 800-808

Tigges, S.; Arepalli, C.D.; Tridandapani, S.; Oshinski, J.; Kurz, C.R.; Richer, E.J.; Chen, Z.; Stillman, A.E.; Raggi, P. 2012: A phantom study of the effect of heart rate, coronary artery displacement and vessel trajectory on coronary artery calcium score: potential for risk misclassification. Journal of Cardiovascular Computed Tomography 6(4): 260-267

Chang, H.-H.; Lee, H.-F.; Sung, C.-C.; Liao, T.-I.; Huang, Y.-J. 2013: A phantom study of the immobilization and the indications for using virtual isocenter in stereoscopic X-ray image guidance system referring to position localizer in frameless radiosurgery. Journal of Applied Clinical Medical Physics 14(4): 4133

Bansal, A.K.; Semwal, M.K.; Arora, D.; Sharma, D.N.; Julka, P.K.; Rath, G.K. 2013: A phantom study on bladder and rectum dose measurements in brachytherapy of cervix cancer using FBX aqueous chemical dosimeter. Physica Medica: Pm: An International Journal Devoted to the Applications of Physics to Medicine and Biology: Official Journal of the Italian Association of Biomedical Physics 29(4): 368-373

Miyakoshi, M.; Tomiyasu, M.; Bagarinao, E.; Murakami, S.; Nakai, T. 2009: A phantom study on component segregation for MR images using ICA. Academic Radiology 16(8): 1025-1028

Yan, H.; Zhang, L.; Yin, F.-F. 2008: A phantom study on target localization accuracy using cone-beam computed tomography. Clinical Medicine. Oncology 2: 501-510

Padmanaban, S.; Boopathy, R.; Kunjithapatham, B.; Sukumar, P.; Nagarajan, V. 2010: A phantom study on the effects of target motion in non-gated kV-CBCT imaging. Australasian Physical and Engineering Sciences in Medicine 33(1): 59-64

Olsson, M-L.; Tingberg, A.; Mattsson, S. 2010: A phantom study showing the importance of compression in conventional diagnostic X-ray examinations. Radiation Protection Dosimetry 139(1-3): 78-80

Harikrishnaperumal, S.; Kurup, G.; Venkatraman, M.; Jagadeesan, V. 2012: A phantom study to determine the optimum size of a single collimator for shortening the treatment time in CyberKnife stereotactic radiosurgery of spherical targets. Journal of Applied Clinical Medical Physics 13(5): 3864

Mudaliar, A.V.; Ellis, B.E.; Ricketts, P.L.; Lanz, O.I.; Scott, E.P.; Diller, T.E. 2008: A phantom tissue system for the calibration of perfusion measurements. Journal of Biomechanical Engineering 130(5): 051002

De las Heras, H.; Schöfer, F.; Tiller, B.; Chevalier, M.; Zwettler, G.; Semturs, F. 2013: A phantom using titanium and Landolt rings for image quality evaluation in mammography. Physics in Medicine and Biology 58(8): L17-L30

Miao, H.; Wu, X.; Zhao, H.; Liu, H. 2012: A phantom-based calibration method for digital x-ray tomosynthesis. Journal of X-Ray Science and Technology 20(1): 17-29

Huggett, J.; Mukonoweshuro, W.; Loader, R. 2013: A phantom-based evaluation of three commercially available patient organ shields for computed tomography X-ray examinations in diagnostic radiology. Radiation Protection Dosimetry 155(2): 161-168

Morgat, C.ém.; Mazère, J.; Fernandez, P.; Buj, S.éb.; Vimont, D.; Schulz, J.ür.; Lamare, F.éd.ér. 2015: A phantom-based method to standardize dose-calibrators for new β+-emitters. Nuclear Medicine Communications 36(2): 201-206

Lahoz-Beneytez, J.; Schnizler, K.; Eissing, T. 2015: A pharma perspective on the systems medicine and pharmacology of inflammation. Mathematical Biosciences 260: 2-5

Park, J.S.; Shim, J.Y.; Nguyen, K.V.T.; Park, J.S.; Shin, S.; Choi, Y.W.; Lee, J.; Yoon, J.-H.; Jeong, S.H. 2010: A pharma-robust design method to investigate the effect of PEG and PEO on matrix tablets. International Journal of Pharmaceutics 393(1-2): 79-87

Eussen, S.R.B.M.; van der Elst, M.E.; Klungel, O.H.; Rompelberg, C.J.M.; Garssen, J.; Oosterveld, M.H.; de Boer, A.; de Gier, J.J.; Bouvy, M.L. 2010: A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Annals of PharmacoTherapy 44(12): 1905-1913

Harrison, L.I.; Stoesz, J.D.; Battiste, J.L.; Nelson, R.J.; Zarraga, I.E. 2009: A pharmaceutical comparison of different commercially available imiquimod 5% cream products. Journal of Dermatological Treatment 20(3): 1-5

Parente, S.T. 2009: A pharmaceutical economic stimulus plan. Minnesota Medicine 92(5): 38-39

Hartman, R.; Blustein, L.; Morel, D.; Davis, L. 2014: A pharmaceutical industry elective course on practice experience selection and fellowship pursuit by pharmacy students. American journal of pharmaceutical education 78(6): 126

Gastfriend, D.R. 2014: A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders. Annals of the new York Academy of Sciences 1327: 112-130

Hardt, R.A. 1956: A pharmaceutical manufacturer looks at the Food and Drug Administration. Antibiotics and ChemoTherapy 6(5): 316-318

Ling, S.; Luo, R.; Dai, A.; Guo, Z.; Guo, R.; Komesaroff, P.A. 2009: A pharmaceutical preparation of Salvia miltiorrhiza protects cardiac myocytes from tumor necrosis factor-induced apoptosis and reduces angiotensin II-stimulated collagen synthesis in fibroblasts. Phytomedicine: International Journal of PhytoTherapy and Phytopharmacology 16(1): 56-64

Peterson, N.T. 1947: A pharmacist analyses his prescription practice. Journal of the American Pharmaceutical Association. American Pharmaceutical Association 8(4): 203

Gerber, B.S.; Cano, A.I.; Caceres, M.L.; Smith, D.E.; Wilken, L.A.; Michaud, J.B.; Ruggiero, L.A.; Sharp, L.K. 2010: A pharmacist and health promoter team to improve medication adherence among Latinos with diabetes. Annals of PharmacoTherapy 44(1): 70-79

Chan, C-Wai.; Siu, S-Chung.; Wong, C.K.W.; Lee, V.W.Y. 2012: A pharmacist care program: positive impact on cardiac risk in patients with type 2 diabetes. Journal of Cardiovascular Pharmacology and Therapeutics 17(1): 57-64

Devaux, G.; Méré, P. 2012: A pharmacist designer and manufacturer of veterinarian patent medicines, Paul Méré, de Chantilly. Revue d'Histoire de la Pharmacie 59(372): 485-502

Tye, A. 1947: A pharmacist in North China. Australasian Journal of Pharmacy 28(333): 936

Devaux, G.; Arléry, S.; Lechaux, M.Victor.Julien. 2014: A pharmacist specialist in Bordeaux at the end of XIXth century, Marie, Victor Julien Lechaux (1840-1900). Revue d'histoire de la pharmacie 62(382): 237-250

Edwards, H.D.; Webb, R.D.; Scheid, D.C.; Britton, M.L.; Armor, B.L. 2012: A pharmacist visit improves diabetes standards in a patient-centered medical home (PCMH). American Journal of Medical Quality: the Official Journal of the American College of Medical Quality 27(6): 529-534

Swain, L.D. 2012: A pharmacist's contribution to an ambulatory neurology clinic. Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists 27(1): 49-57

Haddad, A.R.; Coover, K.; Faulkner, M. 2007: A pharmacist's introduction to the effects of aging on patients with cerebral palsy. Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists 22(8): 669-674

Miesner, A.R. 2014: A pharmacist's reflection on serving as a preceptor to a medical student. American Journal of Pharmaceutical Education 78(1): 23

Roberts, R.W.; Russell, W.L. 2007: A pharmacist-based toxicology service. 1978. Annals of PharmacoTherapy 41(10): 1719-1724

Verrue, C.; Mehuys, E.; Boussery, K.; Adriaens, E.; Remon, J.P.; Petrovic, M. 2012: A pharmacist-conducted medication review in nursing home residents: impact on the appropriateness of prescribing. Acta clinica Belgica 67(6): 423-429

Gallimore, C.; Kushner, K. 2013: A pharmacist-guided protocol for improved monitoring of patients on antidepressants. Wmj: Official Publication of the State Medical Society of Wisconsin 112(3): 124-128

Garcia, B.Hennie.; Storli, S.Lisa.; Småbrekke, L. 2014: A pharmacist-led follow-up program for patients with coronary heart disease in North Norway--a qualitative study exploring patient experiences. Bmc Research Notes 7: 197

Lee, C.Yin.; George, J.; Elliott, R.A.; Stewart, K. 2011: A pharmacist-led intervention for increasing the uptake of Home Medicines Review (HMR) among residents of retirement villages (PHARMER): protocol for a cluster randomised controlled trial. BMC health services research 11: 292

Magid, D.J.; Olson, K.L.; Billups, S.J.; Wagner, N.M.; Lyons, E.E.; Kroner, B.A. 2013: A pharmacist-led, American Heart Association Heart360 Web-enabled home blood pressure monitoring program. Circulation. Cardiovascular quality and outcomes 6(2): 157-163

You, A.; Kawamoto, J.; Smith, J.P. 2014: A pharmacist-managed telemedicine clinic for hepatitis C care: a descriptive analysis. Journal of Telemedicine and Telecare 20(2): 99-101

Pietrzak, B.ła.; Zwierzyńska, E.; Krupa, A. 2014: A pharmaco-EEG-based assessment of the interaction between ethanol and zonisamide. Alcohol and Alcoholism 49(5): 505-514

Treur, M.; Heeg, B.; Möller, H.-J.ür.; Schmeding, A.; van Hout, B. 2009: A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss. Bmc Health Services Research 9: 32

Oedegaard, K.J.; Riise, T.; Dilsaver, S.C.; Lund, A.; Akiskal, H.S.; Fasmer, O.B.; Hundal, Øi. 2011: A pharmaco-epidemiological study of migraine and antidepressant medications: complete one year data from the Norwegian population. Journal of Affective Disorders 129(1-3): 198-204

Sonibare, M.A.; Oke, T.A.; Soladoye, M.O. 2014: A pharmacobotanical study of two medicinal species of Fabaceae. Asian Pacific Journal of Tropical Biomedicine 4(2): 131-136

Eagye, K.J.; Nicolau, D.P.; Lockhart, S.R.; Quinn, J.P.; Doern, G.V.; Gallagher, G.; Abramson, M.A. 2007: A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004. Annals of Clinical Microbiology and Antimicrobials 6: 11

Angiolillo, D.J.; Badimon, J.J.; Saucedo, J.F.; Frelinger, A.L.; Michelson, A.D.; Jakubowski, J.A.; Zhu, B.; Ojeh, C.K.; Baker, B.A.; Effron, M.B. 2011: A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy in diabetes MellitUS (OPTIMUS)-3 Trial. European Heart Journal 32(7): 838-846

Curl, L.; Barker, C.; Dreyer, C.; Sampson, W. 2012: A pharmacodynamic investigation into the efficacy of osteoprotegerin during aseptic inflammation. Australian Orthodontic Journal 28(2): 219-224

Tham, L.-S.; Wang, L.; Soo, R.A.; Lee, S.-C.; Lee, H.-S.; Yong, W.-P.; Goh, B.-C.; Holford, N.H.G. 2008: A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 14(13): 4213-4218

Mistry, H.B.; MacCallum, D.E.; Jackson, R.C.; Chaplain, M.A.J.; Davidson, F.A. 2010: A pharmacodynamic model of Aurora kinase inhibitors in the spindle assembly checkpoint. Frontiers in Bioscience 15(1): 249-258

Jackson, R.C.; Radivoyevitch, T. 2014: A pharmacodynamic model of Bcr-Abl signalling in chronic myeloid leukaemia. Cancer ChemoTherapy and Pharmacology 74(4): 765-776

Zhang, T.; Xu, X.-Y.; Zhou, H.; Zhao, X.; Song, M.; Zhang, T.-T.; Yin, H.; Li, T.; Li, P.-T.; Cai, D.-Y. 2012: A pharmacodynamic model of portal hypertension in isolated perfused rat liver. World Journal of Gastroenterology 18(5): 472-478

Ni, W.-t.; Liang, B.-b.; Cai, Y.; Liu, Y.-p.; Bai, N.; Cui, J.-c.; Wang, R. 2014: A pharmacodynamic simulation to evaluate tigecycline in treatment of nosocomial pneumonia caused by multidrug-resistant Acinetobacter baumannii. Pakistan Journal of Pharmaceutical Sciences 27(3): 463-467

Kiffer, C.R.V.; Kuti, J.L.; Mendes, C.M.F.; Oplustil, C.P.; Amarante, J.B.; Biancalana, M.L.; Xavier, N.; Nicolau, D.P. 2007: A pharmacodynamic strategy to optimize empirical antibiotic therapy for gram-negative bacteria in a Brazilian Intensive Care Unit. Brazilian Journal of Infectious Diseases: An Official Publication of the Brazilian Society of Infectious Diseases 11(2): 183-185

Kelly, R.J.; Draper, D.; Chen, C.C.; Robey, R.W.; Figg, W.D.; Piekarz, R.L.; Chen, X.; Gardner, E.R.; Balis, F.M.; Venkatesan, A.M.; Steinberg, S.M.; Fojo, T.; Bates, S.E. 2011: A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 17(3): 569-580

Armstrong, A.J.; Netto, G.J.; Rudek, M.A.; Halabi, S.; Wood, D.P.; Creel, P.A.; Mundy, K.; Davis, S.L.; Wang, T.; Albadine, R.; Schultz, L.; Partin, A.W.; Jimeno, A.; Fedor, H.; Febbo, P.G.; George, D.J.; Gurganus, R.; De Marzo, A.M.; Carducci, M.A. 2010: A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 16(11): 3057-3066

Pratz, K.W.; Cortes, J.; Roboz, G.J.; Rao, N.; Arowojolu, O.; Stine, A.; Shiotsu, Y.; Shudo, A.; Akinaga, S.; Small, D.; Karp, J.E.; Levis, M. 2009: A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood 113(17): 3938-3946

Kelly, R.J.; Robey, R.W.; Chen, C.C.; Draper, D.; Luchenko, V.; Barnett, D.; Oldham, R.K.; Caluag, Z.; Frye, A.Robin.; Steinberg, S.M.; Fojo, T.; Bates, S.E. 2012: A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors. Oncologist 17(4): 512

Wang, X.; Lee, W.Y.W.; Zhou, X.; Or, P.M.Y.; Yeung, J.H.K. 2010: A pharmacodynamic-pharmacokinetic (PD-PK) study on the effects of Danshen (Salvia miltiorrhiza) on midazolam, a model CYP3A probe substrate, in the rat. Phytomedicine: International Journal of PhytoTherapy and Phytopharmacology 17(11): 876-883

Tabernero, J.; Elez, M.E.; Herranz, M.; Rico, I.; Prudkin, L.; Andreu, J.; Mateos, J.; Carreras, M.J.; Han, M.; Gifford, J.; Credi, M.; Yin, W.; Agarwal, S.; Komarnitsky, P.; Baselga, J. 2014: A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 20(10): 2793-2804

Yang, X.; Dong, X.-G.; Liu, A.-M.; Sun, S.-Y.; Xie, L.-X.; Wang, S.-G. 2007: A pharmacodynamics study of an intravitreal amphotericin B drug delivery system for the treatment of experimental Aspergillus fumigatus endophthalmitis. Chinese Journal of Ophthalmology 43(6): 546-553

Damen, J.; Thuresson, P.-O.; Heeg, B.; Lothgren, M. 2008: A pharmacoeconomic analysis of compliance gains on antipsychotic medications. Applied Health Economics and Health Policy 6(4): 189-197

Guardia, C.G.; Moya, F.R.; Sinha, S.; Simmons, P.D.; Segal, R.; Greenspan, J.S. 2012: A pharmacoeconomic analysis of in-hospital costs resulting from reintubation in preterm infants treated with lucinactant, beractant, or poractant alfa. Journal of Pediatric Pharmacology and Therapeutics: Jppt: the Official Journal of Ppag 17(3): 220-227

Clifford, T.M.; Johnston, T.D.; Jeon, H.; Gedaly, R.; Ranjan, D. 2007: A pharmacoeconomic analysis of liver transplant charges. Progress in Transplantation 17(4): 310-314

Lindström, E.; Eberhard, J.; Fors, B.ör.M.; Hansen, K.; Sapin, C. 2011: A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden. Nordic Journal of Psychiatry 65(6): 403-413

Staidle, J.P.; Dabade, T.S.; Feldman, S.R. 2011: A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opinion on PharmacoTherapy 12(13): 2041-2054

Lai, P.L.; Panatto, D.; Gasparini, R. 2011: A pharmacoeconomic appraisal of the strategy to tackle the H1N1v (A/California/07/09) pandemic in Italy: relevance of the CIRI-IV surveillance system. Journal of Preventive Medicine and Hygiene 52(3): 142-143

Yan, X.; Hu, H.-T.; Liu, S.; Sun, Y.-H.; Gao, X. 2015: A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China. Neurological Research 37(4): 352-358

Balabanov, P.P.; Zahariev, Z.I. 2006: A pharmacoeconomic comparison of monotherapy with Tegretol, Finlepsin and Trileptal (preliminary data). Folia Medica 48(2): 37-43

Marchetti, A.; Lapensee, K.; Wang, L. 1997: A pharmacoeconomic evaluation of staging modalities for patients with newly diagnosed and occult recurrent adenocarcinoma of the prostate. Urologic Oncology 3(5-6): 154-165

Fendrick, A.Mark. 2010: A pharmacoeconomic perspective on stroke prevention in atrial fibrillation. American Journal of Managed Care 16(10 Suppl): S284-S290

Bansback, N.; Brennan, A.; Anis, A.H. 2005: A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis. Expert Review of Pharmacoeconomics and Outcomes Research 5(5): 519-529

Simoens, S.; Decramer, M. 2008: A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin. Expert Opinion on PharmacoTherapy 9(10): 1735-1744

Khattak, S.K.; Mehsud, S.U.; Haider, I.Z.; Burki, M.R. 2012: A pharmacoeconomic study in two tertiary care hospitals in Abbottabad. Journal of Ayub Medical College Abbottabad: Jamc 24(2): 147-149

Shagrova, E.V.; Orekhova, N.V.; Vlasov, P.N.; Leonova, M.V.; Shchderkina, I.O. 2013: A pharmacoeconomical analysis of idiopathic epilepsy. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 113(4 Part 2): 71-75

Cavanaugh, T.M.; Buring, S.; Cluxton, R. 2012: A pharmacoeconomics and formulary management collaborative project to teach decision analysis principles. American Journal of Pharmaceutical Education 76(6): 115

Zedler, B.K.; Joyce, A.; Murrelle, L.; Kakad, P.; Harpe, S.E. 2011: A pharmacoepidemiologic analysis of the impact of calendar packaging on adherence to self-administered medications for long-term use. Clinical therapeutics 33(5): 581-597

Crentsil, V.; Ricks, M.O.; Xue, Q.-L.; Fried, L.P. 2010: A pharmacoepidemiologic study of community-dwelling, disabled older women: Factors associated with medication use. American Journal of Geriatric PharmacoTherapy 8(3): 215-224

Vella, S-Legigh.; Pai, N. 2011: A pharmacoepidemiological analysis of clozapine use in a region of Australia. Acta psychiatrica Scandinavica 124(5): 413-4; author reply 414

Fredheim, O.M.S.; Borchgrevink, P.C.; Mahic, M.; Skurtveit, S. 2013: A pharmacoepidemiological cohort study of subjects starting strong opioids for nonmalignant pain: a study from the Norwegian Prescription Database. Pain 154(11): 2487-2493

Reis, B.Y.; Olson, K.L.; Tian, L.; Bohn, R.L.; Brownstein, J.S.; Park, P.J.; Cziraky, M.J.; Wilson, M.D.; Mandl, K.D. 2012: A pharmacoepidemiological network model for drug safety surveillance: statins and rhabdomyolysis. Drug Safety 35(5): 395-406

Abasolo-Osinaga, E.; Abecia-Inchaurregui, L.C.; Etxeandia-Ikobaltzeta, I.; Burgos-Alonso, N.; García-del Pozo, J. 2008: A pharmacoepidemiological study of antiepileptic drug consumption (1992-2004). Revista de Neurologia 46(8): 449-453

Mino-León, D.; Galván-Plata, M.E.; Doubova, S.V.; Flores-Hernandez, S.; Reyes-Morales, H. 2011: A pharmacoepidemiological study of potential drug interactions and their determinant factors in hospitalized patients. Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion 63(2): 170-178

Osinaga, E.Abasolo.; Inchaurregui, L.Carlos.Abecia.; Ikobaltzeta, I.Etxeandia.; Alonso, N.Burgos.; Del Pozo, J.García. 2007: A pharmacoepidemiological study of the consumption of antiparkinson drugs in the Basque Autonomous Community (Spain) (1992-2004). Parkinsonism and Related Disorders 13(8): 500-504

Gesualdo, L.; London, G.ér.; Turner, M.; Lee, C.; Macdonald, K.; Goldsmith, D.; Covic, A.; Zaoui, P.; Combe, C.; Mann, J.; Dellanna, F.; Muenzberg, M.; Abraham, I. 2013: A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study. Internal and Emergency Medicine 8(5): 389-399

Gamazon, E.R.; Zhang, W.; Huang, R.S.; Dolan, M.E.; Cox, N.J. 2009: A pharmacogene database enhanced by the 1000 Genomes Project. Pharmacogenetics and Genomics 19(10): 829-832

Brugts, J.J.; Isaacs, A.; de Maat, M.Pm.; Boersma, E.; van Duijn, C.M.; Akkerhuis, K.Martijn.; Uitterlinden, A.G.; Witteman, J.Cm.; Cambien, F.; Ceconi, C.; Remme, W.; Bertrand, M.; Ninomiya, T.; Harrap, S.; Chalmers, J.; Macmahon, S.; Fox, K.; Ferrari, R.; Simoons, M.L.; Danser, A.Jan. 2011: A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. Journal of Hypertension 29(3): 509-519

Wu, X.; Katz, E.; Della Valle, M.C.; Mascioli, K.; Flanagan, J.J.; Castelli, J.P.; Schiffmann, R.; Boudes, P.; Lockhart, D.J.; Valenzano, K.J.; Benjamin, E.R. 2011: A pharmacogenetic approach to identify mutant forms of α-galactosidase a that respond to a pharmacological chaperone for Fabry disease. Human Mutation 32(8): 965-977

Tkáč, I.; Javorský, M.; Klimčáková, L.; Židzik, J.; Gaľa, I.; Babjaková, E.; Schroner, Z.; Štolfová, Mária.; Hermanová, H.; Habalová, V. 2015: A pharmacogenetic association between a variation in calpain 10 (CAPN10) gene and the response to metformin treatment in patients with type 2 diabetes. European Journal of Clinical Pharmacology 71(1): 59-63

Vallender, E.J.; Rüedi-Bettschen, D.; Miller, G.M.; Platt, D.M. 2010: A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys. Drug and Alcohol Dependence 109(1-3): 252-256

De Graan, A.-J.M.; Elens, L.; Smid, M.; Martens, J.W.; Sparreboom, A.; Nieuweboer, A.J.M.; Friberg, L.E.; Elbouazzaoui, S.; Wiemer, E.A.C.; van der Holt, B.; Verweij, J.; van Schaik, R.H.N.; Mathijssen, R.H.J. 2013: A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 19(18): 5210-5217

Ramírez, J.; Kim, T.W.; Liu, W.; Myers, J.L.; Mirkov, S.; Owzar, K.; Watson, D.; Mulkey, F.; Gamazon, E.R.; Stock, W.; Undevia, S.; Innocenti, F.; Ratain, M.J. 2014: A pharmacogenetic study of aldehyde oxidase i in patients treated with XK469. Pharmacogenetics and Genomics 24(2): 129-132

Owley, T.; Brune, C.W.; Salt, J.; Walton, L.; Guter, S.; Ayuyao, N.; Gibbons, R.D.; Leventhal, B.L.; Cook, E.H. 2010: A pharmacogenetic study of escitalopram in autism spectrum disorders. Autism Research: Official Journal of the International Society for Autism Research 3(1): 1-7

Wu, X.; Zhu, X.; Zhu, S.; Li, J.; Ma, J.; Li, Z.; Li, H.; Liu, Y. 2009: A pharmacogenetic study of polymorphisms in interferon pathway genes and response to interferon-alpha treatment in chronic hepatitis B patients. Antiviral Research 83(3): 252-256

Xiong, Y.; Wei, Z.; Huo, R.; Wu, X.; Shen, L.; Li, Y.; Gong, X.; Wu, Z.; Feng, G.; Li, W.; He, L.; Xing, Q.; Qin, S. 2014: A pharmacogenetic study of risperidone on chemokine (C-C motif) ligand 2 (CCL2) in Chinese Han schizophrenia patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry 51: 153-158

Kang, S.P.; Ramirez, J.; House, L.; Zhang, W.; Mirkov, S.; Liu, W.; Haverfield, E.; Ratain, M.J. 2010: A pharmacogenetic study of vorinostat glucuronidation. Pharmacogenetics and Genomics 20(10): 638-641

Cecchin, E.; De Mattia, E.; Mazzon, G.; Cauci, S.; Trombetta, C.; Toffoli, G. 2014: A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation. International Journal of Biological Markers 29(4): E310-E316

Kimmel, S.E.; French, B.; Kasner, S.E.; Johnson, J.A.; Anderson, J.L.; Gage, B.F.; Rosenberg, Y.D.; Eby, C.S.; Madigan, R.A.; McBane, R.B.; Abdel-Rahman, S.Z.; Stevens, S.M.; Yale, S.; Mohler, E.R.; Fang, M.C.; Shah, V.; Horenstein, R.B.; Limdi, N.A.; Muldowney, J.A.S.; Gujral, J.; Delafontaine, P.; Desnick, R.J.; Ortel, T.L.; Billett, H.H.; Pendleton, R.C.; Geller, N.L.; Halperin, J.L.; Goldhaber, S.Z.; Caldwell, M.D.; Califf, R.M.; Ellenberg, J.H.; McBane, R.D.; Metzger, K.; Lexvold, N.; Streichert-Blair, A.; Wysokinski, W.; Ransone, T.; Randolph, J.; Bla 2013: A pharmacogenetic versus a clinical algorithm for warfarin dosing. New England Journal of Medicine 369(24): 2283-2293

Colognato, R.; Aiello, R.; Dulcetti, F.; Ruggeri, A.M.; De Toffol, S.; Marcato, L.; Irollo, A.M.; Criscuolo, C.; Gangale, M.F.; Maggi, F.; Simoni, G. 2014: A pharmacogenetic-driven approach for controlled ovarian hyperstimulation by FSH treatment. Minerva Ginecologica 66(6): 543-549

Drozda, K.; Labinov, Y.; Jiang, R.; Thomas, M.R.; Wong, S.S.; Patel, S.; Nutescu, E.A.; Cavallari, L.H. 2013: A pharmacogenetics service experience for pharmacy students, residents, and fellows. American journal of pharmaceutical education 77(8): 175

Zabala-Fernández, W.; Barreiro-de Acosta, M.; Echarri, A.; Carpio, D.; Lorenzo, A.; Castro, J.; Martínez-Ares, D.; Pereira, S.; Martin-Granizo, I.; Corton, M.; Carracedo, A.; Barros, F. 2011: A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving Azathioprine. Journal of Gastrointestinal and Liver Diseases: Jgld 20(3): 247-253

Benoit-Biancamano, M.-O.; Adam, J.-P.; Bernard, O.; Court, M.H.; Leblanc, M.-H.él.èn.; Caron, P.; Guillemette, C. 2009: A pharmacogenetics study of the human glucuronosyltransferase UGT1A4. Pharmacogenetics and Genomics 19(12): 945-954

Kitchens, J.W.; Kassem, N.; Wood, W.; Stone, T.W.; Isernhagen, R.; Wood, E.; Hancock, B.A.; Radovich, M.; Waymire, J.; Li, L.; Schneider, B.P. 2013: A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration. Clinical Ophthalmology 7: 1987-1993

Lacchini, R.; Silva, P.S.; Tanus-Santos, J.E. 2010: A pharmacogenetics-based approach to reduce cardiovascular mortality with the prophylactic use of statins. Basic and Clinical Pharmacology and Toxicology 106(5): 357-361

Chen, J.; Shao, L.; Gong, L.; Luo, F.; Wang, J.'e.; Shi, Y.; Tan, Y.; Chen, Q.; Zhang, Y.; Hui, R.; Wang, Y. 2014: A pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients. Plos one 9(8): E105250

Johnson, M.P.; Fernandez, F.; Colson, N.J.; Griffiths, L.R. 2007: A pharmacogenomic evaluation of migraine therapy. Expert Opinion on PharmacoTherapy 8(12): 1821-1835

Petty, W.J.; Knight, S.N.; Mosley, L.; Lovato, J.; Capellari, J.; Tucker, R.; Blackstock, A.W.; Miller, M.S.; Miller, A.A. 2007: A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 2(3): 197-202

Chen, K.K.; Chen, K. 2012: A pharmacognostic and chemical study of ma huang (Ephedra vulgaris var. helvetica). 1925. Journal of the American Pharmacists Association: Japha 52(3): 406-412

Klein, L.C.; de Andrade, S.ér.F.; Cechinel Filho, V. 2012: A pharmacognostic approach to the Polygala genus: phytochemical and pharmacological aspects. Chemistry and Biodiversity 9(2): 181-209

Bernard, B.M.; Pakianathan, N.; Venkataswamy, R.; Divakar, M.C. 1998: A pharmacognostic report on the leaf and root of polyscias fruticosa (L.) harms. Ancient Science of Life 18(2): 165-172

Chitra, M.; Thoppil, J.E. 2008: A pharmacognostical report on the rhizome of Alpinia galanga Linn. (Willd). Ancient Science of Life 27(4): 9-21

Wang, H.; Liu, J.-r.; Li, P.; Cheng, Y.-h. 2008: A pharmacognostical study on Nitraria tangutorum. Zhong Yao Cai 31(1): 28-29

Zamuner, S.; Rabiner, E.A.; Fernandes, S.A.; Bani, M.; Gunn, R.N.; Gomeni, R.; Ratti, E.; Cunningham, V.J. 2012: A pharmacokinetic PET study of NK₁ receptor occupancy. European Journal of Nuclear Medicine and Molecular Imaging 39(2): 226-235

Zimran, A.; Loveday, K.; Fratazzi, C.; Elstein, D. 2007: A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-Activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease. Blood Cells Molecules and Diseases 39(1): 115-118

Kowalski, M.; Stoker, D.G.; Bon, C.; Moore, K.A.; Boesing, S.E. 2010: A pharmacokinetic analysis of diclofenac potassium soft-gelatin capsule in patients after bunionectomy. American Journal of Therapeutics 17(5): 460-468

Monif, T.; Arora, V.; Madan, S.; Arora, R.; Balaji, A.; Jha, D.; Thudi, N.R. 2010: A pharmacokinetic and bioequivalence study of Contiflo ICON 400 µg tablets in healthy Indian subjects. International Journal of Clinical Pharmacology and Therapeutics 48(12): 868-876

Bannwarth, B.; Kostine, M.; Poursac, N. 2013: A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis. Expert Opinion on Drug Metabolism and Toxicology 9(6): 753-761

Davis, L.L.; Li, X.; Bartolucci, A.A.; Williford, R.B.; Lowe, J.S. 2007: A pharmacokinetic and clinical evaluation of switching patients with bipolar i disorder from delayed-release to extended-release divalproex. Journal of Clinical Psychiatry 68(10): 1546-1551

Yamamoto, N.; Sekine, I.; Nakagawa, K.; Takada, M.; Fukuoka, M.; Tanigawara, Y.; Saijo, N. 2009: A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia. Japanese Journal of Clinical Oncology 39(7): 425-430

Löfqvist, C.; Niklasson, A.; Engström, E.; Friberg, L.E.; Camacho-Hübner, C.; Ley, D.; Borg, J.; Smith, L.E.H.; Hellström, A. 2009: A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants. Pediatric Research 65(5): 574-579

Zheng, L.; Li, M.Ping.; Gou, Z.Ping.; Wang, Y.; Xu, N.; Cai, Y.Ming.; Luo, H. 2015: A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects. British Journal of Clinical Pharmacology 79(4): 650-659

Karlson, B.ör.W.; Dellborg, M.; Gullestad, L.; Aberg, J.; Sugg, J.; Herlitz, J. 2014: A pharmacokinetic and pharmacodynamic comparison of immediate-release metoprolol and extended-release metoprolol CR/XL in patients with suspected acute myocardial infarction: a randomized, open-label study. Cardiology 127(2): 73-82

Karsdal, M.A.; Byrjalsen, I.; Henriksen, K.; Riis, B.J.; Christiansen, C. 2009: A pharmacokinetic and pharmacodynamic comparison of synthetic and recombinant oral salmon calcitonin. Journal of Clinical Pharmacology 49(2): 229-234

Wettergren, Y.; Taflin, H.; Odin, E.; Kodeda, K.; Derwinger, K. 2015: A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study. Cancer ChemoTherapy and Pharmacology 75(1): 37-47

Verma, S.; Vanryzin, C.; Sinaii, N.; Kim, M.S.; Nieman, L.K.; Ravindran, S.; Calis, K.A.; Arlt, W.; Ross, R.J.; Merke, D.P. 2010: A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia. Clinical Endocrinology 72(4): 441-447

Zhan, S.; Guo, W.; Shao, Q.; Fan, X.; Li, Z.; Cheng, Y. 2014: A pharmacokinetic and pharmacodynamic study of drug-drug interaction between ginsenoside Rg1, ginsenoside Rb1 and schizandrin after intravenous administration to rats. Journal of Ethnopharmacology 152(2): 333-339

Olesen, A.E.; Upton, R.; Foster, D.J.R.; Staahl, C.; Christrup, L.L.; Arendt-Nielsen, L.; Drewes, A.ør.M. 2010: A pharmacokinetic and pharmacodynamic study of oral oxycodone in a human experimental pain model of hyperalgesia. Clinical Pharmacokinetics 49(12): 817-827

Wermeling, D.P.; Record, K.A.; Archer, S.M.; Rudy, A.C. 2009: A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation. Epilepsy Research 83(2-3): 124-132

ter Heine, R.; Scherpbier, H.J.; Crommentuyn, K.M.L.; Bekker, V.; Beijnen, J.H.; Kuijpers, T.W.; Huitema, A.D.R. 2008: A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. Antiviral Therapy 13(6): 779-787

Sweeney, C.J.; Takimoto, C.; Wood, L.; Porter, J.M.; Tracewell, W.G.; Darwish, M.; D'Andrea, D.M.; Remick, S.C. 2010: A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. Cancer ChemoTherapy and Pharmacology 66(2): 345-356

He, X.; Li, S.; Huang, H.; Li, Z.; Chen, L.; Ye, S.; Huang, J.; Zhan, J.; Lin, T. 2011: A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours. British Journal of Clinical Pharmacology 71(6): 860-870

Liu, R.; Dong, H.-F.; Jiang, M.-S. 2012: A pharmacokinetic approach to assess artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria. Expert Review of Clinical Pharmacology 5(5): 521-524

Perelman, M.; Knight, A. 2013: A pharmacokinetic assessment of an alternate titration strategy for fentanyl pectin nasal spray. International Journal of Clinical Pharmacology and Therapeutics 51(12): 942-947

Rhee, E.G.; Rizk, M.L.; Brainard, D.M.; Gendrano, I.N.; Jin, B.; Wenning, L.A.; Wagner, J.A.; Iwamoto, M. 2014: A pharmacokinetic comparison of adult and paediatric formulations of raltegravir in healthy adults. Antiviral Therapy 19(6): 619-624

Darwish, M.; Chang, S.; Hellriegel, E.T. 2009: A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers. Clinical Therapeutics 31(1): 108-114

Briciu, C.; Neag, M.; Muntean, D.; Vlase, L.; Bocsan, C.; Buzoianu, A.; Gheldiu, A.-M.; Achim, M.; Popa, A. 2014: A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. Journal of Clinical Pharmacy and Therapeutics 39(5): 535-540

Madan, A.; O'Brien, Z.; Wen, J.; O'Brien, C.; Farber, R.H.; Beaton, G.; Crowe, P.; Oosterhuis, B.; Garner, R.C.; Lappin, G.; Bozigian, H.P. 2009: A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects. British Journal of Clinical Pharmacology 67(3): 288-298

Markowitz, J.S.; Brinda, B.J. 2014: A pharmacokinetic evaluation of oral edivoxetine hydrochloride for the treatment of attention deficit-hyperactivity disorder. Expert Opinion on Drug Metabolism and Toxicology 10(9): 1289-1299

Musa, F.; Blank, S.; Muggia, F. 2013: A pharmacokinetic evaluation of topotecan as a cervical cancer therapy. Expert Opinion on Drug Metabolism and Toxicology 9(2): 215-224

Helleberg, L.; Rubin, A.; Wolen, R.L.; Rodda, B.E.; Ridolfo, A.S.; Gruber, C.M. 1974: A pharmacokinetic interaction in man between phenobarbitone and fenoprofen, a new anti-inflammatory agent. British Journal of Clinical Pharmacology 1(5): 371-374

Teng, R.; Butler, K. 2013: A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. European Journal of Clinical Pharmacology 69(10): 1801-1808

Lledó-García, R.; Nácher, A.; Casabó, V.G.; Merino-Sanjuán, M. 2011: A pharmacokinetic model for evaluating the impact of hepatic and intestinal first-pass loss of saquinavir in the rat. Drug Metabolism and Disposition: the Biological Fate of Chemicals 39(2): 294-301

Lv, Y.; Cheung, N.-K.V.; Fu, B.M. 2009: A pharmacokinetic model for radioimmunotherapy delivered through cerebrospinal fluid for the treatment of leptomeningeal metastases. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 50(8): 1324-1331

Bisker, G.; Iverson, N.M.; Ahn, J.; Strano, M.S. 2015: A pharmacokinetic model of a tissue implantable insulin sensor. Advanced Healthcare Materials 4(1): 87-97

Scholz, M.; Ackermann, M.; Engel, C.; Emmrich, F.; Loeffler, M.; Kamprad, M. 2009: A pharmacokinetic model of filgrastim and pegfilgrastim application in normal mice and those with cyclophosphamide-induced granulocytopaenia. Cell Proliferation 42(6): 813-822

Hamidi, M.; Azadi, A.; Rafiei, P.; Ashrafi, H. 2013: A pharmacokinetic overview of nanotechnology-based drug delivery systems: an ADME-oriented approach. Critical Reviews in Therapeutic Drug Carrier Systems 30(5): 435-467

Weber, B.; Hochhaus, G. 2013: A pharmacokinetic simulation tool for inhaled corticosteroids. Aaps Journal 15(1): 159-171

La Marca, G.; Rosati, A.; Falchi, M.; Malvagia, S.; Della Bona, M.L.; Pellacani, S.; Guerrini, R. 2013: A pharmacokinetic study and correlation with clinical response of rufinamide in infants with epileptic encephalopathies. Pharmacology 91(5-6): 275-280

Kodama, T.; Abe, M.; Iida, S.; Ozaki, S.; Sakai, A.; Sawamura, M.; Shimazaki, C.; Miyata, A.; Wakayama, T.; Murakami, H. 2009: A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma. Clinical Lymphoma and Myeloma 9(2): 154-159

Perbet, S.; Bourdeaux, D.; Sautou, V.; Pereira, B.; Chabanne, R.; Constantin, J.M.; Chopineau, J.; Bazin, J.E. 2014: A pharmacokinetic study of 48-hour sevoflurane inhalation using a disposable delivery system (AnaConDa®) in ICU patients. Minerva Anestesiologica 80(6): 655-665

Al-Musawi, A.; Matar, K.; Kombian, S.B.; Andersson, L. 2012: A pharmacokinetic study of a topical anesthetic (EMLA® ) in mouse soft tissue laceration. Dental Traumatology: Official Publication of International Association for Dental Traumatology 28(6): 483-487

Klein, H.; Hasselschwert, D.; Handt, L.; Kastello, M. 2008: A pharmacokinetic study of enrofloxacin and its active metabolite ciprofloxacin after oral and intramuscular dosing of enrofloxacin in rhesus monkeys (Macaca mulatta). Journal of Medical Primatology 37(4): 177-183

Schöller-Gyüre, M.; Kakuda, T.N.; De Smedt, G.; Vanaken, H.; Bouche, M.-P.; Peeters, M.; Woodfall, B.; Hoetelmans, R.M.W. 2008: A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers. British Journal of Clinical Pharmacology 66(4): 508-516

MacFarland, R.; Hard, M.L.; Scarborough, R.; Badel, K.; Calandra, G. 2010: A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 16(1): 95-101

Liu, Z.; Peng, Y.; Ma, B.; Bi, K.; Liu, Y.; Sun, G.; Ping, G.; Guo, Y. 2014: A pharmacokinetic study on a novel anti-HBV agent imidol hydrochloride in rats. International Journal of Pharmaceutics 461(1-2): 514-518

Venkatakrishnan, K.; Kramer, W.G.; Synold, T.W.; Goodman, D.B.; Sides, E.; Oliva, C. 2012: A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers. European Journal of Clinical Pharmacology 68(10): 1347-1355

Fleury, A.èl.; Lavé, T.; Jonsson, F.; Schmitt, M.; Hirkaler, G.; Polonchuk, L.; Breidenbach, A. 2011: A pharmacokinetic-pharmacodynamic model for cardiovascular safety assessment of R1551. Journal of Pharmacological and Toxicological Methods 63(1): 123-133

Westin, J.; Nyholm, D.; Pålhagen, S.; Willows, T.; Groth, T.; Dougherty, M.; Karlsson, M.O. 2011: A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. Clinical Neuropharmacology 34(2): 61-65

Verstuyft, C.él.; Delavenne, X.; Rousseau, A.; Robert, A.; Tod, M.; Diquet, B.; Lebot, M.; Jaillon, P.; Becquemont, L. 2012: A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy. Clinical Pharmacokinetics 51(1): 41-53

Di Salvo, A.; Della Rocca, G.; Bazzica, C.; Giontella, A.; Cagnardi, P.; Nannarone, S. 2014: A pharmacokinetic/clinical approach to postulate a local action of intra-articular xylazine administration in the horse: a preliminary study. Journal of Veterinary Pharmacology and Therapeutics 37(5): 464-471

Mohamed, A.F.; Cars, O.; Friberg, L.E. 2014: A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing. Journal of Antimicrobial ChemoTherapy 69(5): 1350-1361

Shen, J.; Xiao, J.; Pickthorn, K.; Huang, S.; Bell, G.; Vick, A.; Chen, P. 2014: A pharmacokinetic/pharmacodynamic model for AMG 416, a novel calcimimetic peptide, following a single intravenous dose in healthy subjects. Journal of Clinical Pharmacology 54(10): 1125-1133

Ji, J.; Mould, D.R.; Blum, K.A.; Ruppert, A.S.; Poi, M.; Zhao, Y.; Johnson, A.J.; Byrd, J.C.; Grever, M.R.; Phelps, M.A. 2013: A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 19(5): 1269-1280

Kharidia, J.; Fogarty, C.M.; Laforce, C.F.; Maier, G.; Hsu, R.; Dunnington, K.M.; Curry, L.; Baumgartner, R.A.; Hanrahan, J.P. 2008: A pharmacokinetic/pharmacodynamic study comparing arformoterol tartrate inhalation solution and racemic formoterol dry powder inhaler in subjects with chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics 21(4): 657-662

Canini, L.; Chatterjee, A.; Guedj, J.; Lemenuel-Diot, A.; Brennan, B.; Smith, P.F.; Perelson, A.S. 2015: A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV. Antiviral Therapy 20(5): 469-477

Griese, M.; Eismann, C.; Börner, G.; Denk, O.; Schierholz, J.ör.M.; Keller, M.; Mazurek, H.; Kappler, M. 2014: A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBi. Journal of Aerosol Medicine and Pulmonary Drug Delivery 27(3): 185-192

Pelham, R.W.; Alcorn, H.; Cleveland, M.v. 2010: A pharmacokinetics evaluation of a new, low-volume, oral sulfate colon cleansing preparation in patients with renal or hepatic impairment and healthy volunteers. Journal of Clinical Pharmacology 50(3): 350-354

Gerber, P.; Carr, R. 2013: A pharmacokinetics module taught within a pediatrics pharmacotherapy course. American Journal of Pharmaceutical Education 77(6): 126

Kao, H.-W.; Chan, C.-J.; Chang, Y.-C.; Hsu, Y.-H.; Lu, M.; Shian-Jy Wang, J.; Lin, Y.-Y.; Wang, S.-J.; Wang, H.-E. 2013: A pharmacokinetics study of radiolabeled micelles of a poly(ethylene glycol)-block-poly(caprolactone) copolymer in a colon carcinoma-bearing mouse model. Applied Radiation and Isotopes: Including Data Instrumentation and Methods for use in Agriculture Industry and Medicine 80: 88-94

Mishra, R.C.; Wulff, H.; Cole, W.C.; Braun, A.P. 2014: A pharmacologic activator of endothelial KCa channels enhances coronary flow in the hearts of type 2 diabetic rats. Journal of Molecular and Cellular Cardiology 72: 364-373

Van der Speeten, K.; Stuart, O.A.; Mahteme, H.; Sugarbaker, P.H. 2009: A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin. Cancer ChemoTherapy and Pharmacology 63(5): 799-805

Sloane, P.A.; Shastry, S.; Wilhelm, A.; Courville, C.; Tang, L.P.; Backer, K.; Levin, E.; Raju, S.V.; Li, Y.; Mazur, M.; Byan-Parker, S.; Grizzle, W.; Sorscher, E.J.; Dransfield, M.T.; Rowe, S.M. 2012: A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease. Plos one 7(6): E39809

Caritis, S.N.; Hebert, M.F. 2013: A pharmacologic approach to the use of glyburide in pregnancy. Obstetrics and Gynecology 121(6): 1309-1312

Salerno, P.R.; Coon, J.M. 1949: A pharmacologic comparison of hexaethyl tetraphosphate and teraethyl pyrophosphate with physostigmine neostigmine and diisopropyl fluorophosphate. Journal of Pharmacology and Experimental Therapeutics 95(2): 240-255

Coon, J.M.; Salerno, P.R. 1948: A pharmacologic comparison of hexaethyl tetraphosphate and tetraethyl pyrophosphate with physostigmine and neostigmine. Federation Proceedings 7(1 Part 1): 212

Wilson, C.; Cullen, E.; Sendell, K. 1984: A pharmacologic investigation of the 'transport response' in the white rat. International Journal of Developmental Neuroscience: the Official Journal of the International Society for Developmental Neuroscience 2(4): 323-329

Kwon, H.J.; Kim, H.Y. 2009: A pharmacologic pupillary test in the diagnosis of diabetic autonomic neuropathy. Korean Journal of Ophthalmology: Kjo 23(4): 291-295

Wagner, B.J.; Yunker, N.S. 2014: A pharmacologic review of cardiac arrest. Plastic Surgical Nursing: Official Journal of the American Society of Plastic and Reconstructive Surgical Nurses 34(3): 133-138; Quiz: 139-140

Graham, B.E.; Kuizenga, M.H. 1948: A pharmacologic study of ortho-methoxy-beta-phenyl-Isopropyl methylamine hydrochloride, and 13 related methoxy analogues. Journal of Pharmacology and Experimental Therapeutics 94(2): 150-166

Roberts, T.J.; Williams, S.C.R.; Modo, M. 2008: A pharmacological MRi assessment of dizocilpine (MK-801) in the 3-nitroproprionic acid-lesioned rat. Neuroscience Letters 444(1): 42-47

Zhang, X.; Gao, R.; Li, J.; Qi, Y.; Song, X.; Zhao, L.; Wang, H.; Pu, Y.; Xu, K.; Li, J. 2010: A pharmacological activator of AMP-activated protein kinase protects hypoxic neurons in a concentration-dependent manner. Neurochemical Research 35(8): 1281-1289

Novotny, A.; Edsparr, K.; Nylund, G.; Khorram-Manesh, A.; Albertsson, P.; Nordgren, S.; Delbro, D.S. 2010: A pharmacological analysis of the cholinergic regulation of urokinase-type plasminogen activator secretion in the human colon cancer cell line, HT-29. European Journal of Pharmacology 646(1-3): 22-30

Thompson, S.N.; Carrico, K.M.; Mustafa, A.G.; Bains, M.; Hall, E.D. 2010: A pharmacological analysis of the neuroprotective efficacy of the brain- and cell-permeable calpain inhibitor MDL-28170 in the mouse controlled cortical impact traumatic brain injury model. Journal of Neurotrauma 27(12): 2233-2243

Raskova, H.; Votava, Z. 1949: A pharmacological analysis of the o-tolylether of glycerol. Archives Internationales de Pharmacodynamie et de Therapie 80(2-3): 320-330

Parratt, J.R.; Végh, A. 2008: A pharmacological analysis of the possible role of vasoactive mediators in compensatory coronary blood flow. Experimental and Clinical Cardiology 13(1): 7-14

Winter, K.L.; Isbister, G.K.; McGowan, S.; Konstantakopoulos, N.; Seymour, J.E.; Hodgson, W.C. 2010: A pharmacological and biochemical examination of the geographical variation of Chironex fleckeri venom. Toxicology Letters 192(3): 419-424

Rahmatullah, M.; Rahman, M.A.; Hossan, M.S.; Taufiq-Ur-Rahman, M.; Jahan, R.; Mollik, M.A.H. 2010: A pharmacological and phytochemical evaluation of medicinal plants used by the Harbang clan of the Tripura tribal community of Mirsharai area, Chittagong district, Bangladesh. Journal of Alternative and Complementary Medicine 16(7): 769-785

Ostro, M.; Macht, D.I. 1946: A pharmacological and radiological study of hemophilia. Southern Medical Journal 39(11): 860-867

Lansdown, A.B.G. 2010: A pharmacological and toxicological profile of silver as an antimicrobial agent in medical devices. Advances in Pharmacological Sciences 2010: 910686

Khan, V.; Najmi, A.K.; Akhtar, M.; Aqil, M.; Mujeeb, M.; Pillai, K.K. 2012: A pharmacological appraisal of medicinal plants with antidiabetic potential. Journal of Pharmacy and Bioallied Sciences 4(1): 27-42

Peng, G.E.; Wilson, S.R.; Weiner, O.D. 2011: A pharmacological cocktail for arresting actin dynamics in living cells. Molecular Biology of the Cell 22(21): 3986-3994

Brasel, C.M.; Sawyer, G.W.; Stevens, C.W. 2008: A pharmacological comparison of the cloned frog and human mu opioid receptors reveals differences in opioid affinity and function. European Journal of Pharmacology 599(1-3): 36-43

Moiseeva, T.N.; Serpik, V.G.; Kulikov, A.I. 2011: A pharmacological cost-effective analysis of vobenzim use in combined treatment of chronic prostatitis. Urologiia 3: 31-35

Pavuluri, M.N.; Passarotti, A.M.; Parnes, S.A.; Fitzgerald, J.M.; Sweeney, J.A. 2010: A pharmacological functional magnetic resonance imaging study probing the interface of cognitive and emotional brain systems in pediatric bipolar disorder. Journal of Child and Adolescent Psychopharmacology 20(5): 395-406

Hughes, R.J.A.; Angus, J.A.; Winkel, K.D.; Wright, C.E. 2012: A pharmacological investigation of the venom extract of the Australian box jellyfish, Chironex fleckeri, in cardiac and vascular tissues. Toxicology Letters 209(1): 11-20

Ye, X.; Linton, J.M.; Schork, N.J.; Buck, L.B.; Petrascheck, M. 2014: A pharmacological network for lifespan extension in Caenorhabditis elegans. Aging Cell 13(2): 206-215

Feuerstein, T.J. 2014: A pharmacological paradox: may a neutral antagonist shift an agonist concentration-response curve to the left?. Naunyn-Schmiedeberg's Archives of Pharmacology 387(7): 601-603

Andresen, B.T. 2011: A pharmacological primer of biased agonism. Endocrine Metabolic and Immune Disorders Drug Targets 11(2): 92-98

Yan, T.D.; Cao, C.Q.; Munkholm-Larsen, S. 2010: A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy. World Journal of Gastrointestinal Oncology 2(2): 109-116

Beraki, S.; Litrus, L.; Soriano, L.; Monbureau, M.; To, L.K.; Braithwaite, S.P.; Nikolich, K.; Urfer, R.; Oksenberg, D.; Shamloo, M. 2013: A pharmacological screening approach for discovery of neuroprotective compounds in ischemic stroke. Plos one 8(7): E69233

Smith, M. 1950: A pharmacological study of 3 sulphones; the specific toxic phenomena. Leprosy Review 21(1): 17-29

Castillo, J.C.; De Beer, E.J.; Jaros, S.H. 1949: A pharmacological study of N-methyl-N'-(4-chlorobenzhydryl) piperazine dihydrochloride, a new antihistaminic. Journal of Pharmacology and Experimental Therapeutics 96(4 Part 1): 388-395

Ahlquist, R.P.; Hobensack, B.; Woodbury, R.A. 1949: A pharmacological study of N-methyl-N-cinnamyl-2-phenyl-propylamine. Journal of the American Pharmaceutical Association. American Pharmaceutical Association 38(8): 425-428

El Aziz Sharaf, A. 1948: A pharmacological study of the Egyptian plant, Euphorbia peplus. British Veterinary Journal 104(9): 313-318

Haley, T.J.; Edwards, L.D.; Johnson, C.H. 1947: A pharmacological study of two isomeric sodium hydroxymercuribenzoates. Journal of the American Pharmaceutical Association. American Pharmaceutical Association 36(8): 229-234

Jacobs, G.E.; van Gerven, J.M.A.; de Kam, M.l.; Elassaiss-Schaap, J.; Ruigt, G.; van Pelt, J.; Peeters, B.W.M.M.; Peeters, P.A.M.; Hulskotte, E.G.J. 2011: A pharmacological tool to assess vasopressinergic co-activation of the hypothalamus-pituitary-adrenal axis more integrally in healthy volunteers. Journal of Psychopharmacology 25(3): 361-369

Peter, J.-C.; Lecourt, A.-C.; Weckering, M.; Zipfel, G.ér.; Niehoff, M.L.; Banks, W.A.; Hofbauer, K.G. 2010: A pharmacologically active monoclonal antibody against the human melanocortin-4 receptor: effectiveness after peripheral and central administration. Journal of Pharmacology and Experimental Therapeutics 333(2): 478-490

Billy, F.éd.ér.; Ribba, B.; Saut, O.; Morre-Trouilhet, H.él.èn.; Colin, T.; Bresch, D.; Boissel, J.-P.; Grenier, E.; Flandrois, J.-P. 2009: A pharmacologically based multiscale mathematical model of angiogenesis and its use in investigating the efficacy of a new cancer treatment strategy. Journal of Theoretical Biology 260(4): 545-562

Schmalhofer, W.A.; Swensen, A.M.; Thomas, B.S.; Felix, J.P.; Haedo, R.J.; Solly, K.; Kiss, L.; Kaczorowski, G.J.; Garcia, M.L. 2010: A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel. Assay and Drug Development Technologies 8(6): 714-726

Perera, V.; Gross, A.S.; Forrest, A.; Landersdorfer, C.B.; Xu, H.; Ait-Oudhia, S.; McLachlan, A.J. 2013: A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activity. Drug Metabolism and Disposition: the Biological Fate of Chemicals 41(11): 1957-1966

Zhang, L.; Boulton, D.W.; Pfister, M. 2012: A pharmacometric approach to quantify the impact of chronic kidney disease and hemodialysis on systemic drug exposure: application to saxagliptin. Journal of Clinical Pharmacology 52(1 Suppl): 126s-133s

McGregor, M.J. 2007: A pharmacophore map of small molecule protein kinase inhibitors. Journal of Chemical Information and Modeling 47(6): 2374-2382

Zhang, T.; Wei, D.-Q.; Chou, K.-C. 2012: A pharmacophore model specific to active site of CYP1A2 with a novel molecular modeling explorer and CoMFA. Medicinal Chemistry 8(2): 198-207

Maluf, F.V.; Andricopulo, A.D.; Oliva, G.; Guido, R.Vc. 2013: A pharmacophore-based virtual screening approach for the discovery of Trypanosoma cruzi GAPDH inhibitors. Future Medicinal Chemistry 5(17): 2019-2035

McConville, J.T.; Hodges, L.-A.; Jones, T.; Band, J.P.; O'Mahony, B.; Lindsay, B.; Ross, A.C.; Florence, A.J.; Stanley, A.J.; Humphrey, M.J.; Wilson, C.G.; Stevens, H.N.E. 2009: A pharmacoscintigraphic study of three time-delayed capsule formulations in healthy male volunteers. Journal of Pharmaceutical Sciences 98(11): 4251-4263

Conway, J.M.; Ahmed, G.F. 2012: A pharmacotherapy capstone course to advance pharmacy students' clinical documentation skills. American Journal of Pharmaceutical Education 76(7): 134

Usta, C.şk.; Cilli, A.; Celenk, B.; Uzun, R.şe. 2012: A pharmacovigilance study in chest diseases outpatient clinic. Tuberkuloz Ve Toraks 60(2): 123-128

Braithwaite, E.C.; Hill, J.; Pickles, A.; Glover, V.; O'Donnell, K.; Sharp, H. 2018: Associations between maternal prenatal cortisol and fetal growth are specific to infant sex: findings from the Wirral Child Health and Development Study. Journal of Developmental Origins of Health and Disease 9(4): 425-431

van den Heuvel, M.I.; van Assen, M.A.L.M.; Glover, V.; Claes, S.; Van den Bergh, B.R.H. 2018: Associations between maternal psychological distress and salivary cortisol during pregnancy: A mixed-models approach. Psychoneuroendocrinology 96: 52-60

Dube, N.M.; Summers, R.; Tint, K.-S.; Mayayise, G. 2012: A pharmacovigilance study of adults on highly active antiretroviral therapy, South Africa: 2007 - 2011. Pan African Medical Journal 11: 39

Hussain, A.; Aqil, M.; Alam, M.S.; Khan, M.R.; Kapur, P.; Pillai, K.K. 2009: A pharmacovigilance study of antihypertensive medicines at a South delhi hospital. Indian Journal of Pharmaceutical Sciences 71(3): 338-341

Jamali, A.N.; Aqil, M.; Alam, M.S.; Pillai, K.K.; Kapur, P. 2010: A pharmacovigilance study on patients of bronchial asthma in a teaching hospital. Journal of Pharmacy and Bioallied Sciences 2(4): 333-336

Naik-Panvelkar, P.; Saini, B.; LeMay, K.S.; Emmerton, L.M.; Stewart, K.; Burton, D.L.; Bosnic-Anticevich, S.Z.; Krass, I.; Smith, L.D.; Armour, C.L. 2015: A pharmacy asthma service achieves a change in patient responses from increased awareness to taking responsibility for their asthma. International Journal of Pharmacy Practice 23(3): 182-191

Rollins, B.L.; Gunturi, R.; Sullivan, D. 2014: A pharmacy business management simulation exercise as a practical application of business management material and principles. American Journal of Pharmaceutical Education 78(3): 62

Bookstaver, P.B.; Capino, A.C.; Bookstaver, N.K. 2014: A pharmacy concierge service to optimize fidaxomicin therapy. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 71(12): 986-987

Sorensen, T.D.; Traynor, A.P.; Janke, K.K. 2009: A pharmacy course on leadership and leading change. American Journal of Pharmaceutical Education 73(2): 23

Louie, C.; Mertz, E.; Penfil, B.; O'Neil, E. 2009: A pharmacy leadership action study. Journal of the American Pharmacists Association: Japha 49(1): 98-104

Child, A.; Clarke, A.; Fox, C.; Maidment, I. 2012: A pharmacy led program to review anti-psychotic prescribing for people with dementia. Bmc Psychiatry 12: 155

Geerts, A.F.J.; Scherpbier-de Haan, N.D.; de Koning, F.H.P.; van der Sterren, T.M.J.W.; van Weel, C.; Vervoort, G.M.M.; de Smet, P.A.G.M.; de Grauw, W.J.C. 2012: A pharmacy medication alert system based on renal function in older patients. British Journal of General Practice: the Journal of the Royal College of General Practitioners 62(601): E525-E529

Blake, E.W.; Powell, P.H. 2011: A pharmacy political advocacy elective course. American Journal of Pharmaceutical Education 75(7): 137

Harrold, M.W.; McFalls, M.A. 2010: A pharmacy practice laboratory exercise to apply biochemistry concepts. American Journal of Pharmaceutical Education 74(8): 144

Guillema, S.; Ly, A.-V. 2009: A pharmacy practice residency (PGY1) with an emphasis on academia. American Journal of Pharmaceutical Education 73(1): 13

Elliott, R.A.; McDowell, J.; Marriott, J.L.; Calandra, A.; Duncan, G. 2009: A pharmacy preregistration course using online teaching and learning methods. American Journal of Pharmaceutical Education 73(5): 77

Cohen, J.M.; Sabot, O.; Sabot, K.; Gordon, M.; Gross, I.; Bishop, D.; Odhiambo, M.; Ipuge, Y.; Ward, L.; Mwita, A.; Goodman, C. 2010: A pharmacy too far? Equity and spatial distribution of outcomes in the delivery of subsidized artemisinin-based combination therapies through private drug shops. Bmc Health Services Research 10(Suppl 1): S6

Erickson, S.; Hambleton, J. 2011: A pharmacy's journey toward the patient-centered medical home. Journal of the American Pharmacists Association: Japha 51(2): 156-160

Anderson, C.; Thornley, T. 2011: A pharmacy-based private chlamydia screening programme: results from the first 2 years of screening and treatment. International journal of clinical pharmacy 33(1): 88-91

Nakiwogga-Muwanga, A.; Katabira, E.; Sempa, J.; Kambugu, A.; Nakibuuka-Lubwama, E.; Lamorde, M.; Mawejje, J.; Colebunders, R. 2014: A pharmacy-only refill program at a large HIV clinic in Uganda: experience and satisfaction of patients. Journal of the International Association of Providers of Aids Care 13(3): 264-268

Leung, N.M.W.; Chan, H.S.; Vlantis, A.C.; Tong, M.C.F. 2010: A pharyngeal foreign body presenting as a painful neck mass. Otolaryngology--Head and Neck Surgery: Official Journal of American Academy of Otolaryngology-Head and Neck Surgery 143(2): 315-316

Sid'Ahmed, L.; Boubacar, A.; Aye, M.; Alhousseini Ag, M. 2010: A pharyngo-esophageal cancer in a patient with Plummer Vinson syndrome. (Apropos of a case). Le Mali Medical 25(2): 56-57

Yip, D.; Le, M.N.; Chan, J.L.-K.; Lee, J.H.; Mehnert, J.A.; Yudd, A.; Kempf, J.; Shih, W.J.; Chen, S.; Goydos, J.S. 2009: A phase 0 trial of riluzole in patients with resectable stage IIi and IV melanoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 15(11): 3896-3902

Wakui, H.; Yamamoto, N.; Kitazono, S.; Mizugaki, H.; Nakamichi, S.; Fujiwara, Y.; Nokihara, H.; Yamada, Y.; Suzuki, K.; Kanda, H.; Akinaga, S.; Tamura, T. 2014: A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors. Cancer ChemoTherapy and Pharmacology 74(1): 15-23

Fang, F.; Balch, C.; Schilder, J.; Breen, T.; Zhang, S.; Shen, C.; Li, L.; Kulesavage, C.; Snyder, A.J.; Nephew, K.P.; Matei, D.E. 2010: A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer 116(17): 4043-4053

McDermott, D.H.; Liu, Q.; Velez, D.; Lopez, L.; Anaya-O'Brien, S.; Ulrick, J.; Kwatemaa, N.; Starling, J.; Fleisher, T.A.; Priel, D.A.L.; Merideth, M.A.; Giuntoli, R.L.; Evbuomwan, M.O.; Littel, P.; Marquesen, M.M.; Hilligoss, D.; DeCastro, R.; Grimes, G.J.; Hwang, S.T.; Pittaluga, S.; Calvo, K.R.; Stratton, P.; Cowen, E.W.; Kuhns, D.B.; Malech, H.L.; Murphy, P.M. 2014: A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood 123(15): 2308-2316

Kirschbaum, M.; Gojo, I.; Goldberg, S.L.; Bredeson, C.; Kujawski, L.A.; Yang, A.; Marks, P.; Frankel, P.; Sun, X.; Tosolini, A.; Eid, J.E.; Lubiniecki, G.M.; Issa, J.-P. 2014: A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. British Journal of Haematology 167(2): 185-193

Stuurman, F.E.; Lolkema, M.P.; Huitema, A.D.R.; Soetekouw, P.M.M.B.; Rosing, H.; Rolfe, L.; Kaur, P.; Beijnen, J.H.; van Tinteren, H.; Voest, E.E.; Schellens, J.H.M. 2013: A phase 1 comparative pharmacokinetic and cardiac safety study of two intravenous formulations of CO-101 in patients with advanced solid tumors. Journal of Clinical Pharmacology 53(8): 878-883

Sinha, R.; Kaufman, J.L.; Khoury, H.J.; King, N.; Shenoy, P.J.; Lewis, C.; Bumpers, K.; Hutchison-Rzepka, A.; Tighiouart, M.; Heffner, L.T.; Lechowicz, M.J.; Lonial, S.; Flowers, C.R. 2012: A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. Cancer 118(14): 3538-3548

Olivier, G.; Clavert, A.; Lacotte-Thierry, L.; Gardembas, M.; Escoffre-Barbe, M.; Brion, A.; Cumin, I.; Legouffe, E.; Solal-Celigny, P.; Chabin, M.èl.; Ingrand, P.; Colombat, P.; Delwail, V. 2014: A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. the GOELAMS LCP 99 trial. American Journal of Hematology 89(11): 1024-1029

O'Connor, O.A.; Stewart, A.K.; Vallone, M.; Molineaux, C.J.; Kunkel, L.A.; Gerecitano, J.F.; Orlowski, R.Z. 2009: A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 15(22): 7085-7091

Hong, D.S.; Kurzrock, R.; Oh, Y.; Wheler, J.; Naing, A.; Brail, L.; Callies, S.; André, V.ér.; Kadam, S.K.; Nasir, A.; Holzer, T.R.; Meric-Bernstam, F.; Fishman, M.; Simon, G. 2011: A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 17(20): 6582-6591

Khoury, H.J.; Garcia-Manero, G.; Borthakur, G.; Kadia, T.; Foudray, M.C.; Arellano, M.; Langston, A.; Bethelmie-Bryan, B.; Rush, S.; Litwiler, K.; Karan, S.; Simmons, H.; Marcus, A.I.; Ptaszynski, M.; Kantarjian, H. 2012: A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Cancer 118(14): 3556-3564

Kumar, A.; Blum, K.A.; Fung, H.C.; Smith, M.R.; Foster, P.A.; Younes, A. 2015: A phase 1 dose-escalation study of XmAb® 2513 in patients with relapsed or refractory Hodgkin lymphoma. British Journal of Haematology 168(6): 902-904

Tse, A.N.; Klimstra, D.S.; Gonen, M.; Shah, M.; Sheikh, T.; Sikorski, R.; Carvajal, R.; Mui, J.; Tipian, C.; O'Reilly, E.; Chung, K.; Maki, R.; Lefkowitz, R.; Brown, K.; Manova-Todorova, K.; Wu, N.; Egorin, M.J.; Kelsen, D.; Schwartz, G.K. 2008: A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 14(20): 6704-6711

Rienhoff, H.Y.; Viprakasit, V.; Tay, L.; Harmatz, P.; Vichinsky, E.; Chirnomas, D.; Kwiatkowski, J.L.; Tapper, A.; Kramer, W.; Porter, J.B.; Neufeld, E.J. 2011: A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica 96(4): 521-525

Hawkins, A.K. 2012: A phase 1 enzyme replacement study offers promise for severe hypophospahatasia. Clinical Genetics 82(3): 220-221

Bartlett, N.L.; Younes, A.; Carabasi, M.H.; Forero, A.; Rosenblatt, J.D.; Leonard, J.P.; Bernstein, S.H.; Bociek, R.G.; Lorenz, J.M.; Hart, B.W.; Barton, J. 2008: A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 111(4): 1848-1854

Zorzi, F.; Calabrese, E.; Monteleone, I.; Fantini, M.; Onali, S.; Biancone, L.; Pallone, F.; Monteleone, G. 2012: A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease. Alimentary Pharmacology and Therapeutics 36(9): 850-857

Papadopoulos, K.P.; Goel, S.; Beeram, M.; Wong, A.; Desai, K.; Haigentz, M.; Milián, M.ía.L.; Mani, S.; Tolcher, A.; Lalani, A.S.; Sarantopoulos, J. 2008: A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 14(21): 7110-7115

Ghamande, S.; Lin, C.-C.; Cho, D.C.; Shapiro, G.I.; Kwak, E.L.; Silverman, M.H.; Tseng, Y.; Kuo, M.-W.; Mach, W.B.; Hsu, S.-C.; Coleman, T.; Yang, J.C.-H.; Cheng, A.-L.; Ghalib, M.H.; Chuadhary, I.; Goel, S. 2014: A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors. Investigational new Drugs 32(3): 445-451

Steele, N.L.; Plumb, J.A.; Vidal, L.; Tjørnelund, J.; Knoblauch, P.; Rasmussen, A.; Ooi, C.E.; Buhl-Jensen, P.; Brown, R.; Evans, T.R.J.; DeBono, J.S. 2008: A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 14(3): 804-810

McGowan, I.; Hoesley, C.; Cranston, R.D.; Andrew, P.; Janocko, L.; Dai, J.Y.; Carballo-Dieguez, A.; Ayudhya, R.K.N.; Piper, J.; Hladik, F.; Mayer, K. 2013: A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007). Plos one 8(4): E60147

Freeman, S.M.; Franco, J.L.B.; Kenady, D.E.; Baltzer, L.; Roth, Z.; Brandwein, H.J.; Hadden, J.W. 2011: A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck. American Journal of Clinical Oncology 34(2): 173-178

Hudis, C.; Swanton, C.; Janjigian, Y.Y.; Lee, R.; Sutherland, S.; Lehman, R.; Chandarlapaty, S.; Hamilton, N.; Gajria, D.; Knowles, J.; Shah, J.; Shannon, K.; Tetteh, E.; Sullivan, D.M.; Moreno, C.; Yan, L.; Han, H.S. 2013: A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Research: Bcr 15(6): R110

Singh, D.; Kane, B.; Molfino, N.A.; Faggioni, R.; Roskos, L.; Woodcock, A. 2010: A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. Bmc Pulmonary Medicine 10: 3

Byrd, J.C.; Pagel, J.M.; Awan, F.T.; Forero, A.; Flinn, I.W.; Deauna-Limayo, D.P.; Spurgeon, S.E.; Andritsos, L.A.; Gopal, A.K.; Leonard, J.P.; Eisenfeld, A.J.; Bannink, J.E.; Stromatt, S.C.; Furman, R.R. 2014: A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood 123(9): 1302-1308

Chyung, Y.; Vince, B.; Iarrobino, R.; Sexton, D.; Kenniston, J.; Faucette, R.; TenHoor, C.; Stolz, L.E.; Stevens, C.; Biedenkapp, J.; Adelman, B. 2014: A phase 1 study investigating DX-2930 in healthy subjects. Annals of Allergy Asthma and Immunology: Official Publication of the American College of Allergy Asthma and Immunology 113(4): 460-6.E2

Grudzinski, J.J.; Titz, B.; Kozak, K.; Clarke, W.; Allen, E.; Trembath, L.; Stabin, M.; Marshall, J.; Cho, S.Y.; Wong, T.Z.; Mortimer, J.; Weichert, J.P. 2014: A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety. Plos one 9(11): E111652

Attie, K.M.; Allison, M.J.; McClure, T.; Boyd, I.E.; Wilson, D.M.; Pearsall, A.E.; Sherman, M.L. 2014: A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. American Journal of Hematology 89(7): 766-770

Rudman, S.M.; Jameson, M.B.; McKeage, M.J.; Savage, P.; Jodrell, D.I.; Harries, M.; Acton, G.; Erlandsson, F.; Spicer, J.F. 2011: A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 17(7): 1998-2005

Heath, E.I.; Lorusso, P.; Ramalingam, S.S.; Awada, A.; Egorin, M.J.; Besse-Hamer, T.; Cardoso, F.; Valdivieso, M.; Has, T.; Alland, L.; Zhou, X.; Belani, C.P. 2011: A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies. Investigational new Drugs 29(6): 1426-1431

Herrera, L.; Bostrom, B.; Gore, L.; Sandler, E.; Lew, G.; Schlegel, P.G.; Aquino, V.; Ghetie, V.; Vitetta, E.S.; Schindler, J. 2009: A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. Journal of Pediatric Hematology/Oncology 31(12): 936-941

Siegel, D.; Jagannath, S.; Vesole, D.H.; Borello, I.; Mazumder, A.; Mitsiades, C.; Goddard, J.; Dunbar, J.; Normant, E.; Adams, J.; Grayzel, D.; Anderson, K.C.; Richardson, P. 2011: A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. Leukemia and Lymphoma 52(12): 2308-2315

Zhang, M.; Zhang, J.; Yan, M.; Luo, D.; Zhu, W.; Kaiser, P.K.; Yu, D.-C.; Zhang, M.; Zhang, J.; Tan, Q.; Meng, D.; Shen, Q.; Zhou, M. 2011: A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology 118(4): 672-678

Macpherson, I.R.; Poondru, S.; Simon, G.R.; Gedrich, R.; Brock, K.; Hopkins, C.A.; Stewart, K.; Stephens, A.; Evans, T.R.J. 2013: A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours. European Journal of Cancer 49(4): 782-789

Gordon, M.S.; Rosen, L.S.; Mendelson, D.; Ramanathan, R.K.; Goldman, J.; Liu, L.; Xu, Y.; Gerson, S.L.; Anthony, S.P.; Figg, W.D.; Spencer, S.; Adams, B.J.; Theuer, C.P.; Leigh, B.R.; Weiss, G.J. 2013: A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. Investigational new Drugs 31(3): 714-723

Keiser, P.B.; Gibbs, B.T.; Coster, T.S.; Moran, E.E.; Stoddard, M.B.; Labrie, J.E.; Schmiel, D.H.; Pinto, V.; Chen, P.; Zollinger, W.D. 2010: A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA. Vaccine 28(43): 6970-6976

Keiser, P.B.; Biggs-Cicatelli, S.; Moran, E.E.; Schmiel, D.H.; Pinto, V.B.; Burden, R.E.; Miller, L.B.; Moon, J.E.; Bowden, R.A.; Cummings, J.F.; Zollinger, W.D. 2011: A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 29(7): 1413-1420

Weber, J.S.; Vogelzang, N.J.; Ernstoff, M.S.; Goodman, O.B.; Cranmer, L.D.; Marshall, J.L.; Miles, S.; Rosario, D.; Diamond, D.C.; Qiu, Z.; Obrocea, M.; Bot, A. 2011: A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. Journal of ImmunoTherapy 34(7): 556-567

Mark, T.M.; Reid, W.; Niesvizky, R.; Gergis, U.; Pearse, R.; Mayer, S.; Greenberg, J.; Coleman, M.; Van Besien, K.; Shore, T. 2013: A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 19(5): 831-837

Pishvaian, M.J.; Marshall, J.L.; Wagner, A.J.; Hwang, J.J.; Malik, S.; Cotarla, I.; Deeken, J.F.; He, A.R.; Daniel, H.; Halim, A.-B.; Zahir, H.; Copigneaux, C.; Liu, K.; Beckman, R.A.; Demetri, G.D. 2012: A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer 118(21): 5403-5413

Fury, M.G.; Lee, N.Y.; Sherman, E.; Ho, A.L.; Rao, S.; Heguy, A.; Shen, R.; Korte, S.; Lisa, D.; Ganly, I.; Patel, S.; Wong, R.J.; Shaha, A.; Shah, J.; Haque, S.; Katabi, N.; Pfister, D.G. 2013: A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer. International Journal of Radiation Oncology Biology Physics 87(3): 479-486

Harzstark, A.L.; Small, E.J.; Weinberg, V.K.; Sun, J.; Ryan, C.J.; Lin, A.M.; Fong, L.; Brocks, D.R.; Rosenberg, J.E. 2011: A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer 117(18): 4194-4200

Lutzky, J.; Weber, R.; Nunez, Y.; Gillett, M.; Spitler, L. 2009: A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma. Journal of ImmunoTherapy 32(1): 79-85

Tsimberidou, A.M.; Fu, S.; Ng, C.; Lim, J.A.; Wen, S.; Hong, D.; Wheler, J.; Bedikian, A.Y.; Eng, C.; Wallace, M.; Camacho, L.H.; Kurzrock, R. 2010: A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer 116(17): 4086-4094

Chen, G.L.; Arai, S.; Flowers, M.E.D.; Otani, J.M.; Qiu, J.; Cheng, E.C.; McMillan, A.; Johnston, L.J.; Shizuru, J.A.; Miklos, D.B. 2011: A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Blood 118(15): 4070-4078

Horinouchi, H.; Yamamoto, N.; Nokihara, H.; Horai, T.; Nishio, M.; Ohyanagi, F.; Horiike, A.; Nakagawa, K.; Terashima, M.; Okabe, T.; Kaneda, H.; McKee, M.D.; Carlson, D.M.; Xiong, H.; Tamura, T. 2014: A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC). Cancer ChemoTherapy and Pharmacology 74(1): 37-43

Bensinger, W.; Maziarz, R.T.; Jagannath, S.; Spencer, A.; Durrant, S.; Becker, P.S.; Ewald, B.; Bilic, S.; Rediske, J.; Baeck, J.; Stadtmauer, E.A. 2012: A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. British Journal of Haematology 159(1): 58-66

Hotte, S.éb.J.; Hirte, H.W.; Chen, E.X.; Siu, L.L.; Le, L.H.; Corey, A.; Iacobucci, A.; MacLean, M.; Lo, L.; Fox, N.L.; Oza, A.M. 2008: A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 14(11): 3450-3455

Saulnier Sholler, G.L.; Bergendahl, G.M.; Brard, L.; Singh, A.P.; Heath, B.W.; Bingham, P.M.; Ashikaga, T.; Kamen, B.A.; Homans, A.C.; Slavik, M.A.; Lenox, S.R.; Higgins, T.J.; Ferguson, W.S. 2011: A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma. Journal of Pediatric Hematology/Oncology 33(1): 25-30

Sehn, L.H.; Assouline, S.E.; Stewart, D.A.; Mangel, J.; Gascoyne, R.D.; Fine, G.; Frances-Lasserre, S.; Carlile, D.J.; Crump, M. 2012: A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 119(22): 5118-5125

Azzoli, C.G.; Krug, L.M.; Gomez, J.; Miller, V.A.; Kris, M.G.; Ginsberg, M.S.; Henry, R.; Jones, J.; Tyson, L.; Dunne, M.; Pizzo, B.; Farmer, A.; Venkatraman, E.; Steffen, R.; Sirotnak, F.M. 2007: A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 13(9): 2692-2698

Jakubowski, J.A.; Zhou, C.; Jurcevic, S.; Winters, K.J.; Lachno, D.R.; Frelinger, A.L.; Gupta, N.; Howard, J.; Payne, C.D.; Mant, T.G. 2014: A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation. Thrombosis Research 133(2): 190-195

Beasley, G.M.; McMahon, N.; Sanders, G.; Augustine, C.K.; Selim, M.A.; Peterson, B.; Norris, R.; Peters, W.P.; Ross, M.I.; Tyler, D.S. 2009: A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Cancer 115(20): 4766-4774

Tolcher, A.W.; Rodrigueza, W.V.; Rasco, D.W.; Patnaik, A.; Papadopoulos, K.P.; Amaya, A.; Moore, T.D.; Gaylor, S.K.; Bisgaier, C.L.; Sooch, M.P.; Woolliscroft, M.J.; Messmann, R.A. 2014: A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors. Cancer ChemoTherapy and Pharmacology 73(2): 363-371

Kahl, B.S.; Spurgeon, S.E.; Furman, R.R.; Flinn, I.W.; Coutre, S.E.; Brown, J.R.; Benson, D.M.; Byrd, J.C.; Peterman, S.; Cho, Y.; Yu, A.; Godfrey, W.R.; Wagner-Johnston, N.D. 2014: A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood 123(22): 3398-3405

Hofmeister, C.C.; Williams, N.; Geyer, S.; Hade, E.M.; Bowers, M.A.; Earl, C.T.; Vaughn, J.; Bingman, A.; Humphries, K.; Lozanski, G.; Baiocchi, R.A.; Jaglowski, S.M.; Blum, K.; Porcu, P.; Flynn, J.; Penza, S.; Benson, D.M.; Andritsos, L.A.; Devine, S.M. 2015: A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma. Leukemia and Lymphoma 56(4): 1043-1049

Beeram, M.; Krop, I.E.; Burris, H.A.; Girish, S.R.; Yu, W.; Lu, M.W.; Holden, S.N.; Modi, S. 2012: A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer 118(23): 5733-5740

Moulder, S.; Gladish, G.; Ensor, J.; Gonzalez-Angulo, A.M.; Cristofanilli, M.; Murray, J.L.; Booser, D.; Giordano, S.H.; Brewster, A.; Moore, J.; Rivera, E.; Hortobagyi, G.N.; Tran, H.T. 2012: A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer 118(9): 2378-2384

Mostafa, N.M.; Chiu, Y.-L.; Rosen, L.S.; Bessudo, A.; Kovacs, X.; Giranda, V.L. 2014: A phase 1 study to evaluate effect of food on veliparib pharmacokinetics and relative bioavailability in subjects with solid tumors. Cancer ChemoTherapy and Pharmacology 74(3): 583-591

Koteff, J.; Borland, J.; Chen, S.; Song, I.; Peppercorn, A.; Koshiba, T.; Cannon, C.; Muster, H.; Piscitelli, S.C. 2013: A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. British Journal of Clinical Pharmacology 75(4): 990-996

Mehendale, S.; van Lunzen, J.; Clumeck, N.; Rockstroh, J.; Vets, E.; Johnson, P.R.; Anklesaria, P.; Barin, B.; Boaz, M.; Kochhar, S.; Lehrman, J.; Schmidt, C.; Peeters, M.; Schwarze-Zander, C.; Kabamba, K.; Glaunsinger, T.; Sahay, S.; Thakar, M.; Paranjape, R.; Gilmour, J.; Excler, J.-L.; Fast, P.; Heald, A.E. 2008: A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. Aids Research and Human Retroviruses 24(6): 873-880

Fox, E.; Aplenc, R.; Bagatell, R.; Chuk, M.K.; Dombi, E.; Goodspeed, W.; Goodwin, A.; Kromplewski, M.; Jayaprakash, N.; Marotti, M.; Brown, K.H.; Wenrich, B.; Adamson, P.C.; Widemann, B.C.; Balis, F.M. 2010: A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 28(35): 5174-5181

Gordon, M.S.; Mendelson, D.; Carr, R.; Knight, R.A.; Humerickhouse, R.A.; Iannone, M.; Stopeck, A.T. 2008: A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer. Cancer 113(12): 3420-3429

Nabors, L.B.; Fiveash, J.B.; Markert, J.M.; Kekan, M.S.; Gillespie, G.Y.; Huang, Z.; Johnson, M.J.; Meleth, S.; Kuo, H.; Gladson, C.L.; Fathallah-Shaykh, H.M. 2010: A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Archives of Neurology 67(3): 313-319

Rocha-Lima, C.M.; Bayraktar, S.; Macintyre, J.; Raez, L.; Flores, A.M.; Ferrell, A.; Rubin, E.H.; Poplin, E.A.; Tan, A.R.; Lucarelli, A.; Zojwalla, N. 2012: A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors. Cancer 118(17): 4262-4270

McCarthy, J.S.; Marjason, J.; Elliott, S.; Fahey, P.; Bang, G.; Malkin, E.; Tierney, E.; Aked-Hurditch, H.; Adda, C.; Cross, N.; Richards, J.S.; Fowkes, F.J.I.; Boyle, M.J.; Long, C.; Druilhe, P.; Beeson, J.G.; Anders, R.F. 2011: A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720. Plos one 6(9): E24413

Liesveld, J.L.; Phillips, G.L.; Becker, M.; Constine, L.S.; Friedberg, J.; Andolina, J.R.; Milner, L.A.; DeBolt, J.; Smudzin, T.; Hyrien, O.; Erickson-Miller, C.L.; Johnson, B.M.; Dawson, K.-L.; Chen, Y. 2013: A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 19(12): 1745-1752

Horsley, L.; Cummings, J.; Middleton, M.; Ward, T.; Backen, A.; Clamp, A.; Dawson, M.; Farmer, H.; Fisher, N.; Halbert, G.; Halford, S.; Harris, A.; Hasan, J.; Hogg, P.; Kumaran, G.; Little, R.; Parker, G.J.M.; Potter, P.; Saunders, M.; Roberts, C.; Shaw, D.; Smith, N.; Smythe, J.; Taylor, A.; Turner, H.; Watson, Y.; Dive, C.; Jayson, G.C. 2013: A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours. Cancer ChemoTherapy and Pharmacology 72(6): 1343-1352

Dixon, B.; Santamaria, J.D.; Campbell, D.J. 2008: A phase 1 trial of nebulised heparin in acute lung injury. Critical Care 12(3): R64

Harris, D.S.; Everhart, T.; Jacob, P.; Lin, E.; Mendelson, J.E.; Jones, R.T. 2009: A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion. Bmc Clinical Pharmacology 9: 13

Woyach, J.A.; Awan, F.; Flinn, I.W.; Berdeja, J.G.; Wiley, E.; Mansoor, S.; Huang, Y.; Lozanski, G.; Foster, P.A.; Byrd, J.C. 2014: A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood 124(24): 3553-3560

Benson, D.M.; Hofmeister, C.C.; Padmanabhan, S.; Suvannasankha, A.; Jagannath, S.; Abonour, R.; Bakan, C.; Andre, P.; Efebera, Y.; Tiollier, J.ér.ôm.; Caligiuri, M.A.; Farag, S.S. 2012: A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 120(22): 4324-4333

Vey, N.; Bourhis, J.-H.; Boissel, N.; Bordessoule, D.; Prebet, T.; Charbonnier, A.; Etienne, A.; Andre, P.; Romagne, F.ço.; Benson, D.; Dombret, H.; Olive, D. 2012: A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 120(22): 4317-4323

Saif, M.W.; Takimoto, C.; Mita, M.; Banerji, U.; Lamanna, N.; Castro, J.; O'Brien, S.; Stogard, C.; Von Hoff, D. 2014: A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 20(2): 445-455

Gottlieb, A.B.; Cooper, K.D.; McCormick, T.S.; Toichi, E.; Everitt, D.E.; Frederick, B.; Zhu, Y.; Pendley, C.E.; Graham, M.A.; Mascelli, M.A. 2007: A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Current Medical Research and Opinion 23(5): 1081-1092

Chu, F.M.; Picus, J.; Fracasso, P.M.; Dreicer, R.; Lang, Z.; Foster, B. 2011: A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Investigational new Drugs 29(4): 674-679

Carmona Martinez, A.; Salamanca de la Cueva, I.; Boutet, P.; Vanden Abeele, C.; Smolenov, I.; Devaster, J.-M. 2014: A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months. Human Vaccines and Immunotherapeutics 10(7): 1959-1968

Von Mehren, M.; Britten, C.D.; Pieslor, P.; Saville, W.; Vassos, A.; Harris, S.; Galluppi, G.R.; Darif, M.; Wainberg, Z.A.; Cohen, R.B.; Leong, S. 2014: A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors. Investigational new Drugs 32(3): 518-525

Watabe, M.; Cheng, Y.-F.; Nilsson, D.; Itoh, Y.; Kumagai, Y. 2007: A phase 1, placebo-controlled, randomised, double-blind (within dose panels) study evaluating the safety, tolerability and pharmacokinetics of intravenous NXY-059 in Japanese subjects. Current Medical Research and Opinion 23(8): 1849-1857

Sheldon, E.A.; Schwartz, H.; Jiang, Q.; Giardina, P.C.; Perez, J.L. 2012: A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults. Human Vaccines and Immunotherapeutics 8(7): 888-895

Jabbour, E.; Kantarjian, H.; Ravandi, F.; Garcia-Manero, G.; Estrov, Z.; Verstovsek, S.; O'Brien, S.; Faderl, S.; Thomas, D.A.; Wright, J.J.; Cortes, J. 2011: A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 117(6): 1236-1244

Weber, J.S.; Samlowski, W.E.; Gonzalez, R.; Ribas, A.; Stephenson, J.; O'Day, S.; Sato, T.; Dorr, R.; Grenier, K.; Hersh, E. 2010: A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Cancer 116(15): 3683-3691

Akutsu, Y.; Shuto, K.; Kono, T.; Uesato, M.; Hoshino, I.; Shiratori, T.; Miyazawa, Y.; Isozaki, Y.; Akanuma, N.; Matsubara, H. 2012: A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma. Hepato-Gastroenterology 59(119): 2095-2098

Maddocks, K.; Christian, B.; Jaglowski, S.; Flynn, J.; Jones, J.A.; Porcu, P.; Wei, L.; Jenkins, C.; Lozanski, G.; Byrd, J.C.; Blum, K.A. 2015: A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Blood 125(2): 242-248

Hong, T.S.; Ryan, D.P.; Borger, D.R.; Blaszkowsky, L.S.; Yeap, B.Y.; Ancukiewicz, M.; Deshpande, V.; Shinagare, S.; Wo, J.Y.; Boucher, Y.; Wadlow, R.C.; Kwak, E.L.; Allen, J.N.; Clark, J.W.; Zhu, A.X.; Ferrone, C.R.; Mamon, H.J.; Adams, J.; Winrich, B.; Grillo, T.; Jain, R.K.; DeLaney, T.F.; Fernandez-del Castillo, C.; Duda, D.G. 2014: A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. International Journal of Radiation Oncology Biology Physics 89(4): 830-838

Thongcharoen, P.; Suriyanon, V.; Paris, R.M.; Khamboonruang, C.; de Souza, M.S.; Ratto-Kim, S.; Karnasuta, C.; Polonis, V.R.; Baglyos, L.; Habib, R.El.; Gurunathan, S.; Barnett, S.; Brown, A.E.; Birx, D.L.; McNeil, J.G.; Kim, J.H. 2007: A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. Journal of Acquired Immune Deficiency Syndromes 46(1): 48-55

Nechushtan, H.; Vainer, G.; Stainberg, H.; Salmon, A.Y.; Hamburger, T.; Peretz, T. 2014: A phase 1/2 of a combination of cetuximab and taxane for "triple negative" breast cancer patients. Breast 23(4): 435-438

Kibuuka, H.; Kimutai, R.; Maboko, L.; Sawe, F.; Schunk, M.S.; Kroidl, A.; Shaffer, D.; Eller, L.A.; Kibaya, R.; Eller, M.A.; Schindler, K.B.; Schuetz, A.; Millard, M.; Kroll, J.; Dally, L.; Hoelscher, M.; Bailer, R.; Cox, J.H.; Marovich, M.; Birx, D.L.; Graham, B.S.; Michael, N.L.; de Souza, M.S.; Robb, M.L. 2010: A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). Journal of Infectious Diseases 201(4): 600-607

Stadtmauer, E.A.; Sullivan, K.M.; Marty, F.M.; Dadwal, S.S.; Papanicolaou, G.A.; Shea, T.C.; Mossad, S.B.; Andreadis, C.; Young, J.-A.H.; Buadi, F.K.; El Idrissi, M.; Heineman, T.C.; Berkowitz, E.M. 2014: A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood 124(19): 2921-2929

Russell, H.V.; Strother, D.; Mei, Z.; Rill, D.; Popek, E.; Biagi, E.; Yvon, E.; Brenner, M.; Rousseau, R. 2008: A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. Journal of ImmunoTherapy 31(9): 812-819

Berenson, J.R.; Hilger, J.D.; Yellin, O.; Boccia, R.V.; Matous, J.; Dressler, K.; Ghazal, H.H.; Jamshed, S.; Kingsley, E.C.; Harb, W.A.; Noga, S.J.; Nassir, Y.; Swift, R.A.; Vescio, R. 2014: A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Annals of Hematology 93(1): 89-98

Couldwell, W.T.; Surnock, A.A.; Tobia, A.J.; Cabana, B.E.; Stillerman, C.B.; Forsyth, P.A.; Appley, A.J.; Spence, A.M.; Hinton, D.R.; Chen, T.C. 2011: A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas. Cancer 117(21): 4905-4915

Kutlar, A.; Ataga, K.; Reid, M.; Vichinsky, E.P.; Neumayr, L.; Blair-Britt, L.; Labotka, R.; Glass, J.; Keefer, J.R.; Wargin, W.A.; Berenson, R.; Perrine, S.P. 2012: A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease. American Journal of Hematology 87(11): 1017-1021

Phatak, P.; Brissot, P.; Wurster, M.; Adams, P.C.; Bonkovsky, H.L.; Gross, J.; Malfertheiner, P.; McLaren, G.D.; Niederau, C.; Piperno, A.; Powell, L.W.; Russo, M.W.; Stoelzel, U.; Stremmel, W.; Griffel, L.; Lynch, N.; Zhang, Y.; Pietrangelo, A. 2010: A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology 52(5): 1671-1779

Rudek, M.A.; Moore, P.C.; Mitsuyasu, R.T.; Dezube, B.J.; Aboulafia, D.; Gerecitano, J.; Sullivan, R.; Cianfrocca, M.E.; Henry, D.H.; Ratner, L.; Haigentz, M.; Dowlati, A.; Little, R.F.; Ivy, S.P.; Deeken, J.F. 2014: A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. Cancer 120(8): 1194-1202

Hoffer, F.A.; Daw, N.C.; Xiong, X.; Anghelescu, D.; Krasin, M.; Yan, X.; Davidoff, A.M.; Furman, W.L.; Rodriguez-Galindo, C.; Spunt, S.L. 2009: A phase 1/pilot study of radiofrequency ablation for the treatment of recurrent pediatric solid tumors. Cancer 115(6): 1328-1337

Perez, A.T.; Arun, B.; Tripathy, D.; Tagliaferri, M.A.; Shaw, H.S.; Kimmick, G.G.; Cohen, I.; Shtivelman, E.; Caygill, K.A.; Grady, D.; Schactman, M.; Shapiro, C.L. 2010: A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. Breast Cancer Research and Treatment 120(1): 111-118

Wainberg, Z.A.; Messersmith, W.A.; Peddi, P.F.; Kapp, A.V.; Ashkenazi, A.; Royer-Joo, S.; Portera, C.C.; Kozloff, M.F. 2013: A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Clinical Colorectal Cancer 12(4): 248-254

Chawla, S.P.; Chua, V.S.; Hendifar, A.F.; Quon, D.V.; Soman, N.; Sankhala, K.K.; Wieland, D.S.; Levitt, D.J. 2015: A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma. Cancer 121(4): 570-579

Higgs, B.W.; Zhu, W.; Morehouse, C.; White, W.I.; Brohawn, P.; Guo, X.; Rebelatto, M.; Le, C.; Amato, A.; Fiorentino, D.; Greenberg, S.A.; Drappa, J.; Richman, L.; Greth, W.; Jallal, B.; Yao, Y. 2014: A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type i IFN signature in blood of dermatomyositis and polymyositis patients. Annals of the Rheumatic Diseases 73(1): 256-262

Molina, A.M.; Hutson, T.E.; Larkin, J.; Gold, A.M.; Wood, K.; Carter, D.; Motzer, R.; Michaelson, M.D. 2014: A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer ChemoTherapy and Pharmacology 73(1): 181-189

Ouédraogo, A.; Tiono, A.B.; Kargougou, Désiré.; Yaro, J.Baptiste.; Ouédraogo, E.; Kaboré, Y.; Kangoye, D.; Bougouma, E.C.; Gansane, A.; Henri, N.; Diarra, A.; Sanon, S.; Soulama, I.; Konate, A.T.; Watson, N.L.; Brown, V.; Hendriks, J.; Pau, M.Grazia.; Versteege, I.; Wiesken, E.; Sadoff, J.; Nebie, I.; Sirima, S.B. 2013: A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. PloS one 8(11): e78679

Chambers, D.C.; Enever, D.; Ilic, N.; Sparks, L.; Whitelaw, K.; Ayres, J.; Yerkovich, S.T.; Khalil, D.; Atkinson, K.M.; Hopkins, P.M.A. 2014: A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis. Respirology 19(7): 1013-1018

Vergote, I.; Schilder, R.J.; Pippitt, C.H.; Wong, S.; Gordon, A.N.; Scudder, S.; Kridelka, F.; Dirix, L.; Leach, J.W.; Ananda, S.; Nanayakkara, N.; Melara, R.; Bass, M.B.; Litten, J.; Adewoye, H.; Wenham, R.M. 2014: A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. Gynecologic Oncology 135(1): 25-33

Wuthrick, E.J.; Kamrava, M.; Curran, W.J.; Werner-Wasik, M.; Camphausen, K.A.; Hyslop, T.; Axelrod, R.; Andrews, D.W.; Glass, J.; Machtay, M.; Dicker, A.P. 2011: A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies. Cancer 117(24): 5548-5559

Vergote, I.; Oaknin, A.; Baurain, J.-F.; Ananda, S.; Wong, S.; Su, X.; Wu, B.; Zhong, Z.; Warner, D.; Casado, A. 2014: A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery. European Journal of Cancer 50(14): 2408-2416

Lancet, J.E.; Roboz, G.J.; Cripe, L.D.; Michelson, G.C.; Fox, J.A.; Leavitt, R.D.; Chen, T.; Hawtin, R.; Craig, A.R.; Ravandi, F.; Maris, M.B.; Stuart, R.K.; Karp, J.E. 2015: A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica 100(2): 231-237

Messing, E.; Gee, J.R.; Saltzstein, D.R.; Kim, K.; diSant'Agnese, A.; Kolesar, J.; Harris, L.; Faerber, A.; Havighurst, T.; Young, J.M.; Efros, M.; Getzenberg, R.H.; Wheeler, M.A.; Tangrea, J.; Parnes, H.; House, M.; Busby, J.Erik.; Hohl, R.; Bailey, H. 2012: A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prevention Research 5(4): 621-630

Rizzieri, D.A.; Feldman, E.; Dipersio, J.F.; Gabrail, N.; Stock, W.; Strair, R.; Rivera, V.M.; Albitar, M.; Bedrosian, C.L.; Giles, F.J. 2008: A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 14(9): 2756-2762

Hersh, E.M.; O'Day, S.J.; Ribas, A.; Samlowski, W.E.; Gordon, M.S.; Shechter, D.E.; Clawson, A.A.; Gonzalez, R. 2010: A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer 116(1): 155-163

Muro, K.; Yoshino, T.; Doi, T.; Shirao, K.; Takiuchi, H.; Hamamoto, Y.; Watanabe, H.; Yang, B.-B.; Asahi, D. 2009: A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. Japanese Journal of Clinical Oncology 39(5): 321-326

Siefker-Radtke, A.O.; Dinney, C.P.; Shen, Y.; Williams, D.L.; Kamat, A.M.; Grossman, H.B.; Millikan, R.E. 2013: A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer 119(3): 540-547

Bepler, G.; Zinner, R.G.; Moon, J.; Calhoun, R.; Kernstine, K.; Williams, C.C.; Mack, P.C.; Oliveira, V.; Zheng, Z.; Stella, P.J.; Redman, M.W.; Gandara, D.R. 2014: A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage i non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120(15): 2343-2351

Genovese, M.C.; Lee, E.; Satterwhite, J.; Veenhuizen, M.; Disch, D.; Berclaz, P.-Y.; Myers, S.; Sides, G.; Benichou, O. 2013: A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. Annals of the Rheumatic Diseases 72(9): 1453-1460

Schilder, R.J.; Blessing, J.A.; Shahin, M.S.; Miller, D.S.; Tewari, K.S.; Muller, C.Y.; Warshal, D.P.; McMeekin, S.; Rotmensch, J. 2010: A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 20(7): 1137-1141

Bruggers, C.S.; Greene, D. 2007: A phase 2 feasibility study of sequential, dose intensive chemotherapy to treat progressive low-grade gliomas in children. Journal of Pediatric Hematology/Oncology 29(9): 602-607

Raspagliesi, F.; Ditto, A.; Selvaggi, L.; Frigerio, L.; Melpignano, M.; Scambia, G.; Apolloni, C.; Scollo, P.; Pignata, S.; Panici, P.Benedetti. 2010: A phase 2 multicenter study of irinotecan and cisplatinum as neoadjuvant treatment in patients with locally advanced cervical cancer. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 20(9): 1569-1575

Laskowitz, D.T.; Kolls, B.J. 2010: A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 74(24): 2026; Author Reply 2026-7

Bhatt, R.S.; Merchan, J.; Parker, R.; Wu, H.-K.; Zhang, L.; Seery, V.; Heymach, J.V.; Atkins, M.B.; McDermott, D.; Sukhatme, V.P. 2010: A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer 116(7): 1751-1756

Carvajal, R.D.; Wong, M.K.; Thompson, J.A.; Gordon, M.S.; Lewis, K.D.; Pavlick, A.C.; Wolchok, J.D.; Rojas, P.B.; Schwartz, J.D.; Bedikian, A.Y. 2014: A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma. European Journal of Cancer 50(12): 2099-2107

Prymula, R.; Esposito, S.; Zuccotti, G.V.; Xie, F.; Toneatto, D.; Kohl, I.; Dull, P.M. 2014: A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I). Human Vaccines and Immunotherapeutics 10(7): 1993-2004

Esposito, S.; Prymula, R.; Zuccotti, G.V.; Xie, F.; Barone, M.; Dull, P.M.; Toneatto, D. 2014: A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II). Human Vaccines and Immunotherapeutics 10(7): 2005-2014

Raza, A.; Galili, N.; Smith, S.E.; Godwin, J.; Boccia, R.V.; Myint, H.; Mahadevan, D.; Mulford, D.; Rarick, M.; Brown, G.L.; Schaar, D.; Faderl, S.; Komrokji, R.S.; List, A.F.; Sekeres, M. 2012: A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. Cancer 118(8): 2138-2147

Salloway, S.; Sperling, R.; Keren, R.; Porsteinsson, A.P.; van Dyck, C.H.; Tariot, P.N.; Gilman, S.; Arnold, D.; Abushakra, S.; Hernandez, C.; Crans, G.; Liang, E.; Quinn, G.; Bairu, M.; Pastrak, A.; Cedarbaum, J.M. 2011: A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 77(13): 1253-1262

Crawford, J.; Swanson, P.; Schwarzenberger, P.; Sandler, A.; Prager, D.; Zhang, K.; Freeman, D.J.; Johnson, C.W.; Krishnan, K.; Johnson, D. 2013: A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 8(12): 1510-1518

Cardiel, M.H.; Tak, P.P.; Bensen, W.; Burch, F.X.; Forejtova, S.; Badurski, J.E.; Kakkar, T.; Bevirt, T.; Ni, L.; McCroskery, E.; Jahreis, A.; Zack, D.J. 2010: A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis. Arthritis Research and Therapy 12(5): R192

Guntupalli, K.; Dean, N.; Morris, P.E.; Bandi, V.; Margolis, B.; Rivers, E.; Levy, M.; Lodato, R.F.; Ismail, P.M.; Reese, A.; Schaumberg, J.P.; Malik, R.; Dellinger, R.P.; Arroliga, A.; Balk, R.; Cannon, C.; Dean, N.; Dellinger, P.; Dennen, P.; Figueroa, J.; Fletcher, E.; Guntupalli, K.K.; Huang, D.T.; Levy, M.; Lo, T.; Malik, I.; Margolis, B.; Matuschak, G.; Moore, L.; Moran, G.J.; Moretti, E.; Morris, P.; Panacek, E.; Rivers, E.; Schmidt, G.; Seneff, M.G.; Steingrub, J.; Taylor, R. 2013: A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis. Critical Care Medicine 41(3): 706-716

Lendvai, N.; Hilden, P.; Devlin, S.; Landau, H.; Hassoun, H.; Lesokhin, A.M.; Tsakos, I.; Redling, K.; Koehne, G.; Chung, D.J.; Schaffer, W.L.; Giralt, S.A. 2014: A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood 124(6): 899-906

Leong, S.P.L.; Kim, J.; Ross, M.; Faries, M.; Scoggins, C.R.; Metz, W.L.R.; Cope, F.O.; Orahood, R.C. 2011: A phase 2 study of (99m)Tc-tilmanocept in the detection of sentinel lymph nodes in melanoma and breast cancer. Annals of Surgical Oncology 18(4): 961-969

Peterson, L.M.; Kurland, B.F.; Schubert, E.K.; Link, J.M.; Gadi, V.K.; Specht, J.M.; Eary, J.F.; Porter, P.; Shankar, L.K.; Mankoff, D.A.; Linden, H.M. 2014: A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC). Molecular Imaging and Biology 16(3): 431-440

Inati, A.; Kahale, M.; Perrine, S.P.; Chui, D.H.K.; Taher, A.T.; Koussa, S.; Abi Nasr, T.; Abbas, H.A.; Ghalie, R.G. 2014: A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in β-thalassaemia intermedia. British Journal of Haematology 164(3): 456-458

Antonarakis, E.S.; Heath, E.I.; Posadas, E.M.; Yu, E.Y.; Harrison, M.R.; Bruce, J.Y.; Cho, S.Y.; Wilding, G.E.; Fetterly, G.J.; Hangauer, D.G.; Kwan, M.-F.R.; Dyster, L.M.; Carducci, M.A. 2013: A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. Cancer ChemoTherapy and Pharmacology 71(4): 883-892

Valle, J.W.; Armstrong, A.; Newman, C.; Alakhov, V.; Pietrzynski, G.; Brewer, J.; Campbell, S.; Corrie, P.; Rowinsky, E.K.; Ranson, M. 2011: A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Investigational new Drugs 29(5): 1029-1037

Popat, R.; Plesner, T.; Davies, F.; Cook, G.; Cook, M.; Elliott, P.; Jacobson, E.; Gumbleton, T.; Oakervee, H.; Cavenagh, J. 2013: A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. British Journal of Haematology 160(5): 714-717

Hortobagyi, G.N.; Heim, W.; Hutchins, L.; Rivera, E.; Mason, B.; Booser, D.J.; Kirshner, J. 2010: A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer. Cancer 116(6): 1440-1445

Hortobagyi, G.N.; Young, R.R.; Karwal, M.; Ibrahim, N.K.; Hermann, R.; Murray, J.L.; Watkins, S.P.; Gore, I. 2010: A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer. Cancer 116(10): 2301-2306

Satoh, T.; Uemura, H.; Tanabe, K.; Nishiyama, T.; Terai, A.; Yokomizo, A.; Nakatani, T.; Imanaka, K.; Ozono, S.; Akaza, H. 2014: A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy. Japanese Journal of Clinical Oncology 44(12): 1206-1215

Forbes, G.M.; Sturm, M.J.; Leong, R.W.; Sparrow, M.P.; Segarajasingam, D.; Cummins, A.G.; Phillips, M.; Herrmann, R.P. 2014: A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Clinical Gastroenterology and Hepatology: the Official Clinical Practice Journal of the American Gastroenterological Association 12(1): 64-71

Retsch-Bogart, G.Z.; Burns, J.L.; Otto, K.L.; Liou, T.G.; McCoy, K.; Oermann, C.; Gibson, R.L. 2008: A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatric Pulmonology 43(1): 47-58

Kirschbaum, M.H.; Foon, K.A.; Frankel, P.; Ruel, C.; Pulone, B.; Tuscano, J.M.; Newman, E.M. 2014: A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leukemia and Lymphoma 55(10): 2301-2304

Fury, M.G.; Lee, N.Y.; Sherman, E.; Lisa, D.; Kelly, K.; Lipson, B.; Carlson, D.; Stambuk, H.; Haque, S.; Shen, R.; Kraus, D.; Shah, J.; Pfister, D.G. 2012: A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer. Cancer 118(20): 5008-5014

Anonymous 2014: A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results in patients with DLBCL and other B-cell lymphomas. Clinical Advances in Hematology and Oncology: H&o 12(2 Suppl. 6): 3-4

Kim, E.S.; Mauer, A.M.; William, W.N.; Tran, H.T.; Liu, D.; Lee, J.J.; Windt, P.; Hong, W.K.; Vokes, E.E.; Herbst, R.S. 2009: A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer 115(8): 1713-1722

Brown, J.R.; Friedberg, J.W.; Feng, Y.; Scofield, S.; Phillips, K.; Dal Cin, P.; Joyce, R.; Takvorian, R.W.; Fisher, D.C.; Fisher, R.I.; Liesveld, J.; Marquis, D.; Neuberg, D.; Freedman, A.S. 2009: A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. British Journal of Haematology 145(6): 741-748

Lukina, E.; Watman, N.; Arreguin, E.A.; Banikazemi, M.; Dragosky, M.; Iastrebner, M.; Rosenbaum, H.; Phillips, M.; Pastores, G.M.; Rosenthal, D.I.; Kaper, M.; Singh, T.; Puga, A.C.; Bonate, P.L.; Peterschmitt, M.J. 2010: A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 116(6): 893-899

Picus, J.; Halabi, S.; Kelly, W.K.; Vogelzang, N.J.; Whang, Y.E.; Kaplan, E.B.; Stadler, W.M.; Small, E.J.; George, S.; Grubbs, S.S.; Winer, E.P.; Lilenbaum, R.; Budman, D.R.; Bloomfield, C.D.; Sikov, W.; Kirshner, J.; Venook, A.P.; Fleming, G.; Peterson, B.A.; Kessinger, A.; Shea, T.; Muss, H.B.; Hurd, D.D.; Bartlett, N.L.; Shadduck, R. 2011: A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer 117(3): 526-533

Hurvitz, S.A.; Dalenc, F.; Campone, M.; O'Regan, R.M.; Tjan-Heijnen, V.C.; Gligorov, J.; Llombart, A.; Jhangiani, H.; Mirshahidi, H.R.; Tan-Chiu, E.; Miao, S.; El-Hashimy, M.; Lincy, J.; Taran, T.; Soria, J-Charles.; Sahmoud, T.; André, F. 2013: A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Research and Treatment 141(3): 437-446

Rodriguez-Torres, M.; Yoshida, E.M.; Marcellin, P.; Srinivasan, S.; Purohit, V.S.; Wang, C.; Hammond, J.L. 2014: A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV. Annals of Hepatology 13(4): 364-375

Lin, R.; Fan, N.; Wu, G.; Chen, Y.; Guo, Z.; Wang, X.; Jin, F.; Chen, L.; Liu, J. 2015: A phase 2 study of fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as a salvage treatment in patients with refractory or relapsed advanced gastric cancer. Journal of ChemoTherapy 27(1): 52-56

Bedikian, A.Y.; Richards, J.; Kharkevitch, D.; Atkins, M.B.; Whitman, E.; Gonzalez, R. 2010: A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Research 20(3): 218-226

Fehniger, T.A.; Uy, G.L.; Trinkaus, K.; Nelson, A.D.; Demland, J.; Abboud, C.N.; Cashen, A.F.; Stockerl-Goldstein, K.E.; Westervelt, P.; DiPersio, J.F.; Vij, R. 2011: A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood 117(6): 1828-1833

Han, J-Youn.; Lim, K.Young.; Yu, S.Young.; Yun, T.; Kim, H.Tae.; Lee, J.Soo. 2011: A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer. Cancer 117(10): 2178-2185

Sekeres, M.A.; Gundacker, H.; Lancet, J.; Advani, A.; Petersdorf, S.; Liesveld, J.; Mulford, D.; Norwood, T.; Willman, C.L.; Appelbaum, F.R.; List, A.F. 2011: A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood 118(3): 523-528

Manvelian, G.; Hochberg, M.C.; Daniels, S.E.; Altman, R.D.; Young, C.L. 2014: A phase 2 study of lower-dose, indomethacin submicron particle capsules demonstrates early onset of acute pain relief. Clinical Journal of Pain 30(10): 846-851

Young, C.L.; Strand, V.; Altman, R.; Daniels, S. 2013: A phase 2 study of naproxen submicron particle capsules in patients with post-surgical dental pain. Advances in Therapy 30(10): 885-896

Stein, S.M.; Tiersten, A.; Hochster, H.S.; Blank, S.V.; Pothuri, B.; Curtin, J.; Shapira, I.; Levinson, B.; Ivy, P.; Joseph, B.; Guddati, A.K.; Muggia, F. 2013: A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 23(9): 1577-1582

Chi, K.N.; Beardsley, E.; Eigl, B.J.; Venner, P.; Hotte, S.J.; Winquist, E.; Ko, Y.-J.; Sridhar, S.S.; Weber, D.; Saad, F. 2012: A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a. Annals of Oncology: Official Journal of the European Society for Medical Oncology 23(1): 53-58

Warren, K.; Bent, R.; Wolters, P.L.; Prager, A.; Hanson, R.; Packer, R.; Shih, J.; Camphausen, K. 2012: A phase 2 study of pegylated interferon α-2b (PEG-Intron(®)) in children with diffuse intrinsic pontine glioma. Cancer 118(14): 3607-3613

Fury, M.G.; Haque, S.; Stambuk, H.; Shen, R.; Carlson, D.; Pfister, D. 2011: A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer. Cancer 117(4): 795-801

Laurie, S.A.; Siu, L.L.; Winquist, E.; Maksymiuk, A.; Harnett, E.L.; Walsh, W.; Tu, D.; Parulekar, W.R. 2010: A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group. Cancer 116(2): 362-368

Verstovsek, S.; Passamonti, F.; Rambaldi, A.; Barosi, G.; Rosen, P.J.; Rumi, E.; Gattoni, E.; Pieri, L.; Guglielmelli, P.; Elena, C.; He, S.; Contel, N.; Mookerjee, B.; Sandor, V.; Cazzola, M.; Kantarjian, H.M.; Barbui, T.; Vannucchi, A.M. 2014: A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 120(4): 513-520

Siegel, D.S.; Martin, T.; Wang, M.; Vij, R.; Jakubowiak, A.J.; Lonial, S.; Trudel, S.; Kukreti, V.; Bahlis, N.; Alsina, M.; Chanan-Khan, A.; Buadi, F.; Reu, F.J.; Somlo, G.; Zonder, J.; Song, K.; Stewart, A.Keith.; Stadtmauer, E.; Kunkel, L.; Wear, S.; Wong, A.F.; Orlowski, R.Z.; Jagannath, S. 2012: A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120(14): 2817-2825

Kirkwood, J.M.; Gonzalez, R.; Reintgen, D.; Clingan, P.R.; McWilliams, R.R.; de Alwis, D.P.; Zimmermann, A.; Brown, M.P.; Ilaria, R.L.; Millward, M.J. 2011: A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma. Cancer 117(20): 4732-4739

Okuno, S.; Bailey, H.; Mahoney, M.R.; Adkins, D.; Maples, W.; Fitch, T.; Ettinger, D.; Erlichman, C.; Sarkaria, J.N. 2011: A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C). Cancer 117(15): 3468-3475

Kohail, H.; Shehata, S.; Mansour, O.; Gouda, Y.; Gaafar, R.; Hamid, T.A.; El Nowieam, S.; Al Khodary, A.; El Zawahry, H.; Wareth, A.A.; Halim, I.A.; Taleb, F.A.; Hamada, E.; Barsoum, M.; Abdullah, M.; Meshref, M. 2012: A phase 2 study of the combination of gemcitabine and cisplatin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines with/without taxanes. Hematology/Oncology and Stem Cell Therapy 5(1): 42-48

Reidy-Lagunes, D.L.; Vakiani, E.; Segal, M.F.; Hollywood, E.M.; Tang, L.H.; Solit, D.B.; Pietanza, M.C.; Capanu, M.; Saltz, L.B. 2012: A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer 118(19): 4795-4800

Slomovitz, B.M.; Lu, K.H.; Johnston, T.; Coleman, R.L.; Munsell, M.; Broaddus, R.R.; Walker, C.; Ramondetta, L.M.; Burke, T.W.; Gershenson, D.M.; Wolf, J. 2010: A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 116(23): 5415-5419

Neufeld, E.J.; Galanello, R.; Viprakasit, V.; Aydinok, Y.; Piga, A.; Harmatz, P.; Forni, G.Luca.; Shah, F.T.; Grace, R.F.; Porter, J.B.; Wood, J.C.; Peppe, J.; Jones, A.; Rienhoff, H.Young. 2012: A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood 119(14): 3263-3268

Sandborn, W.J.; Ghosh, S.; Panes, J.; Vranic, I.; Wang, W.; Niezychowski, W.; Vermeire, S.A.R.A.; Dewit, O.; Peeters, H.; Stehlik, J.; Vanasek, T.; Laharie, D.; Colombel, J.F.; Bigard, M.-A.é; Varga, M.; Zeher, M.; Novak, J.; Hunyady, B.; Salamon, A.; Racz, I.; Gionchetti, P.; Kohn, A.; Prantera, C.; Stokkers, P.C.F.; Slomka, M.; Paradowski, L.; Arlukowicz, T.; Kuzela, L.; Baricky, B.; Hlavaty, T.; Vera, M.I.; Panes, J.; Guardiola, J.; Probert, C.; Shaffer, J.L.; Fleisher, M.; Pruitt, R.E.; Sandborn, W.J.; Goff, J.S.; Weber, J.; Bell, R.L.; Zwick, A.H.; Gutierrez, A.; Levine, R.H.; Hanauer, S.B.; Lavelle, L.A.; Kottoor, R.K.; Dryden, G.W.; Hardi, R.; Glorioso, D.V.; Swaroop, P.; Lee, S.D.; Patrick, T.J.; Scheinert, S.; Sninsky, C.A.; Katz, 2014: A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clinical Gastroenterology and Hepatology: the Official Clinical Practice Journal of the American Gastroenterological Association 12(9): 1485-93.E2

Cook, N.; Basu, B.; Biswas, S.; Kareclas, P.; Mann, C.; Palmer, C.; Thomas, A.; Nicholson, S.; Morgan, B.; Lomas, D.; Sirohi, B.; Mander, A.P.; Middleton, M.; Corrie, P.G. 2010: A phase 2 study of vatalanib in metastatic melanoma patients. European Journal of Cancer 46(15): 2671-2673

Kirschbaum, M.H.; Goldman, B.H.; Zain, J.M.; Cook, J.R.; Rimsza, L.M.; Forman, S.J.; Fisher, R.I. 2012: A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leukemia and Lymphoma 53(2): 259-262

Schaefer, E.W.; Loaiza-Bonilla, A.; Juckett, M.; DiPersio, J.F.; Roy, V.; Slack, J.; Wu, W.; Laumann, K.; Espinoza-Delgado, I.; Gore, S.D. 2009: A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica 94(10): 1375-1382

Paik, P.K.; James, L.P.; Riely, G.J.; Azzoli, C.G.; Miller, V.A.; Ng, K.K.; Sima, C.S.; Heelan, R.T.; Kris, M.G.; Moore, E.; Rizvi, N.A. 2011: A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion. Cancer ChemoTherapy and Pharmacology 68(5): 1331-1337

Jain, N.; Wierda, W.; Ferrajoli, A.; Wong, F.; Lerner, S.; Keating, M.; O'Brien, S. 2009: A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia. Cancer 115(19): 4533-4539

Vardas, E.; Kaleebu, P.; Bekker, L.-G.; Hoosen, A.; Chomba, E.; Johnson, P.R.; Anklesaria, P.; Birungi, J.; Barin, B.; Boaz, M.; Cox, J.; Lehrman, J.; Stevens, G.; Gilmour, J.; Tarragona, T.; Hayes, P.; Lowenbein, S.; Kizito, E.; Fast, P.; Heald, A.E.; Schmidt, C. 2010: A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus. Aids Research and Human Retroviruses 26(8): 933-942

Amato, R.J.; Jac, J.; Giessinger, S.; Saxena, S.; Willis, J.P. 2009: A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 115(11): 2438-2446

Amir, E.; Simmons, C.E.; Freedman, O.C.; Dranitsaris, G.; Cole, D.E.C.; Vieth, R.; Ooi, W.S.; Clemons, M. 2010: A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases. Cancer 116(2): 284-291

Patthamalai, P.; Fuchareon, S.; Chaneiam, N.; Ghalie, R.G.; Chui, D.H.K.; Boosalis, M.S.; Perrine, S.P. 2014: A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia. Blood 123(12): 1956-1957

Pappo, A.S.; Vassal, G.; Crowley, J.J.; Bolejack, V.; Hogendoorn, P.C.W.; Chugh, R.; Ladanyi, M.; Grippo, J.F.; Dall, G.; Staddon, A.P.; Chawla, S.P.; Maki, R.G.; Araujo, D.M.; Geoerger, B.; Ganjoo, K.; Marina, N.; Blay, J.-Y.; Schuetze, S.M.; Chow, W.A.; Helman, L.J. 2014: A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. Cancer 120(16): 2448-2456

Matsubara, N.; Uemura, H.; Satoh, T.; Suzuki, H.; Nishiyama, T.; Uemura, H.; Hashine, K.; Imanaka, K.; Ozono, S.; Akaza, H. 2014: A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study). Japanese Journal of Clinical Oncology 44(12): 1216-1226

Nand, S.; Othus, M.; Godwin, J.E.; Willman, C.L.; Norwood, T.H.; Howard, D.S.; Coutre, S.E.; Erba, H.P.; Appelbaum, F.R. 2013: A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Blood 122(20): 3432-3439

Grignol, V.P.; Olencki, T.; Relekar, K.; Taylor, C.; Kibler, A.; Kefauver, C.; Wei, L.; Walker, M.J.; Chen, H.X.; Kendra, K.; Carson, W.E. 2011: A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma. Journal of ImmunoTherapy 34(6): 509-515

Argiris, A.; Ghebremichael, M.; Burtness, B.; Axelrod, R.S.; Deconti, R.C.; Forastiere, A.A. 2011: A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303). Cancer 117(15): 3374-3382

Bejanyan, N.; Tiu, R.V.; Raza, A.; Jankowska, A.; Kalaycio, M.; Advani, A.; Chan, J.; Saunthararajah, Y.; Mooney, L.; Maciejewski, J.P.; Sekeres, M.A. 2012: A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF). Cancer 118(16): 3968-3976

Sosman, J.A.; Moon, J.; Tuthill, R.J.; Warneke, J.A.; Vetto, J.T.; Redman, B.G.; Liu, P.Y.; Unger, J.M.; Flaherty, L.E.; Sondak, V.K. 2011: A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer 117(20): 4740

Reckamp, K.L.; Giaccone, G.; Camidge, D.R.; Gadgeel, S.M.; Khuri, F.R.; Engelman, J.A.; Koczywas, M.; Rajan, A.; Campbell, A.K.; Gernhardt, D.; Ruiz-Garcia, A.; Letrent, S.; Liang, J.; Taylor, I.; O'Connell, J.P.; Jänne, P.A. 2014: A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer 120(8): 1145-1154

Kluger, H.M.; Dudek, A.Z.; McCann, C.; Ritacco, J.; Southard, N.; Jilaveanu, L.B.; Molinaro, A.; Sznol, M. 2011: A phase 2 trial of dasatinib in advanced melanoma. Cancer 117(10): 2202-2208

Mayer, E.L.; Baurain, J.-F.; Sparano, J.; Strauss, L.; Campone, M.; Fumoleau, P.; Rugo, H.; Awada, A.; Sy, O.; Llombart-Cussac, A. 2011: A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 17(21): 6897-6904

Ilson, D.H.; Kelsen, D.; Shah, M.; Schwartz, G.; Levine, D.A.; Boyd, J.; Capanu, M.; Miron, B.; Klimstra, D. 2011: A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer 117(7): 1409-1414

Grant, B.W.; Jung, S.-H.; Johnson, J.L.; Kostakoglu, L.; Hsi, E.; Byrd, J.C.; Jones, J.; Leonard, J.P.; Martin, S.E.; Cheson, B.D. 2013: A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer 119(21): 3797-3804

Bible, K.C.; Peethambaram, P.P.; Oberg, A.L.; Maples, W.; Groteluschen, D.L.; Boente, M.; Burton, J.K.; Gomez Dahl, L.C.; Tibodeau, J.D.; Isham, C.R.; Maguire, J.L.; Shridhar, V.; Kukla, A.K.; Voll, K.J.; Mauer, M.J.; Colevas, A.D.; Wright, J.; Doyle, L.A.; Erlichman, C. 2012: A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261. Gynecologic Oncology 127(1): 55-62

Zinzani, P.Luigi.; Tani, M.; Fanti, S.; Stefoni, V.; Musuraca, G.; Vitolo, U.; Perrotti, A.; Fina, M.; Derenzini, E.; Baccarani, M. 2008: A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. Cancer 112(4): 856-862

Mamon, H.J.; Niedzwiecki, D.; Hollis, D.; Tan, B.R.; Mayer, R.J.; Tepper, J.E.; Goldberg, R.M.; Blackstock, A.W.; Fuchs, C.S. 2011: A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003. Cancer 117(12): 2620-2628

Chiorean, E.G.; Dragovich, T.; Hamm, J.; Barrios, C.H.; Gorini, C.F.; Langmuir, V.K.; Kroll, S.; Jung, D.T.; Tidmarsh, G.T.; Loehrer, P.J. 2010: A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma. American Journal of Clinical Oncology 33(2): 111-116

Grignani, G.; Palmerini, E.; Stacchiotti, S.; Boglione, A.; Ferraresi, V.; Frustaci, S.; Comandone, A.; Casali, P.G.; Ferrari, S.; Aglietta, M. 2011: A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β: An Italian Sarcoma Group study. Cancer 117(4): 826-831

Koç, O.N.; Redfern, C.; Wiernik, P.H.; Rosenfelt, F.; Winter, J.N.; Carter, W.D.; Gold, D.P.; Stewart, M.E.; Ghalie, R.G.; Bender, J.F. 2010: A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma. Journal of ImmunoTherapy 33(2): 178-184

Rocha Lima, C.M.; Lin, E.H.; Kim, G.P.; Giguere, J.K.; Marshall, J.; Zalupski, M.; Papageorgio, C.; Auber, M.L.; Kaleta, R.; McHenry, M.B.; Trifan, O.C.; Philip, P.A. 2012: A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer. Gastrointestinal Cancer Research: Gcr 5(5): 155-160

Richardson, P.G.; Xie, W.; Jagannath, S.; Jakubowiak, A.; Lonial, S.; Raje, N.S.; Alsina, M.; Ghobrial, I.M.; Schlossman, R.L.; Munshi, N.C.; Mazumder, A.; Vesole, D.H.; Kaufman, J.L.; Colson, K.; McKenney, M.; Lunde, L.E.; Feather, J.; Maglio, M.E.; Warren, D.; Francis, D.; Hideshima, T.; Knight, R.; Esseltine, D.-L.; Mitsiades, C.S.; Weller, E.; Anderson, K.C. 2014: A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood 123(10): 1461-1469

Juretzka, M.; Hensley, M.L.; Tew, W.; Konner, J.; Aghajanian, C.; Leitao, M.; Iasonos, A.; Soslow, R.; Park, K.; Sabbatini, P. 2008: A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission. European Journal of Gynaecological Oncology 29(6): 568-572

Cortes, J.E.; Kim, D-W.; Pinilla-Ibarz, J.; le Coutre, P.; Paquette, R.; Chuah, C.; Nicolini, F.E.; Apperley, J.F.; Khoury, H.J.; Talpaz, M.; DiPersio, J.; DeAngelo, D.J.; Abruzzese, E.; Rea, D.; Baccarani, M.; Müller, M.C.; Gambacorti-Passerini, C.; Wong, S.; Lustgarten, S.; Rivera, V.M.; Clackson, T.; Turner, C.D.; Haluska, F.G.; Guilhot, F.; Deininger, M.W.; Hochhaus, A.; Hughes, T.; Goldman, J.M.; Shah, N.P.; Kantarjian, H.; Hughes, T.; Schwarer, A.; MacCallum, P.; Seymour, J.; Arthur, C.; Mills, A.; Knoops, L.; Verhoef, G.; Assouline, S.; Lipton, J.H.; Forrest, D.; Bence-Bruckler, I.; Laneuville, P.; Etienne, G.; Rousselot, P.; Coiteux, V.; Rea, D.; Nicolini, F..E.; Guilhot, F.; Legros, L.; Huguet- Rigal, F.; Guerci-Bresler, A-P.; 2013: A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. New England Journal of Medicine 369(19): 1783-1796

Cho, H.; Nam, B.-H.; Kim, S.M.; Cho, C.-H.; Kim, B.G.; Ryu, H.-S.; Kang, S.B.; Kim, J.-H. 2014: A phase 2 trial of radiation therapy with concurrent paclitaxel chemotherapy after surgery in patients with high-risk endometrial cancer: a Korean Gynecologic Oncologic Group study. International Journal of Radiation Oncology Biology Physics 90(1): 140-146

Tarhini, A.A.; Kirkwood, J.M.; Gooding, W.E.; Moschos, S.; Agarwala, S.S. 2008: A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma. Cancer 113(7): 1632-1640

Raizer, J.J.; Grimm, S.; Chamberlain, M.C.; Nicholas, M.K.; Chandler, J.P.; Muro, K.; Dubner, S.; Rademaker, A.W.; Renfrow, J.; Bredel, M. 2010: A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 116(22): 5297-5305

Stopeck, A.T.; Unger, J.M.; Rimsza, L.M.; LeBlanc, M.; Farnsworth, B.; Iannone, M.; Glenn, M.J.; Fisher, R.I.; Miller, T.P. 2012: A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood 120(6): 1210-1217

Brennan, C.; Yang, T.Jonathan.; Hilden, P.; Zhang, Z.; Chan, K.; Yamada, Y.; Chan, T.A.; Lymberis, S.C.; Narayana, A.; Tabar, V.; Gutin, P.H.; Ballangrud, Åse.; Lis, E.; Beal, K. 2014: A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases. International Journal of Radiation Oncology Biology Physics 88(1): 130-136

Yoo, G.H.; Moon, J.; Leblanc, M.; Lonardo, F.; Urba, S.; Kim, H.; Hanna, E.; Tsue, T.; Valentino, J.; Ensley, J.; Wolf, G. 2009: A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. Archives of Otolaryngology--Head and Neck Surgery 135(9): 869-874

Tolosa, E.; Litvan, I.; Höglinger, G.ün.U.; Burn, D.; Lees, A.; Andrés, M.ía.V.; Gómez-Carrillo, B.én.; León, T.; Del Ser, T.; Gómez, J.C.; Tijero, B.; Berganzo, K.; de Yebenes, J. G.ía.; Lopez Sendón, J.L.; Garcia, G.; Tolosa, E.; Buongiorno, M.T.; Bargalló, N.; Burguera, J.A.; Martinez, I.; Ruiz-Martínez, J.; Narrativel, I.; Vivancos, F.; Ybot, I.; Aguilar, M.; Quilez, P.; Boada, M.; Lafuente, A.; Hernandez, I.; López- Lozano, J.J.; Mata, M.; Kupsch, A.; Lipp, A.; Ebersbach, G.; Schmidt, T.; Hahn, K.; oglinger, G. H.; Höllerhage, M.; Oertel, W.H.; Respondek, G.; Stamelou, M.; Reichmann, H.; Wolz, M.; Schneider, C.; Klingelhöfer, L.; Berg, D.; Maetzler, W.; Srulijes, K.K.; Ludolph, A.; Kassubek, J.; Steiger, M.; Tyler, K.; B 2014: A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Movement Disorders: Official Journal of the Movement Disorder Society 29(4): 470-478

Baruchel, S.; Pappo, A.; Krailo, M.; Baker, K.Scott.; Wu, B.; Villaluna, D.; Lee-Scott, M.; Adamson, P.C.; Blaney, S.M. 2012: A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group. European Journal of Cancer 48(4): 579-585

Chamberlain, M.C.; Grimm, S.; Phuphanich, S.; Recht, L.; Zhu, J.Z.; Kim, L.; Rosenfeld, S.; Fadul, C.E. 2014: A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational Consortium (BTIC). Journal of Neuro-Oncology 118(2): 335-343

Cassier, P.A.; Ray-Coquard, I.; Sunyach, M.-P.; Lancry, L.; Guastalla, J.-P.; Ferlay, C.él.; Gomez, F.éd.ér.; Curé, H.é; Lortholary, A.; Claude, L.; Blay, J.-Y.; Bachelot, T. 2008: A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer. Cancer 113(9): 2532-2538

Vollmer, T.L.; Wynn, D.R.; Alam, M.S.; Valdes, J. 2011: A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis. Multiple Sclerosis 17(2): 181-191

Dayan, S.H.; Arkins, J.P.; Sharma, V.; Paterson, E.; Barnes, D. 2011: A phase 2, double-blind, randomized, placebo-controlled trial of a novel nutritional supplement product to promote healthy skin. Journal of Drugs in Dermatology: Jdd 10(10): 1106-1114

Morschhauser, F.; Fitoussi, O.; Haioun, C.; Thieblemont, C.; Quach, H.; Delarue, R.; Glaisner, S.; Gabarre, J.; Bosly, A.é; Lister, J.; Li, J.; Coiffier, B. 2013: A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. European Journal of Cancer 49(13): 2869-2876

Volf, E.M.; Au, S.-C.; Dumont, N.; Scheinman, P.; Gottlieb, A.B. 2012: A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. Journal of Drugs in Dermatology: Jdd 11(3): 341-346

Wong, C.J.; Witcher, J.; Mallinckrodt, C.; Dean, R.A.; Anton, R.F.; Chen, Y.; Fijal, B.A.; Ouyang, H.; Dharia, S.; Sundseth, S.S.; Schuh, K.J.; Kinon, B.J. 2014: A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence. Alcoholism Clinical and Experimental Research 38(2): 511-520

Furie, R.A.; Leon, G.; Thomas, M.; Petri, M.A.; Chu, A.D.; Hislop, C.; Martin, R.S.; Scheinberg, M.A. 2015: A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Annals of the Rheumatic Diseases 74(9): 1667-1675

Tarhini, A.A.; Millward, M.; Mainwaring, P.; Kefford, R.; Logan, T.; Pavlick, A.; Kathman, S.J.; Laubscher, K.H.; Dar, M.M.; Kirkwood, J.M. 2009: A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer 115(4): 859-868

Schachar, R.A.; Raber, S.; Courtney, R.; Zhang, M. 2011: A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Current Eye Research 36(9): 809-817

Fernández, P.; Trenholme, A.; Abarca, K.; Griffin, M.P.; Hultquist, M.; Harris, B.; Losonsky, G.A.; McCreanor, J.; Nissen, M.; Reynolds, G.; Robertson, C.; Wake, C.; Lindemann, C.; Mena, P.; Novoa, J.; Peña, V.; Vivanco, G.; Austin, N.; Brown, J.; Jackson, P.; Weston, P. 2010: A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. Bmc Pediatrics 10: 38

Gittelman, M.; Weiss, H.; Seidman, L. 2014: A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women. Journal of Urology 191(4): 1014-1021

Garcia-Manero, G.; Gartenberg, G.; Steensma, D.P.; Schipperus, M.R.; Breems, D.A.; de Paz, R.; Valcárcel, D.; Kranenburg, B.; Reddy, M.; Komrokji, R.S. 2014: A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome. American Journal of Hematology 89(9): E156-E162

Ratziu, V.; Sheikh, M.Y.; Sanyal, A.J.; Lim, J.K.; Conjeevaram, H.; Chalasani, N.; Abdelmalek, M.; Bakken, A.; Renou, C.; Palmer, M.; Levine, R.A.; Bhandari, B.R.; Cornpropst, M.; Liang, W.; King, B.; Mondou, E.; Rousseau, F.S.; McHutchison, J.; Chojkier, M. 2012: A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 55(2): 419-428

Orlowski, R.Z.; Gercheva, L.; Williams, C.; Sutherland, H.; Robak, T.; Masszi, T.ás.; Goranova-Marinova, V.; Dimopoulos, M.A.; Cavenagh, J.D.; Špička, I.; Maiolino, A.; Suvorov, A.; Bladé, J.; Samoylova, O.; Puchalski, T.A.; Reddy, M.; Bandekar, R.; van de Velde, H.; Xie, H.; Rossi, J.-F.ςo. 2015: A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. American Journal of Hematology 90(1): 42-49

Markman, M. 2009: A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecologic oncology 114(1): 136-7; authore reply 137

Halse, J.; Greenspan, S.; Cosman, F.; Ellis, G.; Santora, A.; Leung, A.; Heyden, N.; Samanta, S.; Doleckyj, S.; Rosenberg, E.; Denker, A.E. 2014: A phase 2, randomized, placebo-controlled, dose-ranging study of the calcium-sensing receptor antagonist MK-5442 in the treatment of postmenopausal women with osteoporosis. Journal of Clinical Endocrinology and Metabolism 99(11): E2207-E2215

Mitchell, P.L.; Quinn, M.A.; Grant, P.T.; Allen, D.G.; Jobling, T.W.; White, S.C.; Zhao, A.; Karanikas, V.; Vaughan, H.; Pietersz, G.; McKenzie, I.F.; Gargosky, S.E.; Loveland, B.E. 2014: A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer. Journal for ImmunoTherapy of Cancer 2: 16

Garcia, J.A.; Hudes, G.R.; Choueiri, T.K.; Stadler, W.M.; Wood, L.S.; Gurtler, J.; Bhatia, S.; Joshi, A.; Hozak, R.R.; Xu, Y.; Schwartz, J.D.; Thompson, J.A. 2014: A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. Cancer 120(11): 1647-1655

Sultan, M.B.; Zhou, D.; Loftus, J.; Dombi, T.; Ice, K.S.; Bird, A.; D'Amico, D.; Herson, J.; Klein, R.; Wallisch, M.; de Gronckel, S.; Danielson, L.; Quinaz, E.; Wang, K.; Balbueno, S.; Mikusova, B.; Spiller, H.-W.; Cameron, P.; Sawa, M.; Wallace, S.; Altaweel, M.; Danis, R.; Domalpally, A.; Alexander, S.; Corkery, E.; Daywalt, M.; Dohm, K.; Endres, R.; Goulding, A.; Reimers, J.; Susman, R.; Wabers, H.; Whilhelmson, T.; White, J.; Lim, L.; Wong, T.; Mitchell, P.; Kralinger, M.; Stur, M.; Avila, M.; Farah, M.; Lavinsky, J.; Maberly, D.; Olivier, S.; Rosemont, P.; Dusova, J.; Ernest, J.; Fiser, I.; Kolar, P.; Rehak, J.; Larsen, M.; Berrod, J.-P.; Devin, F.; Koenig-Supiot, F.; Massin, P.; Soubrane, G.; Dithmar, S.; Holz, F.; Joussen, A.; 2011: A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 118(6): 1107-1118

Orri, M.; Abraham, L.; Giraldi, A. 2013: A phase 2a multicenter, double-blind, placebo-controlled, crossover trial to investigate the efficacy, safety, and toleration of CP-866,087 (a high-affinity mu-opioid receptor antagonist) in premenopausal women diagnosed with female sexual arousal disorder (FSAD). Journal of Sexual Medicine 10(10): 2484-2496

Stocks, J.D.; Taneja, B.K.; Baroldi, P.; Findling, R.L. 2012: A phase 2a randomized, parallel group, dose-ranging study of molindone in children with attention-deficit/hyperactivity disorder and persistent, serious conduct problems. Journal of Child and Adolescent Psychopharmacology 22(2): 102-111

Stratton, S.P.; Alberts, D.S.; Einspahr, J.G.; Sagerman, P.M.; Warneke, J.A.; Curiel-Lewandrowski, C.; Myrdal, P.B.; Karlage, K.L.; Nickoloff, B.J.; Brooks, C.; Saboda, K.; Yozwiak, M.L.; Krutzsch, M.F.; Hu, C.; Lluria-Prevatt, M.; Dong, Z.; Bowden, G.Timothy.; Bartels, P.H. 2010: A phase 2a study of topical perillyl alcohol cream for chemoprevention of skin cancer. Cancer Prevention Research 3(2): 160-169

Lawitz, E.; Poordad, F.; Kowdley, K.V.; Cohen, D.E.; Podsadecki, T.; Siggelkow, S.; Larsen, L.; Menon, R.; Koev, G.; Tripathi, R.; Pilot-Matias, T.; Bernstein, B. 2013: A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. Journal of Hepatology 59(1): 18-23

Harden, R.N.; Freeman, R.; Rainka, M.; Zhang, L.; Bell, C.; Berges, A.; Chen, C.; Graff, O.; Harding, K.; Hunter, S.; Kavanagh, S.; Schwartzbach, C.; Warren, S.; McClung, C. 2013: A phase 2a, randomized, crossover trial of gabapentin enacarbil for the treatment of postherpetic neuralgia in gabapentin inadequate responders. Pain Medicine 14(12): 1918-1932

Yasui, H.; Muro, K.; Shimada, Y.; Tsuji, A.; Sameshima, S.; Baba, H.; Satoh, T.; Denda, T.; Ina, K.; Nishina, T.; Yamaguchi, K.; Esaki, T.; Tokunaga, S.; Kuwano, H.; Boku, N.; Komatsu, Y.; Watanabe, M.; Hyodo, I.; Morita, S.; Sugihara, K. 2015: A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. Journal of Cancer Research and Clinical Oncology 141(1): 153-160

Awad, S.S.; Rodriguez, A.H.; Chuang, Y.-C.; Marjanek, Z.; Pareigis, A.J.; Reis, G.; Scheeren, T.W.L.; Sánchez, A.S.; Zhou, X.; Saulay, M.ël.; Engelhardt, M. 2014: A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 59(1): 51-61

Jean-Pierre, P.; Morrow, G.R.; Roscoe, J.A.; Heckler, C.; Mohile, S.; Janelsins, M.; Peppone, L.; Hemstad, A.; Esparaz, B.T.; Hopkins, J.O. 2010: A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer 116(14): 3513-3520

Katakami, N.; Tada, H.; Mitsudomi, T.; Kudoh, S.; Senba, H.; Matsui, K.; Saka, H.; Kurata, T.; Nishimura, Y.; Fukuoka, M. 2012: A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903). Cancer 118(24): 6126-6135

Agnandji, S.Todagbe.; Lell, B.; Fernandes, Jé.Francisco.; Abossolo, Béatrice.Peggy.; Methogo, B.Gaelle.Nfono.Ondo.; Kabwende, A.Lumeka.; Adegnika, A.Akim.; Mordmüller, B.; Issifou, S.; Kremsner, P.Gottfried.; Sacarlal, J.; Aide, P.; Lanaspa, M.; Aponte, J.J.; Machevo, S.; Acacio, S.; Bulo, H.; Sigauque, B.; Macete, Eébio.; Alonso, P.; Abdulla, S.; Salim, N.; Minja, R.; Mpina, M.; Ahmed, S.; Ali, A.Mohammed.; Mtoro, A.Takadir.; Hamad, A.Said.; Mutani, P.; Tanner, M.; Tinto, H.; D'Alessandro, U.; Sorgho, H.; Valea, I.; Bihoun, Bébo.; Guiraud, I.; Kaboré, B.; Sombié, O.; G 2012: A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. New England Journal of Medicine 367(24): 2284-2295

Berenson, J.R.; Yellin, O.; Shamasunder, H.K.; Chen, C.-S.; Charu, V.; Woliver, T.B.; Sanani, S.; Schlutz, M.; Nassir, Y.; Swift, R.A.; Andreu-Vieyra, C.; Vescio, R. 2015: A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer 23(6): 1503-1512

Perren, T.J.; Swart, A.Marie.; Pfisterer, J.; Ledermann, J.A.; Pujade-Lauraine, E.; Kristensen, G.; Carey, M.S.; Beale, P.; Cervantes, Aés.; Kurzeder, C.; du Bois, A.; Sehouli, J.; Kimmig, R.; Stähle, A.; Collinson, F.; Essapen, S.; Gourley, C.; Lortholary, A.; Selle, Fédéric.; Mirza, M.R.; Leminen, A.; Plante, M.; Stark, D.; Qian, W.; Parmar, M.K.B.; Oza, A.M.; Pfisterer, J.; Krüger, A.; Elser, G.; Paschold, C.; Beha, M.; Peters, N.; Tulusan, A.H.; Sehouli, J.; Potenberg, J.; Keil, E.; Klare, P.; Weiss, E.; Behringer, D.; Gropp, M.; Pölcher, M.; 2011: A phase 3 trial of bevacizumab in ovarian cancer. New England Journal of Medicine 365(26): 2484-2496

Goodman, A.D.; Brown, T.R.; Edwards, K.R.; Krupp, L.B.; Schapiro, R.T.; Cohen, R.; Marinucci, L.N.; Blight, A.R.; Agius, M.; Arnason, B.G.W.; Bethoux, F.A.; Bever, C.T.; Brown, T.R.; Camac, A.; Cooper, J.A.; Chumley, W.F.; Cross, A.; Dietrich, D.W.; Dunnigan, R.T.; Edwards, K.; Freedman, M.; Gitt, J.S.; Hillen, M.; Jeffery, D.R.; Kachuck, N.J.; Khatri, B.O.; Kaufman, M.D.; Khan, O.; Kresa-Reahl, K.; Krupp, L.B.; Leist, T.P.; Lublin, F.D.; Mass, M.K.; Mattson, D.; McGowan, D.; Moon, S.; O'Connell, C.; Oger, J.J.; Panitch, H.; Picone, M.A.; Preiningerova, J.; Rammohan, K.W.; Schapiro, R.T.; Schwid, S.R.; Short, C.; Thrower, B.W.; Tullman, M.; Weinstock-Guttman, B.; Wynn, D.R.; Vollmer, T.L. 2010: A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of Neurology 68(4): 494-502

King, T.E.; Bradford, W.Z.; Castro-Bernardini, S.; Fagan, E.A.; Glaspole, I.; Glassberg, M.K.; Gorina, E.; Hopkins, P.M.; Kardatzke, D.; Lancaster, L.; Lederer, D.J.; Nathan, S.D.; Pereira, C.A.; Sahn, S.A.; Sussman, R.; Swigris, J.J.; Noble, P.W.; Allen, J.N.; Alves, Rério.Lopes.Rufino.; Antin-Ozerkis, D.; Bajwa, A.A.; Bascom, R.; Baughman, R.; Beckert, L.Erwin.Lothar.; Belperio, J.; Ben-Dov, I.; Breuer, R.; Butler, J.A.; de Carvalho, C.Roberto.Ribeiro.; Chan, A.L.; Chang, J.; Chavarría Martínez, U.; Clifford, D.P.; Cordova, F.; Corte, T.; Covelli, H.D.; Davi 2014: A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. New England Journal of Medicine 370(22): 2083-2092

Doody, R.S.; Raman, R.; Farlow, M.; Iwatsubo, T.; Vellas, B.; Joffe, S.; Kieburtz, K.; He, F.; Sun, X.; Thomas, R.G.; Aisen, P.S.; Siemers, E.; Sethuraman, G.; Mohs, R. 2013: A phase 3 trial of semagacestat for treatment of Alzheimer's disease. New England Journal of Medicine 369(4): 341-350

Binkley, N.; Bolognese, M.; Sidorowicz-Bialynicka, A.; Vally, T.; Trout, R.; Miller, C.; Buben, C.E.; Gilligan, J.P.; Krause, D.S.; Yaneva, D.; Cseuz, R.; Bagul, N.; Govindraj, S.; Abdulhakim, E.; Sarmiento, R.; Ellahbadi, R.; Shaw, H.; Thomas, H.; Greenwald, M.; Kivitz, A.; Lewiecki, M.; Aloia, J.; Gallagher, J.; Schwartz, E.; Shergy, W. 2012: A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research 27(8): 1821-1829

Robins, H.Ian.; O'Neill, A.; Mehta, M.; Grossman, S. 2013: A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT & SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320: in regard to Sperduto et al. International Journal of Radiation Oncology Biology Physics 86(5): 809-810

Lynch, D.R.; Perlman, S.L.; Meier, T. 2010: A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Archives of Neurology 67(8): 941-947

Klotz, L.H.; McNeill, I.Y.; Kebabdjian, M.; Zhang, L.; Chin, J.L.; Pommerville, P.; Drachenberg, D.; Rendon, R.; Kapoor, A.; Morales, A.; Siemens, R.; Wilson, J.; Abdelhady, M.; Izawa, J.I.; Paulter, S.; Egerdie, B.; Sachdeva, K.; Morash, C.; Mahoney, J.; Abramovitch, A.; Carr, L.; Jain, U.; Kell, J.; Nam, R.; Pace, K.; Sharir, S.; Singal, R.; Toguri, A.; Simard, J.; Karakiewics, P.; Perrotte, P.; Saad, F.; Valiquette, L.; D Eiley; Claire, P.; Audet, J.; Charrois, R.; Dujardin, T.; Fradet, Y.; Gregoire, M.; Lacombe, L.; Laroche, B.; Thabet, M.; Verina, J. 2013: A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study. European Urology 63(5): 927-935

Rosenberg, R.P.; Bogan, R.K.; Tiller, J.M.; Yang, R.; Youakim, J.M.; Earl, C.Q.; Roth, T. 2010: A phase 3, double-blind, randomized, placebo-controlled study of armodafinil for excessive sleepiness associated with jet lag disorder. Mayo Clinic Proceedings 85(7): 630-638

Mulhall, J.P.; Burnett, A.L.; Wang, R.; McVary, K.T.; Moul, J.W.; Bowden, C.H.; DiDonato, K.; Shih, W.; Day, W.W. 2013: A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy. Journal of Urology 189(6): 2229-2236

Chapman, W.C.; Singla, N.; Genyk, Y.; McNeil, J.W.; Renkens, K.L.; Reynolds, T.C.; Murphy, A.; Weaver, F.A. 2007: A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. Journal of the American College of Surgeons 205(2): 256-265

Maru, A.; Gangadharan, V.P.; Desai, C.J.; Mohapatra, R.K.; Carides, A.D. 2013: A phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: results of an Indian population subanalysis. Indian Journal of Cancer 50(4): 285-291

Silvestri, G.A.; Vincent, B.D.; Wahidi, M.M.; Robinette, E.; Hansbrough, J.R.; Downie, G.H. 2009: A phase 3, randomized, double-blind study to assess the efficacy and safety of fospropofol disodium injection for moderate sedation in patients undergoing flexible bronchoscopy. Chest 135(1): 41-47

Singla, N.K.; Ballard, J.L.; Moneta, G.; Randleman, C.D.; Renkens, K.L.; Alexander, W.A. 2009: A phase 3b, open-label, single-group immunogenicity and safety study of topical recombinant thrombin in surgical hemostasis. Journal of the American College of Surgeons 209(1): 68-74

Karapetis, C.S.; Cheong, K.A.; Yip, D.; Strickland, A.H.; Steer, C.; Marx, G.; Yip, S.; Chrystal, K.; Harper, P.G. 2010: A phase i and Ii trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas. Asia-Pacific Journal of Clinical Oncology 6(4): 298-305

Geyer, J.R.; Stewart, C.F.; Kocak, M.; Broniscer, A.; Phillips, P.; Douglas, J.G.; Blaney, S.M.; Packer, R.J.; Gururangan, S.; Banerjee, A.; Kieran, M.W.; Kun, L.E.; Gilbertson, R.J.; Boyett, J.M. 2010: A phase i and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. European Journal of Cancer 46(18): 3287-3293

Foran, J.; Ravandi, F.; Wierda, W.; Garcia-Manero, G.; Verstovsek, S.; Kadia, T.; Burger, J.; Yule, M.; Langford, G.; Lyons, J.; Ayrton, J.; Lock, V.; Borthakur, G.; Cortes, J.; Kantarjian, H. 2014: A phase i and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. Clinical Lymphoma Myeloma and Leukemia 14(3): 223-230

Roxburgh, P.; Lumsden, G.R.; Paul, J.; Harden, S.; Sweeting, L.; James, A.; Crellin, A.; Morrison, R.; Evans, T.R.J.; McDonald, A.C. 2014: A phase i and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. Cancer ChemoTherapy and Pharmacology 74(1): 131-139

Goss, G.; Shepherd, F.A.; Laurie, S.; Gauthier, I.; Leighl, N.; Chen, E.; Feld, R.; Powers, J.; Seymour, L. 2009: A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. European Journal of Cancer 45(5): 782-788

Salazar, R.; Jones, R.J.; Oaknin, A.; Crawford, D.; Cuadra, C.; Hopkins, C.; Gil, M.; Coronado, C.; Soto-Matos, A.; Cullell-Young, M.; Iglesias Dios, J.L.; Evans, T.R.J. 2012: A phase i and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors. Cancer ChemoTherapy and Pharmacology 70(5): 673-681

Goyal, L.; Wadlow, R.C.; Blaszkowsky, L.S.; Wolpin, B.M.; Abrams, T.A.; McCleary, N.J.; Sheehan, S.; Sundaram, E.; Karol, M.D.; Chen, J.; Zhu, A.X. 2015: A phase i and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. Investigational new Drugs 33(1): 128-137

Van Riel, J.M.; Peters, G.J.; Mammatas, L.H.; Honeywell, R.J.; Laan, A.C.; Ruyter, R.; van den Berg, F.G.; Giaccone, G.; van Groeningen, C.J. 2009: A phase i and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. European Journal of Cancer 45(14): 2519-2527

Plummer, R.; Woll, P.; Fyfe, D.; Boddy, A.V.; Griffin, M.; Hewitt, P.; Carmichael, J.; Namouni, F.; Cohen, M.; Verrill, M. 2008: A phase i and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignancies. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 14(24): 8288-8294

Midgley, R.S.; Kerr, D.J.; Flaherty, K.T.; Stevenson, J.P.; Pratap, S.E.; Koch, K.M.; Smith, D.A.; Versola, M.; Fleming, R.A.; Ward, C.; O'Dwyer, P.J.; Middleton, M.R. 2007: A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Annals of Oncology: Official Journal of the European Society for Medical Oncology 18(12): 2025-2029

Chu, Q.S.C.; Cianfrocca, M.E.; Goldstein, L.J.; Gale, M.; Murray, N.; Loftiss, J.; Arya, N.; Koch, K.M.; Pandite, L.; Fleming, R.A.; Paul, E.; Rowinsky, E.K. 2008: A phase i and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 14(14): 4484-4490

Yang, S.-H.; Lin, C.-C.; Lin, Z.-Z.; Tseng, Y.-L.; Hong, R.-L. 2012: A phase i and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor. Investigational new Drugs 30(1): 282-289

Burris, H.A.; Taylor, C.W.; Jones, S.F.; Koch, K.M.; Versola, M.J.; Arya, N.; Fleming, R.A.; Smith, D.A.; Pandite, L.; Spector, N.; Wilding, G. 2009: A phase i and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 15(21): 6702-6708

Figg, W.D.; Monga, M.; Headlee, D.; Shah, A.; Chau, C.H.; Peer, C.; Messman, R.; Elsayed, Y.A.; Murgo, A.J.; Melillo, G.; Ryan, Q.C.; Kalnitskiy, M.; Senderowicz, A.M.; Hollingshead, M.; Arbuck, S.G.; Sausville, E.A. 2014: A phase i and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms. Cancer ChemoTherapy and Pharmacology 74(5): 955-967

Kobrinsky, B.; Joseph, S.O.; Muggia, F.; Liebes, L.; Beric, A.; Malankar, A.; Ivy, P.; Hochster, H. 2013: A phase i and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity. Cancer ChemoTherapy and Pharmacology 72(5): 1073-1078

Verschraegen, C.F.; Skubitz, K.; Daud, A.; Kudelka, A.P.; Rabinowitz, I.; Allievi, C.; Eisenfeld, A.; Singer, J.W.; Oldham, F.B. 2009: A phase i and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. Cancer ChemoTherapy and Pharmacology 63(5): 903-910

Britten, C.D.; Kabbinavar, F.; Hecht, J.R.; Bello, C.L.; Li, J.; Baum, C.; Slamon, D. 2008: A phase i and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer ChemoTherapy and Pharmacology 61(3): 515-524

Gore, L.; Rothenberg, M.L.; O'Bryant, C.L.; Schultz, M.K.; Sandler, A.B.; Coffin, D.; McCoy, C.; Schott, A.; Scholz, C.; Eckhardt, S.G. 2008: A phase i and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 14(14): 4517-4525

Undevia, S.D.; Innocenti, F.; Ramirez, J.; House, L.; Desai, A.A.; Skoog, L.A.; Singh, D.A.; Karrison, T.; Kindler, H.L.; Ratain, M.J. 2008: A phase i and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. European Journal of Cancer 44(12): 1684-1692

Bekaii-Saab, T.S.; Liu, J.; Chan, K.K.; Balcerzak, S.P.; Ivy, P.S.; Grever, M.R.; Kraut, E.H. 2008: A phase i and pharmacokinetic study of weekly oxaliplatin followed by paclitaxel in patients with solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 14(11): 3434-3440

Chiorean, E.Gabriela.; Porter, J.M.; Foster, A.E.; Al Omari, A.S.H.; Yoder, C.A.; Fife, K.L.; Strother, R.Matthew.; Murry, D.J.; Yu, M.; Jones, D.R.; Sweeney, C.J. 2008: A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 14(4): 1131-1137

Muindi, J.R.; Johnson, C.S.; Trump, D.L.; Christy, R.; Engler, K.L.; Fakih, M.G. 2009: A phase i and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. Cancer ChemoTherapy and Pharmacology 65(1): 33-40

Lee, D.H.; Kim, S.-W.; Bae, K.-S.; Hong, J.-S.; Suh, C.; Kang, Y.-K.; Lee, J.-S. 2007: A phase i and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 13(20): 6182-6186

Dees, E.C.; O'Neil, B.H.; Lindley, C.M.; Collichio, F.; Carey, L.A.; Collins, J.; Riordan, W.J.; Ivanova, A.; Esseltine, D.; Orlowski, R.Z. 2008: A phase i and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. Cancer ChemoTherapy and Pharmacology 63(1): 99-107

Abbas, R.; Hug, B.A.; Leister, C.; Gaaloul, M.E.; Chalon, S.; Sonnichsen, D. 2012: A phase i ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. Cancer ChemoTherapy and Pharmacology 69(1): 221-227

Scott, A.M.; Tebbutt, N.; Lee, F.-T.; Cavicchiolo, T.; Liu, Z.; Gill, S.; Poon, A.M.T.; Hopkins, W.; Smyth, F.E.; Murone, C.; MacGregor, D.; Papenfuss, A.T.; Chappell, B.; Saunder, T.H.; Brechbiel, M.W.; Davis, I.D.; Murphy, R.; Chong, G.; Hoffman, E.W.; Old, L.J. 2007: A phase i biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 13(11): 3286-3292

Klisovic, R.B.; Stock, W.; Cataland, S.; Klisovic, M.I.; Liu, S.; Blum, W.; Green, M.; Odenike, O.; Godley, L.; Burgt, J.V.; Van Laar, E.; Cullen, M.; Macleod, A.R.; Besterman, J.M.; Reid, G.K.; Byrd, J.C.; Marcucci, G. 2008: A phase i biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 14(8): 2444-2449

Bernstein, I.; Byun, H.-M.; Mohrbacher, A.; Douer, D.; Gorospe, G.; Hergesheimer, J.; Groshen, S.; O'Connell, C.; Yang, A.S. 2010: A phase i biological study of azacitidine (Vidaza™) to determine the optimal dose to inhibit DNA methylation. Epigenetics 5(8): 750-757

Majem, M.; Salazar, R.; Garcia, M.; Clopes, A.; Muñoz, C.; Pardo, B.; Martinez, M.; Cuadra, C.; Montes, A.; Mis, R.; Savulsky, C.; Ramon Germa-Lluch, J. 2009: A phase i clinical and pharmacokinetic study (LIPOTEC - GP PHARM/DOXO 01) of a new liposomal doxorubicin given as 3-week schedule in patients with solid tumors. Journal of Liposome Research 19(4): 261-266

Chan, S.; Campone, M.; Santoro, A.; Conte, P.F.; Bostnavaron, M.; Nguyen, L. 2014: A phase i clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer. Cancer ChemoTherapy and Pharmacology 73(5): 903-910

Wang, X.; Zhou, J.; Wang, Y.; Zhu, Z.; Lu, Y.; Wei, Y.; Chen, L. 2010: A phase i clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. European Journal of Cancer 46(8): 1474-1480

Awada, A.; Zhang, S.; Gil, T.; de Valeriola, D.; Lalami, Y.; De Porre, P.; Piccart-Gebhart, M.J. 2007: A phase i clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies. Current Medical Research and Opinion 23(5): 991-1003

Zaman, K.; Durando, X.; Baurain, J.-F.; Humblet, Y.; Mazzeo, F.; Bostnavaron, M.; Meheust, N.; Monnoyer-Favrel, S.; Machiels, J.-P.; Bauer, J. 2011: A phase i clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer. Breast Cancer Research and Treatment 127(3): 689-696

MacDonald, G.C.; Rasamoelisolo, M.èl.; Entwistle, J.; Cizeau, J.; Bosc, D.; Cuthbert, W.; Kowalski, M.; Spearman, M.; Glover, N. 2009: A phase i clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck. Drug Design Development and Therapy 2: 105-114

Thorstensson, R.; Trollfors, B.; Al-Tawil, N.; Jahnmatz, M.; Bergström, J.; Ljungman, M.; Törner, A.; Wehlin, L.; Van Broekhoven, A.; Bosman, F.; Debrie, A.-S.; Mielcarek, N.; Locht, C. 2014: A phase i clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. Plos one 9(1): E83449

Figg, W.D.; Woo, S.; Zhu, W.; Chen, X.; Ajiboye, A.S.; Steinberg, S.M.; Price, D.K.; Wright, J.J.; Parnes, H.L.; Arlen, P.M.; Gulley, J.L.; Dahut, W.L. 2010: A phase i clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. Journal of Urology 183(6): 2219-2226

MacDonald, G.C.; Rasamoelisolo, M.; Entwistle, J.; Cuthbert, W.; Kowalski, M.; Spearman, M.A.; Glover, N. 2009: A phase i clinical study of intratumorally administered VB4-845, an anti-epithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck. Medical Oncology 26(3): 257-264

Gong, X.; Lin, Y.; Bell, M.L.; Zhan, F.Benjamin. 2018: Associations between maternal residential proximity to air emissions from industrial facilities and low birth weight in Texas, USA. Environment international 120: 181-198

Liu, P.; Qin, Y.; Wu, L.; Yang, S.; Li, N.; Wang, H.; Xu, H.; Sun, K.; Zhang, S.; Han, X.; Sun, Y.; Shi, Y. 2014: A phase i clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections. Anti-Cancer Drugs 25(4): 462-471

Poschke, I.; Lövgren, T.; Adamson, L.; Nyström, M.; Andersson, E.; Hansson, J.; Tell, R.; Masucci, G.V.; Kiessling, R. 2014: A phase i clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. Cancer Immunology Immunotherapy: Cii 63(10): 1061-1071

Kim, K.H.; Dmitriev, I.; O'Malley, J.P.; Wang, M.; Saddekni, S.; You, Z.; Preuss, M.A.; Harris, R.D.; Aurigemma, R.; Siegal, G.P.; Zinn, K.R.; Curiel, D.T.; Alvarez, R.D. 2012: A phase i clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 18(12): 3440-3451

Kim, K.H.; Dmitriev, I.P.; Saddekni, S.; Kashentseva, E.A.; Harris, R.D.; Aurigemma, R.; Bae, S.; Singh, K.P.; Siegal, G.P.; Curiel, D.T.; Alvarez, R.D. 2013: A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer. Gynecologic Oncology 130(3): 518-524

Dickson, M.A.; Shah, M.A.; Rathkopf, D.; Tse, A.; Carvajal, R.D.; Wu, N.; Lefkowitz, R.A.; Gonen, M.; Cane, L.M.; Dials, H.J.; Schwartz, G.K. 2010: A phase i clinical trial of FOLFIRi in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Cancer ChemoTherapy and Pharmacology 66(6): 1113-1121

Cox, R.J.; Madhun, A.S.; Hauge, S.; Sjursen, H.; Major, D.; Kuhne, M.; Höschler, K.; Saville, M.; Vogel, F.R.; Barclay, W.; Donatelli, I.; Zambon, M.; Wood, J.; Haaheim, L.R. 2009: A phase i clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 27(13): 1889-1897

Lin, X.; Huang, H.; Li, S.; Li, H.; Li, Y.; Cao, Y.; Zhang, D.; Xia, Y.; Guo, Y.; Huang, W.; Jiang, W. 2007: A phase i clinical trial of an adenovirus-mediated endostatin gene (E10A) in patients with solid tumors. Cancer Biology and Therapy 6(5): 648-653

Zhu, Y.; Zhang, H.; Hu, F. 2000: A phase i clinical trial of combination chemotherapy of paclitaxel with carboplatin and concurrent radiation therapy in locally advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 3(5): 333-335

Tsimberidou, A.M.; Camacho, L.H.; Verstovsek, S.; Ng, C.; Hong, D.S.; Uehara, C.K.; Gutierrez, C.; Daring, S.; Stevens, J.; Komarnitsky, P.B.; Schwartz, B.; Kurzrock, R. 2009: A phase i clinical trial of darinaparsin in patients with refractory solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 15(14): 4769-4776

Gowans, E.J.; Roberts, S.; Jones, K.; Dinatale, I.; Latour, P.A.; Chua, B.; Eriksson, E.M.Y.; Chin, R.; Li, S.; Wall, D.M.; Sparrow, R.L.; Moloney, J.; Loudovaris, M.; Ffrench, R.; Prince, H.M.; Hart, D.; Zeng, W.; Torresi, J.; Brown, L.E.; Jackson, D.C. 2010: A phase i clinical trial of dendritic cell immunotherapy in HCV-infected individuals. Journal of Hepatology 53(4): 599-607

Wakabayashi, T.; Natsume, A.; Hashizume, Y.; Fujii, M.; Mizuno, M.; Yoshida, J. 2008: A phase I clinical trial of interferon-beta gene therapy for high-grade glioma: novel findings from gene expression profiling and autopsy. Journal of Gene Medicine 10(4): 329-339

Crabb, S.J.; Bradbury, J.; Nolan, L.; Selman, D.; Muthuramalingam, S.R.; Cave, J.; Johnson, P.W.M.; Ottensmeier, C. 2012: A phase I clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancer. ChemoTherapy 58(4): 257-263

Amato, R.J.; Khan, M. 2008: A phase i clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma. Cancer ChemoTherapy and Pharmacology 61(6): 1069-1073

Cleary, J.M.; Lima, C.M.S.R.; Hurwitz, H.I.; Montero, A.J.; Franklin, C.; Yang, J.; Graham, A.; Busman, T.; Mabry, M.; Holen, K.; Shapiro, G.I.; Uronis, H. 2014: A phase i clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. Investigational new Drugs 32(5): 937-945

Dickson, M.A.; Carvajal, R.D.; Merrill, A.H.; Gonen, M.; Cane, L.M.; Schwartz, G.K. 2011: A phase i clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 17(8): 2484-2492

Sterman, D.H.; Recio, A.; Carroll, R.G.; Gillespie, C.T.; Haas, A.; Vachani, A.; Kapoor, V.; Sun, J.; Hodinka, R.; Brown, J.L.; Corbley, M.J.; Parr, M.; Ho, M.; Pastan, I.; Machuzak, M.; Benedict, W.; Zhang, X.-q.; Lord, E.M.; Litzky, L.A.; Heitjan, D.F.; June, C.H.; Kaiser, L.R.; Vonderheide, R.H.; Albelda, S.M.; Kanther, M. 2007: A phase i clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 13(15 Part 1): 4456-4466

Habineza Ndikuyeze, G.; Gaurnier-Hausser, A.; Patel, R.; Baldwin, A.S.; May, M.J.; Flood, P.; Krick, E.; Propert, K.J.; Mason, N.J. 2014: A phase i clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma. Plos one 9(5): E95404

Gimsing, P.; Hansen, M.; Knudsen, L.M.; Knoblauch, P.; Christensen, I.J.; Ooi, C.E.; Buhl-Jensen, P. 2008: A phase i clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. European Journal of Haematology 81(3): 170-176

Kim, G.H.; Kellner, C.P.; Hickman, Z.L.; Zacharia, B.E.; Starke, R.M.; Hwang, B.Y.; Ducruet, A.F.; Fernandez, L.; Mayer, S.A.; Tracey, K.J.; Connolly, E.S. 2010: A phase i clinical trial of tiopronin, a putative neuroprotective agent, in aneurysmal subarachnoid hemorrhage. Neurosurgery 67(1): 182-185; Discussion 186

Suzuki, N.; Hazama, S.; Ueno, T.; Matsui, H.; Shindo, Y.; Iida, M.; Yoshimura, K.; Yoshino, S.; Takeda, K.; Oka, M. 2014: A phase i clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer. Journal of ImmunoTherapy 37(1): 36-42

Lancet, J.E.; Duong, V.H.; Winton, E.F.; Stuart, R.K.; Burton, M.; Zhang, S.; Cubitt, C.; Blaskovich, M.A.; Wright, J.J.; Sebti, S.; Sullivan, D.M. 2011: A phase i clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 17(5): 1140-1146

Rajan, A.; Carter, C.A.; Kelly, R.J.; Gutierrez, M.; Kummar, S.; Szabo, E.; Yancey, M.A.; Ji, J.; Mannargudi, B.; Woo, S.; Spencer, S.; Figg, W.D.; Giaccone, G. 2012: A phase i combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 18(8): 2344-2351

Smith, D.C.; Eisenberg, P.D.; Manikhas, G.; Chugh, R.; Gubens, M.A.; Stagg, R.J.; Kapoun, A.M.; Xu, L.; Dupont, J.; Sikic, B. 2014: A phase i dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 20(24): 6295-6303

Martin, L.K.; Bekaii-Saab, T.; Serna, D.; Monk, P.; Clinton, S.K.; Grever, M.R.; Kraut, E.H. 2013: A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors. Onkologie 36(11): 657-660

Chiorean, E.G.; Malireddy, S.; Younger, A.E.; Jones, D.R.; Waddell, M.-J.; Sloop, M.I.; Yu, M.; Hall, S.D.; Schneider, B.; Sweeney, C.J. 2010: A phase i dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors. Cancer ChemoTherapy and Pharmacology 66(3): 441-448

Seiwert, T.Y.; Darga, T.; Haraf, D.; Blair, E.A.; Stenson, K.; Cohen, E.E.W.; Salama, J.K.; Villaflor, V.; Witt, M.E.; Lingen, M.W.; Weichselbaum, R.R.; Vokes, E.E. 2013: A phase i dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Annals of Oncology: Official Journal of the European Society for Medical Oncology 24(3): 769-776

Wang-Gillam, A.; Arnold, S.M.; Bukowski, R.M.; Rothenberg, M.L.; Cooper, W.; Wang, K.K.; Gauthier, E.; Lockhart, A.C. 2012: A phase i dose escalation study of TTI-237 in patients with advanced malignant solid tumors. Investigational new Drugs 30(1): 266-272

Bekaii-Saab, T.; Hill, M.; Campbell, A.; Kosuri, K.; Thomas, J.; Villalona-Calero, M. 2010: A phase i dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies. Cancer ChemoTherapy and Pharmacology 65(5): 863-869

Monjazeb, A.M.; Ayala, D.; Jensen, C.; Case, L.D.; Bourland, J.D.; Ellis, T.L.; McMullen, K.P.; Chan, M.D.; Tatter, S.B.; Lesser, G.J.; Shaw, E.G. 2012: A phase i dose escalation study of hypofractionated IMRT field-in-field boost for newly diagnosed glioblastoma multiforme. International Journal of Radiation Oncology Biology Physics 82(2): 743-748

Welch, J.S.; Niu, H.; Uy, G.L.; Westervelt, P.; Abboud, C.N.; Vij, R.; Stockerl-Goldstein, K.E.; Jacoby, M.; Pusic, I.; Schroeder, M.A.; Dipersio, J.F.; Cashen, A.F. 2014: A phase i dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. American Journal of Hematology 89(8): E103-E108

Pant, S.; Saleh, M.; Bendell, J.; Infante, J.R.; Jones, S.; Kurkjian, C.D.; Moore, K.M.; Kazakin, J.; Abbadessa, G.; Wang, Y.; Chen, Y.; Schwartz, B.; Camacho, L.H. 2014: A phase i dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors. Annals of Oncology: Official Journal of the European Society for Medical Oncology 25(7): 1416-1421

Scott, E.N.; Thomas, A.L.; Molife, L.R.; Ahmed, S.; Blagden, S.; Fong, P.C.; Kowal, K.; McCoy, C.; Wiesinger, H.; Steward, W.; De Bono, J. 2009: A phase i dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours. Cancer ChemoTherapy and Pharmacology 64(2): 425-429

Aglietta, M.; Barone, C.; Sawyer, M.B.; Moore, M.J.; Miller, W.H.; Bagalà, C.; Colombi, F.; Cagnazzo, C.; Gioeni, L.; Wang, E.; Huang, B.; Fly, K.D.; Leone, F. 2014: A phase i dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology 25(9): 1750-1755

Slovin, S.F.; Kehoe, M.; Durso, R.; Fernandez, C.; Olson, W.; Gao, J.P.; Israel, R.; Scher, H.I.; Morris, S. 2013: A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine 31(6): 943-949

Vilar, E.; Grünwald, V.; Schöffski, P.; Singer, H.; Salazar, R.; Iglesias, J.L.; Casado, E.; Cullell-Young, M.; Baselga, J.; Tabernero, J. 2012: A phase i dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors. Investigational new Drugs 30(1): 299-305

Ranson, M.; Shaw, H.; Wolf, J.; Hamilton, M.; McCarthy, S.; Dean, E.; Reid, A.; Judson, I. 2010: A phase i dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin. Cancer ChemoTherapy and Pharmacology 66(1): 53-58

Wisman, L.A.B.; De Cock, E.P.M.; Reijers, J.A.A.; Kamerling, I.M.C.; Van Os, S.H.G.; de Kam, M.L.; Burggraaf, J.; Voortman, G. 2014: A phase i dose-escalation and bioequivalence study of a trastuzumab biosimilar in healthy male volunteers. Clinical Drug Investigation 34(12): 887-894

Morganti, A.G.; Balducci, M.; Salvati, M.; Esposito, V.; Romanelli, P.; Ferro, M.; Calista, F.; Digesù, C.; Macchia, G.; Ianiri, M.; Deodato, F.; Cilla, S.; Piermattei, A.; Valentini, V.; Cellini, N.; Cantore, G.P. 2010: A phase i dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma. International Journal of Radiation Oncology Biology Physics 77(1): 92-97

Becerra, C.R.; Conkling, P.; Vogelzang, N.; Wu, H.; Hong, S.; Narwal, R.; Liang, M.; Tavakkoli, F.; Pandya, N. 2014: A phase i dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors. Cancer ChemoTherapy and Pharmacology 74(5): 917-925

Lockhart, A.C.; Calvo, E.; Tolcher, A.W.; Rowinsky, E.K.; Shackleton, G.; Morrison, J.G.; Rafi, R.; VerMeulen, W.; Rothenberg, M.L. 2009: A phase i dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors. American Journal of Clinical Oncology 32(1): 9-14

Rosen, L.S.; Senzer, N.; Mekhail, T.; Ganapathi, R.; Chai, F.; Savage, R.E.; Waghorne, C.; Abbadessa, G.; Schwartz, B.; Dreicer, R. 2011: A phase i dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 17(24): 7754-7764

Tamura, T.; Minami, H.; Yamada, Y.; Yamamoto, N.; Shimoyama, T.; Murakami, H.; Horiike, A.; Fujisaka, Y.; Shinkai, T.; Tahara, M.; Kawada, K.; Ebi, H.; Sasaki, Y.; Jiang, H.; Saijo, N. 2006: A phase i dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 1(9): 1002-1009

Foster, M.C.; Amin, C.; Voorhees, P.M.; van Deventer, H.W.; Richards, K.L.; Ivanova, A.; Whitman, J.; Chiu, W.M.; Barr, N.D.; Shea, T. 2012: A phase i dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia. Leukemia and Lymphoma 53(7): 1331-1337

Cohen, R.B.; Jones, S.F.; Aggarwal, C.; von Mehren, M.; Cheng, J.; Spigel, D.R.; Greco, F.A.; Mariani, M.; Rocchetti, M.; Ceruti, R.; Comis, S.; Laffranchi, B.; Moll, J.; Burris, H.A. 2009: A phase i dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 15(21): 6694-6701

Saif, M.W.; Sellers, S.; Diasio, R.B.; Douillard, J.-Y. 2010: A phase i dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors. Anti-Cancer Drugs 21(7): 716-723

Dugan, E.; Truax, R.; Meadows, K.L.; Nixon, A.B.; Petros, W.P.; Favaro, J.; Fernando, N.H.; Morse, M.A.; Blobe, G.C.; Hurwitz, H.I. 2010: A phase i dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors. Anticancer Research 30(4): 1251-1256

Sharma, S.; Beck, J.; Mita, M.; Paul, S.; Woo, M.M.; Squier, M.; Gadbaw, B.; Prince, H.Miles. 2013: A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors. Investigational new Drugs 31(4): 974-985

Heath, E.I.; Heilbrun, L.K.; Li, J.; Vaishampayan, U.; Harper, F.; Pemberton, P.; Sarkar, F.H. 2010: A phase i dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer. American Journal of Translational Research 2(4): 402-411

Mross, K.; Frost, A.; Steinbild, S.; Hedbom, S.; Büchert, M.; Fasol, U.; Unger, C.; Krätzschmar, J.ör.; Heinig, R.; Boix, O.; Christensen, O. 2012: A phase i dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 18(9): 2658-2667

Cohn, A.; Lahn, M.M.; Williams, K.E.; Cleverly, A.L.; Pitou, C.; Kadam, S.K.; Farmen, M.W.; Desaiah, D.; Raju, R.; Conkling, P.; Richards, D. 2014: A phase i dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer. International Journal of Oncology 45(6): 2221-2231

Ling, S.; Luo, R.-Z.; Nheu, L.; Guo, Z.-X.; Sun, H.; Komesaroff, P.A. 2012: A phase i dose-escalation study to evaluate tolerability in a Western population to T89, a modern cardiovascular herbal medicine. Journal of Cardiovascular Pharmacology 60(6): 513-519

Abidi, M.H.; Agarwal, R.; Tageja, N.; Ayash, L.; Deol, A.; Al-Kadhimi, Z.; Abrams, J.; Cronin, S.; Ventimiglia, M.; Lum, L.; Ratanatharathorn, V.; Zonder, J.; Uberti, J. 2013: A phase i dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 19(1): 56-61

Jhaveri, K.; Miller, K.; Rosen, L.; Schneider, B.; Chap, L.; Hannah, A.; Zhong, Z.; Ma, W.; Hudis, C.; Modi, S. 2012: A phase i dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 18(18): 5090-5098

Zhou, Q.; Gustafson, D.; Nallapareddy, S.; Diab, S.; Leong, S.; Lewis, K.; Gore, L.; Messersmith, W.A.; Treston, A.M.; Eckhardt, S.G.; Sidor, C.; Camidge, D.R. 2011: A phase i dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. Investigational new Drugs 29(2): 340-346

Lin, J.; Gilbert, J.; Rudek, M.A.; Zwiebel, J.A.; Gore, S.; Jiemjit, A.; Zhao, M.; Baker, S.D.; Ambinder, R.F.; Herman, J.G.; Donehower, R.C.; Carducci, M.A. 2009: A phase i dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 15(19): 6241-6249

Northfelt, D.W.; Ramanathan, R.K.; Cohen, P.A.; Von Hoff, D.D.; Weiss, G.J.; Dietsch, G.N.; Manjarrez, K.L.; Randall, T.D.; Hershberg, R.M. 2014: A phase i dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 20(14): 3683-3691

Timmerman, J.M.; Byrd, J.C.; Andorsky, D.J.; Yamada, R.E.; Kramer, J.; Muthusamy, N.; Hunder, N.; Pagel, J.M. 2012: A phase i dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 18(20): 5752-5760

Hamilton, J.M.; Harding, M.W.; Genna, T.; Bol, D.K. 2009: A phase i dose-ranging study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of AVN944, an IMPDH inhibitor, in healthy male volunteers. Journal of Clinical Pharmacology 49(1): 30-38

Keefer, M.C.; Gilmour, J.; Hayes, P.; Gill, D.; Kopycinski, J.; Cheeseman, H.; Cashin-Cox, M.; Naarding, M.; Clark, L.; Fernandez, N.; Bunce, C.A.; Hay, C.M.; Welsh, S.; Komaroff, W.; Hachaambwa, L.; Tarragona-Fiol, T.; Sayeed, E.; Zachariah, D.; Ackland, J.; Loughran, K.; Barin, B.; Cormier, E.; Cox, J.H.; Fast, P.; Excler, J.-L. 2012: A phase i double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. Plos one 7(8): E41936

Shirao, K.; Yoshino, T.; Boku, N.; Kato, K.; Hamaguchi, T.; Yasui, H.; Yamamoto, N.; Tanigawara, Y.; Nolting, A.; Yoshino, S. 2009: A phase i escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors. Cancer ChemoTherapy and Pharmacology 64(3): 557-564

Patel, S.M.; Atmar, R.L.; El Sahly, H.M.; Cate, T.R.; Keitel, W.A. 2010: A phase i evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine 28(17): 3025-3029

Chiappori, A.A.; Ellis, P.M.; Hamm, J.T.; Bitran, J.D.; Eiseman, I.; Lovalvo, J.; Burnett, D.; Olson, S.; Lenehan, P.; Zinner, R.G. 2006: A phase i evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 1(9): 1010-1019

Sanoff, H.K.; Davies, J.M.; Walko, C.; Irvin, W.; Buie, L.; Keller, K.; Ivanova, A.; Chiu, W.-K.; O'Neil, B.H.; Stinchcombe, T.E.; Dees, E.C. 2011: A phase i evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors. Investigational new Drugs 29(5): 978-983

Gilbert, M.R.; Gonzalez, J.; Hunter, K.; Hess, K.; Giglio, P.; Chang, E.; Puduvalli, V.; Groves, M.D.; Colman, H.; Conrad, C.; Levin, V.; Woo, S.; Mahajan, A.; de Groot, J.; Yung, W.K.Alfred. 2010: A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro-Oncology 12(11): 1167-1172

Van Puymbroeck, M.; Payne, L.L.; Hsieh, P.-C. 2007: A phase i feasibility study of yoga on the physical health and coping of informal caregivers. Evidence-Based Complementary and Alternative Medicine: Ecam 4(4): 519-529

Tabernero, J.; Dirix, L.; Schöffski, P.; Cervantes, A.és.; Lopez-Martin, J.A.; Capdevila, J.; van Beijsterveldt, L.; Platero, S.; Hall, B.; Yuan, Z.; Knoblauch, R.; Zhuang, S.H. 2011: A phase i first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 17(19): 6313-6321

Rosen, L.S.; Hurwitz, H.I.; Wong, M.K.; Goldman, J.; Mendelson, D.S.; Figg, W.D.; Spencer, S.; Adams, B.J.; Alvarez, D.; Seon, B.K.; Theuer, C.P.; Leigh, B.R.; Gordon, M.S. 2012: A phase i first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 18(17): 4820-4829

Hong, D.S.; Kurzrock, R.; Supko, J.G.; He, X.; Naing, A.; Wheler, J.; Lawrence, D.; Eder, J.P.; Meyer, C.J.; Ferguson, D.A.; Mier, J.; Konopleva, M.; Konoplev, S.; Andreeff, M.; Kufe, D.; Lazarus, H.; Shapiro, G.I.; Dezube, B.J. 2012: A phase i first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 18(12): 3396-3406

Lassen, U.N.; Meulendijks, D.; Siu, L.L.; Karanikas, V.; Mau-Sorensen, M.; Schellens, J.H.M.; Jonker, D.J.; Hansen, A.R.; Simcox, M.E.; Schostack, K.J.; Bottino, D.; Zhong, H.; Roessler, M.; Vega-Harring, S.M.; Jarutat, T.; Geho, D.; Wang, K.; DeMario, M.; Goss, G.D. 2015: A phase i monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 21(2): 258-266

Wong, N.S.; Meadows, K.L.; Rosen, L.S.; Adjei, A.A.; Kaufmann, S.H.; Morse, M.A.; Petros, W.P.; Zhu, Y.; Statkevich, P.; Cutler, D.L.; Meyers, M.L.; Hurwitz, H.I. 2011: A phase i multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer. Cancer Investigation 29(9): 617-625

Hussein, M.; Berenson, J.R.; Niesvizky, R.; Munshi, N.; Matous, J.; Sobecks, R.; Harrop, K.; Drachman, J.G.; Whiting, N. 2010: A phase i multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 95(5): 845-848

Davis, I.D.; Wiseman, G.A.; Lee, F.-T.; Gansen, D.N.; Hopkins, W.; Papenfuss, A.T.; Liu, Z.; Moynihan, T.J.; Croghan, G.A.; Adjei, A.A.; Hoffman, E.W.; Ingle, J.N.; Old, L.J.; Scott, A.M. 2007: A phase i multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immunity 7: 13

Du Bois, A.; Huober, J.; Stopfer, P.; Pfisterer, J.; Wimberger, P.; Loibl, S.; Reichardt, V.L.; Harter, P. 2010: A phase i open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Annals of Oncology: Official Journal of the European Society for Medical Oncology 21(2): 370-375

Tolcher, A.W.; Appleman, L.J.; Shapiro, G.I.; Mita, A.C.; Cihon, F.; Mazzu, A.; Sundaresan, P.R. 2011: A phase i open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer ChemoTherapy and Pharmacology 67(4): 751-764

Bennouna, J.; Deslandres, M.; Senellart, H.; de Labareyre, C.; Ruiz-Soto, R.; Wixon, C.; Botbyl, J.; Suttle, A.Benjamin.; Delord, J-Pierre. 2015: A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer. Investigational new Drugs 33(1): 138-147

Ruiz-Garcia, A.; Giri, N.; LaBadie, R.R.; Ni, G.; Boutros, T.; Richie, N.; Kocinsky, H.S.; Checchio, T.M.; Bello, C.L. 2014: A phase i open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers. Journal of Clinical Pharmacology 54(5): 555-562

LoConte, N.K.; Thomas, J.P.; Alberti, D.; Heideman, J.; Binger, K.; Marnocha, R.; Utecht, K.; Geiger, P.; Eickhoff, J.; Wilding, G.; Kolesar, J. 2008: A phase i pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer. Cancer ChemoTherapy and Pharmacology 63(1): 109-115

Bruce, J.Y.; Kolesar, J.M.; Hammers, H.; Stein, M.N.; Carmichael, L.; Eickhoff, J.; Johnston, S.A.; Binger, K.A.; Heideman, J.L.; Perlman, S.B.; Jeraj, R.; Liu, G. 2014: A phase i pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies. Cancer ChemoTherapy and Pharmacology 73(3): 485-493

Lim, C.B.S.; Schug, S.A.; Sunderland, V.B.; Paech, M.J.; Liu, Y. 2012: A phase i pharmacokinetic and bioavailability study of a sublingual fentanyl wafer in healthy volunteers. Anesthesia and Analgesia 115(3): 554-559

Brignone, C.; Escudier, B.; Grygar, C.; Marcu, M.; Triebel, F.éd.ér. 2009: A phase i pharmacokinetic and biological correlative study of IMP321, a novel MHC class Ii agonist, in patients with advanced renal cell carcinoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 15(19): 6225-6231

Liu, G.; Kolesar, J.; McNeel, D.G.; Leith, C.; Schell, K.; Eickhoff, J.; Lee, F.; Traynor, A.; Marnocha, R.; Alberti, D.; Zwiebel, J.; Wilding, G. 2008: A phase i pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 14(9): 2732-2739

Banerji, U.; van Doorn, L.; Papadatos-Pastos, D.; Kristeleit, R.; Debnam, P.; Tall, M.; Stewart, A.; Raynaud, F.; Garrett, M.D.; Toal, M.; Hooftman, L.; De Bono, J.S.; Verweij, J.; Eskens, F.A. 2012: A phase i pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class i selective histone deacetylase inhibitor in refractory solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 18(9): 2687-2694

Shin, S.J.; Jeung, H.-C.; Ahn, J.B.; Rha, S.Y.; Roh, J.K.; Park, K.S.; Kim, D.-H.; Kim, C.; Chung, H.C. 2010: A phase i pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. Investigational new Drugs 28(5): 650-658

Sarker, D.; Molife, R.; Evans, T.R.J.; Hardie, M.; Marriott, C.; Butzberger-Zimmerli, P.; Morrison, R.; Fox, J.A.; Heise, C.; Louie, S.; Aziz, N.; Garzon, F.; Michelson, G.; Judson, I.R.; Jadayel, D.; Braendle, E.; de Bono, J.S. 2008: A phase i pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 14(7): 2075-2081

Atzori, F.; Tabernero, J.; Cervantes, A.és.; Prudkin, L.; Andreu, J.; Rodríguez-Braun, E.; Domingo, A.; Guijarro, J.; Gamez, C.; Rodon, J.; Di Cosimo, S.; Brown, H.; Clark, J.; Hardwick, J.S.; Beckman, R.A.; Hanley, W.D.; Hsu, K.; Calvo, E.; Roselló, S.; Langdon, R.B.; Baselga, J.é 2011: A phase i pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 17(19): 6304-6312

Chiappori, A.A.; Eckhardt, S.G.; Bukowski, R.; Sullivan, D.M.; Ikeda, M.; Yano, Y.; Yamada-Sawada, T.; Kambayashi, Y.; Tanaka, K.; Javle, M.M.; Mekhail, T.; O'bryant, C.L.; Creaven, P.J. 2007: A phase i pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 13(7): 2091-2099

Peethambaram, P.P.; Hartmann, L.C.; Jonker, D.J.; de Jonge, M.; Plummer, E.R.; Martin, L.; Konner, J.; Marshall, J.; Goss, G.D.; Teslenko, V.; Clemens, P.L.; Cohen, L.J.; Ahlers, C.M.; Alland, L. 2015: A phase i pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors. Investigational new Drugs 33(2): 321-331

Kuemmerle, A.; Decosterd, L.A.; Buclin, T.; Liénard, D.; Stupp, R.; Chassot, P.-G.; Mosimann, F.ço.; Lejeune, F. 2009: A phase i pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites. Cancer ChemoTherapy and Pharmacology 63(2): 331-341

Dickson, M.A.; Rathkopf, D.E.; Carvajal, R.D.; Grant, S.; Roberts, J.D.; Reid, J.M.; Ames, M.M.; McGovern, R.M.; Lefkowitz, R.A.; Gonen, M.; Cane, L.M.; Dials, H.J.; Schwartz, G.K. 2011: A phase i pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. Investigational new Drugs 29(5): 1004-1012

Zhu, Z.; Qian, Z.; Yan, Z.; Zhao, C.; Wang, H.; Ying, G. 2013: A phase i pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors. International Journal of Nanomedicine 8: 129-136

Yan, Z.; Zhu, Z.; Li, K.; Chen, P.; Wang, L.; Huang, C.; Xue, J.; Liu, M. 2011: A phase i pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors. Cancer ChemoTherapy and Pharmacology 67(4): 955-961

Fumoleau, P.; Koch, K.M.; Brain, E.; Lokiec, F.ço.; Rezai, K.; Awada, A.; Hayward, L.; Werutsky, G.; Bogaerts, J.; Marréaud, S.; Cardoso, F. 2014: A phase i pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study). Breast 23(5): 663-669

Kuenen, B.; Witteveen, P.O.; Ruijter, R.; Giaccone, G.; Dontabhaktuni, A.; Fox, F.; Katz, T.; Youssoufian, H.; Zhu, J.; Rowinsky, E.K.; Voest, E.E. 2010: A phase i pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 16(6): 1915-1923

Chow, L.Q.M.; Gustafson, D.L.; O'Bryant, C.L.; Gore, L.; Basche, M.; Holden, S.N.; Morrow, M.C.; Grolnic, S.; Creese, B.R.; Roberts, K.L.; Davis, K.; Addison, R.; Eckhardt, S.G. 2008: A phase i pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies. Cancer ChemoTherapy and Pharmacology 63(1): 65-74

Budiharto, T.; Haustermans, K.; Van Cutsem, E.; Van Steenbergen, W.; Topal, B.; Aerts, R.; Ectors, N.; Bielen, D.; Vanbeckevoort, D.; Goethals, L.; Verslype, C. 2008: A phase i radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma. Radiation Oncology 3: 30